Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  15-AUG-2021A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind 
Clinical Study to Evaluate the Efficacy, Safety, and 
Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with 
COVID-19
PRODUCT: MK-4482  1
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD) .
Protocol Title: A Phase 2/3, Randomized, Placebo- Controlled, Double -Blind Clinical Study 
to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK -4482 in Non -Hospitalized 
Adults with COVID- 19.
Protocol Number: 002-04
Compound Number: MK-4482
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey, 08889 -0100, U.S.A.
Regulatory Agency Identifying Number(s):
EudraCT 2020- 003368- 24
IND 147734
NCT NCT 04575597
Approval Date: 15 August 2021
06FSHF
07X3DY
PRODUCT: MK-4482  2
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Sponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by all provisions of this protocol.
Typed Name:
Title:Date
06FSHF
07X3DY
PRODUCT: MK-4482  3
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 04 15-AUG- 2021 To remove the enrollment target of~50% of Part 2 participants who are >60 years of 
age and to add a new exploratory objective for detection of infectious virus from NP
swabs .
Amendment 03 22-JUN-2021 To clarify that participants can only enroll in this study if they have chosen not to 
receive a SARS -CoV -2 monoclonal antibod y(ies)or SARS -CoV -2 monoclonal 
antibodies have not been authorized or approved in their country, update the benefit/risk 
assessment, add new subgroup analyses, and add a description of an unblinded team in 
the case of a positive effic acy finding noted by the eDMC at IA4 .
Amendment 02 14-APR -2021 To provide the selected dose and thedose selection rationale for Part 2 (Phase 3) of the 
study, revise female and male contraception requirements, update the stratification 
factors, revise entry criteria , and increase the sample size for Part 2 (Phase 3) .
Amendment 01 17-DEC -2020 Torevise the dose selection process before initiation of Part 2 (Phase 3), update the 
benefit/risk assessment, clarify the key secondary efficacy objective regarding COVID -
19 signs/symptoms, and add a discontinuation criterion .
Original Protocol 14- SEP-2020 Not applicable
06FSHF
07X3DY
PRODUCT: MK-4482  4
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 04
Overall Rationale for the Amendments:
To remove the enrollment target of~50% of Part 2 participants who are >60 years of age and to add a new exploratory objective for 
detection of infectious virus from NPswabs .
Summary of Changes Table:
Section # and Name Description of Change  Brief Rationale  
4.1Overall Design
6.3.2 StratificationRemoved the enrollment target of
approximately 50% of Part 2 participants 
who are >60 years of age .While the Part 2 study population will continue to be 
enriched for participants at increased risk for seve re
illness from COVID -19, including those >60 years of 
age(Appendix 10 ), the enrollment target of ~50% of 
participants >60 years of age was removed. B ased on 
observed data ,events are occurring across risk factors 
and enrichment for older participants alone is not 
needed . This change was also made to support
increase dfeasibility of enrollment given increasing 
global vaccination rates in the older population. 
06FSHF
07X3DY
PRODUCT: MK-4482  5
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Section # and Name Description of Change  Brief Rationale  
3 Hypotheses, Objectives 
and Endpoints
4.2.1.4 Virology Endpoints
4.2.5 Rationale for Other 
Explor atory Research
8.2.1 Nasopharyngeal and 
Oropharyngeal Swabs
9.4.1.1 Efficacy EndpointsAdded anexploratory objective to evaluate 
the percentage of participants with 
undetectable infectious SARS -CoV -2 in 
NP swabs at various timepoints.
Added associated changes relevant to the 
new exploratory objective .To evaluate theantiviral activity of MK-4482 versus 
placebo via detection of infectious SARS -CoV -2.
1.3 Schedule of Activities
8.1.2 In clusion/Exclusion 
CriteriaAdded statement that laboratory testing to 
confirm SARS -CoV -2 infection may be 
performed at screening if prior results are 
not available.To clarify that sites may perform this testing at 
screening to confirm eligibility.
7.3 Lost to Follow -up Removed: ‚Äú Note: A participant is not 
considered lost to follow -up until the last 
scheduled visit for the individual 
participant. The missing data for the 
participant will be managed via the pre -
specified statistical data handling and 
analysis guidelines. ‚ÄùA participant can be declared as lost to follow -up after 
the site has attempted multiple methods of contact 
rather than waiting until the last scheduled visit (ie, 
LFU Month 7). Given the length of study, it is 
considered reasonable to at tempt contact to a point 
where the data that would be collected may still be 
considered meaningful instead of throughout the full 
duration of the study.
06FSHF
07X3DY
PRODUCT: MK-4482  6
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Section # and Name Description of Change  Brief Rationale  
1.2 Schema Revised footnote ‚Äúa‚Äù tostate that eligible 
participants will have laboratory -
confirmed inf ection and sign s/symptoms 
of COVID -19 for ‚â§7 days in Part 1 and 
‚â§5days in Part 2 prior to randomization.To clarify the difference in eligibility requirements for 
each Part of the study.
Appendix 5, Section 10.5.2 
Contraception RequirementsAdded ‚Äúuser dependent‚Äù before hormonal 
contraceptives in the text describing those 
barrier methods to be used with user 
dependent hormonal contraceptives .To clarify that hormonal contraceptives that require 
additional barrier methods to be used are ‚Äúuser 
dependent ‚Äùhormonal contraceptives as described in 
the preceding text.
Throughout the document Corrected minor typographical and 
grammatical errors.To improve clarity and consistency throughout the 
document.
06FSHF
07X3DY
PRODUCT: MK-4482  7
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 15
1.1 Synopsis ................................................................................................................. 15
1.2 Schema .................................................................................................................. 18
1.3 Schedule of Activities........................................................................................... 19
2 INTRODUCTION .......................................................................................................... 23
2.1 Study Rationale ....................................................................................................23
2.2 Background .......................................................................................................... 23
2.3 Benefit/Risk Assessment ...................................................................................... 26
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 27
4 STUDY DESIGN ............................................................................................................ 29
4.1 Overall Design ......................................................................................................29
4.2 Scientific Rationale for Study Design ................................................................ .31
4.2.1 Rationale for Endpoints ............................................................................... 31
4.2.1.1 Efficacy Endpoints ............................................................................. 31
4.2.1.1.1 Primary Clinical Endpoint ....................................................... 31
4.2.1.1.2 Secondary Endpoints ............................................................... 32
4.2.1.2 Safety Endpoints ................................................................................ 32
4.2.1.3 Pharmacokinetic Endpoints ............................................................... 33
4.2.1.4 Virology Endpoints ............................................................................ 33
4.2.1.5 Future Biomedical Research .............................................................. 33
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 34
4.2.3 Rationale for the Selected Participant Pop ulation .......................................34
4.2.4 Rationale for Collection of Racial, Ethnic, and Gender Identity Data ........35
4.2.5 Rationale for Other Exploratory Research Samples ....................................35
4.3 Justification for Dose ........................................................................................... 36
4.3.1 Rationale for Dosing Duration .....................................................................36
4.3.2 Dose Range for Part 1 (Phase 2) ..................................................................37
4.3.3 Dose Selection for Part 2 (Phase 3) ............................................................. 37
4.4 Beginning and End of Study Definition ............................................................. 39
4.4.1 Clinical Criteria for Early Study Termination ............................................. 39
5 STUDY POPULATION ................................................................................................ 39
5.1 Inclusion Criteria ................................................................................................ .39
5.2 Exclusion Criteria ................................................................................................ 42
06FSHF
07X3DY
PRODUCT: MK-4482  8
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
5.3 Lifestyle Considerations ...................................................................................... 43
5.4 Screen Failures .....................................................................................................44
5.5 Participant Replacement Strategy ......................................................................44
6 STUDY INTERVENTION ............................................................................................ 44
6.1 Study Intervention(s) Administered ...................................................................44
6.2 Preparation/Handling/Storage/Accountability ................................................. 46
6.2.1 Dose Preparation .......................................................................................... 46
6.2.2 Handling, Storage, and Accountability ........................................................ 46
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 47
6.3.1 Intervention Assignment.............................................................................. 47
6.3.2 Stratification ................................................................................................ .47
6.3.3 Blinding ........................................................................................................48
6.4 Study Intervention Compliance .......................................................................... 48
6.5 Concomitant Therapy .......................................................................................... 48
6.5.1 Rescue Medications and Supportive Care ................................................... 50
6.6 Dose Modification (Escalation/Titration/Other) ............................................... 50
6.7 Intervention After the End of the Study ............................................................ 50
6.8 Clinical Supplies Disclosure ................................................................................ 50
7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
WITHDRAWAL ............................................................................................................ 50
7.1 Discontinuation of Study Intervention ............................................................... 50
7.2 Participant Withdrawal From the Study ........................................................... 51
7.3 Lost to Follow -up................................................................................................ .52
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 52
8.1 Administrative and General Procedures ........................................................... 53
8.1.1 Informed Consent ......................................................................................... 53
8.1.1.1 General Informed Consent ................................................................ .53
8.1.1.2 Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 53
8.1.1.3 Consent for PBMC Cohort Blood Sample Collection ....................... 54
8.1.2 Inclusion/Exclusion Criteria ........................................................................54
8.1.3 Participant Identification Card .....................................................................54
8.1.4 Medical History ........................................................................................... 55
8.1.5 Prior and Concomitant Medications Review ............................................... 55
8.1.5.1 Prior Medications ............................................................................... 55
8.1.5.2 Concomitant Medications ..................................................................55
8.1.6 Assignment of Screening Number ............................................................... 55
8.1.7 Assignment of Treatment/Randomization Number .....................................56
06FSHF
07X3DY
PRODUCT: MK-4482  9
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
8.1.8 Study Intervention Administration .............................................................. 56
8.1.8.1 Timing of Dose Administration ......................................................... 56
8.1.9 Discontinuation and Withdrawal ................................................................ .57
8.1.9.1 Withdrawal From Future Biomedical Research ................................ 58
8.1.10 Participant Blinding/Unblinding ..................................................................58
8.1.11 Calibration of Equipment ............................................................................. 59
8.1.12 Collect/Update Secondary Contact Information .......................................... 59
8.1.13 Participant Study Supplies ........................................................................... 59
8.1.14 Study Medication Diary ............................................................................... 60
8.2 Efficacy Assessments ........................................................................................... 60
8.2.1 Nasopharyngeal and Oropharyngeal Swabs ................................................ 60
8.2.2 Respiratory/Oxygenation Status ..................................................................60
8.2.3 Hospitalization ............................................................................................. 61
8.2.4 Survival Status ............................................................................................. 62
8.2.5 MK-4482 Symptom Diary ........................................................................... 62
8.2.6 Functional Status Assessments ....................................................................63
8.3 Safety Assessments ............................................................................................... 63
8.3.1 Physical Examinations ................................................................................. 63
8.3.2 Vital Signs ....................................................................................................63
8.3.3 Clinical Safety Laboratory Assessments ..................................................... 64
8.3.4 Pregnancy Testing ........................................................................................ 64
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events.................................................................................................................... 64
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 65
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......67
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...67
8.4.4 Regulatory Reporti ng Requirements for SAE ............................................. 67
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 67
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ 68
8.4.7 Events of Clinical Interest ............................................................................ 68
8.5 Treatment of Overdose ........................................................................................ 68
8.6 Pharmacokinetics ................................................................................................ .69
8.6.1 Blood Collection for Measurement of NHC in Plasma ............................... 69
8.6.2 Blood Collection for Measurement of NHC -TP in PBMC .......................... 69
8.7 Pharmacodynamics .............................................................................................. 70
8.8 Exploratory Research Samples ........................................................................... 70
06FSHF
07X3DY
PRODUCT: MK-4482  10
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
8.9 Future Biomedical Research Sample Collection ............................................... 70
8.10 Medical Resource Utilization and Health Economics .......................................70
8.11 Visit Requirements ............................................................................................... 70
8.11.1 Infection Prevention Procedures ..................................................................71
8.11.2 Types of Study Visits ................................................................................... 71
8.11.2.1 Screening/Rescreening Visits ............................................................ 71
8.11.2.2 Clinic or At -Home Visits ...................................................................72
8.11.2.3 Virtual Visits ...................................................................................... 72
8.11.3 Participants Who Discontinue or Withdraw ................................................ 72
8.11.4 Late Follow- up (7 Month) Visit ...................................................................73
9 STATISTICAL ANALYSIS PLAN ............................................................................. 73
9.1 Statistical Analysis Plan Summary .....................................................................73
9.2 Responsibility for Analyses/In -house Blinding ................................................. 75
9.3 Hypotheses/Estimation ........................................................................................ 76
9.4 Analysis Endpoints ............................................................................................... 76
9.4.1 Efficacy/Pharmacokinetics Endpoints ......................................................... 76
9.4.1.1 Efficacy Endpoints ............................................................................. 76
9.4.1.2 Pharmacokinetics Endpoints .............................................................. 78
9.4.2 Safety Endpoints .......................................................................................... 78
9.5 Analysis Populations ............................................................................................ 79
9.5.1 Efficacy Analysis Populations .....................................................................79
9.5.2 Safety Analysis Populations ........................................................................79
9.6 Statistical Methods ............................................................................................... 79
9.6.1 Statistical Methods for Efficacy Analyses................................................... 80
9.6.2 Statistical Methods for Safety Analyses ...................................................... 83
9.6.3 Demographic and Baseline Characteristics ................................................. 84
9.7 Interim Analyses ..................................................................................................84
9.8 Multiplicity ........................................................................................................... 88
9.9 Sample Size and Power Calculations ................................................................ .88
9.9.1 Sample Size and Power Calculations for Efficacy Analyses (Part 2) .......... 88
9.9.2 Sample Size and Power Calculations for Virology Analyses (Part 1) .........89
9.9.3 Sample Size and Power Calculations for Safety Analyses (Part 2) ............. 90
9.10 Subgroup Analyses ............................................................................................... 91
9.11 Compliance (Medication Adherence) ................................................................ .92
9.12 Extent of Exposure ............................................................................................... 92
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS .....................................................................................................93
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........93
06FSHF
07X3DY
PRODUCT: MK-4482  11
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.1.1 Code of Conduct for Clinical Trials ............................................................. 93
10.1.2 Financial Disclosure ..................................................................................... 95
10.1.3 Data Protection ............................................................................................. 95
10.1.3.1 Confidentiality of Data ......................................................................96
10.1.3.2 Confidentiality of Partic ipant Records ............................................... 96
10.1.3.3 Confidentiality of IRB/IEC Information ............................................ 96
10.1.4 Committees Structure ................................................................................... 97
10.1.4.1 Executive Oversight Committee ........................................................ 97
10.1.4.2 Internal Data Monitoring Committee ................................................. 97
10.1.4.3 External Data Monitoring Committee ............................................... 97
10.1.5 Publication Policy ........................................................................................ 97
10.1.6 Compliance with Study Registration and Results Posting Requirements ...98
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 98
10.1.8 Data Quality Assurance ............................................................................... 99
10.1.9 Source Documents ..................................................................................... 100
10.1.10 Study and Site Closure ............................................................................... 100
10.2 Appendix 2: Clinical Laboratory Tests ............................................................ 101
10.3 Appendix 3: Adverse Events: Definitions and Proce dures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................. 105
10.3.1 Definition of AE ........................................................................................ 105
10.3.2 Definition of SAE ...................................................................................... 106
10.3.3 Additional Events Reported .......................................................................107
10.3.4 Recording AE and SAE ............................................................................. 107
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ......................................................................................................111
10.4 Appendix 4: Medical Device and Drug -device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up............................................................................................................ 113
10.5 Appendix 5: Contraceptive Guidance .............................................................. 114
10.5.1 Definit ions..................................................................................................114
10.5.2 Contraception Requirements ......................................................................115
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 116
10.7 Appendix 7: Country -specific Requirements .................................................. 121
10.7.1 Country- specific Request for Germany ..................................................... 121
10.8 Appendix 8: Ordinal Outcome Scales .............................................................. 122
10.8.1 World Health Organization 11- Point Scale ............................................... 122
10.9 Appendix 9: COVID- 19 Severity Categorization ............................................ 123
06FSHF
07X3DY
PRODUCT: MK-4482  12
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.10 Appendix 10: Individuals at Increased Ri sk for Severe Illness from 
COVID -19........................................................................................................... 126
10.11 Appendix 11: Calculation of eGFR ..................................................................127
10.12 Appendix 12: Abbreviations ............................................................................. 128
11 REFERENCES ............................................................................................................. 131
06FSHF
07X3DY
PRODUCT: MK-4482  13
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
LIST OF TABLES
Table 1 Study Interventions .................................................................................... 45
Table 2 Prohibited and Allowed Therapies ............................................................. 49
Table 3 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safety Events ................................................................ .66
Table 4 Plasma Sample Collection Schedule for NHC Concentrations ................. 69
Table 5 Analysis Strategy for Key Efficacy Endpoints .......................................... 82
Table 6 Analysis Strategy for Safety Parameters .................................................... 84
Table 7 Description of Interim Analyses ................................................................ 86
Table 8 Study Power by Percentage Hospitalized/Dying N=1550 participants 
(775 for MK- 4482 800 mg and 775 for placebo), alpha=0.025, 1 -sided ...89
Table 9 Power by Detectable Difference and Standard Deviation Viral RNA 
change from baseline (log10 copies/mL) N=60/group, Œ±=0.025, 1-
sided ........................................................................................................... 90
Table 10 Differences in Incidence of AE Rates Between the 2 Treatment Groups 
That Can be Detected With a ~9 0% Probability (Assuming 2- sided 5% 
Alpha Level with 850 Participants in Each Group) ...................................91
Table 11 Protocol -required Laboratory Assessments ............................................. 102
Table 12 Approximate Whole Blood Volumes (mL) ............................................. 103
06FSHF
07X3DY
PRODUCT: MK-4482  14
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
LIST OF FIGURES
Figure 1 Study Schema and Treatment Plan ............................................................ 18
06FSHF
07X3DY
PRODUCT: MK-4482  15
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 2/3, Randomized, Placebo- Controlled, Double -Blind Clinical Study 
to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non -Hospitalized 
Adults with COVID- 19.
Short Title: MK-4482 Ph 2/3 Study in Non- Hospitalized Adults with COVID -19
Acronym: N/A
MOVe -OUT
Hypotheses, Objectives ,and Endpoints :
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
The following objectives will be evaluated in non- hospitalized p articipants ‚â•18 years of age 
with COVID -19.
Primary Objectives Primary Endpoints
-To evaluate efficacy of MK -4482 compared 
to placebo as assessed by the percentage of 
participants who are hospitalized and/or die 
from randomization through Day 29.
Hypothesis: MK -4482 is superior to placebo 
as assessed by the percentage of participants 
who are hospitalized and/or die through Day 
29.-Hospitalization or death
- To evalua te the safety and tolerability of 
MK-4482 compared to placebo.-Adverse events
-Adverse events leading to discontinuation 
of study intervention
Secondary Objectives Secondary Endpoints
-To evaluate the efficacy of MK -4482 
compared to placebo as assessed by time to 
sustained resolution or improvement, and 
time to progression of each targeted self -
reported sign/symptom of COVID- 19 from 
randomization through Day 29.- COVID- 19 signs/symptoms
06FSHF
07X3DY
PRODUCT: MK-4482  16
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
-To evaluate the efficacy of MK -4482 
compared to placebo as assessed by the odds 
of a more favorable response on the WHO 
11-point ordinal scale on Day 3, EOT, Day 
10, Day 15, and Day 29.-WHO 11 -point scale score
Overall Desig n:
Study Phase Phase 2/Phase 3
Primary Purpose Treatment
Indication COVID- 19
Population Participants ‚â•18 years of age with COVID -19not 
requiring hospitalization
Study Type Interventional
Intervention Model Parallel
This is a multi- sitestudy.
Type of Control Placebo -controlled
Study Blinding Double -blind with in -house blinding
Blinding Roles Participants or Subjects
Investigator
Sponsor
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately 12months from the time the first 
participant (or their legally acceptable representative) 
provides documented informed consent until the last 
participant‚Äôs last study-related contact.
Number of Participant s:
Atotal of ~1850 participants will be randomized in the study.
06FSHF
07X3DY
PRODUCT: MK-4482  17
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Intervention Groups and Duration :
Intervention 
Group sIntervention Group 
NameDrugDose 
StrengthDose 
FrequencyRoute of 
Admin istrationTreatment 
Period
Part 1 ( N~300)
MK-4482 ( 200mg) MK-4482 200mg Q12H Oral 5 days (10 
doses total)
MK-4482 ( 400mg) MK-4482 400mg Q12H Oral 5 days (10 
doses total)
MK-4482 ( 800mg) MK-4482 800mg Q12H Oral 5 days (10 
doses total)
Placebo Placebo 0 mg Q12H Oral 5 days (10 
doses total)
Part 2 ( N~1550 )
MK-4482 MK-4482 800mg Q12H Oral 5 days (10 
doses total)
Placebo Placebo 0 mg Q12H Oral 5 days (10 
doses total)
N=number of participants to be enrolled in each part of the study; Q12H= once every 12 hours .
Total 
Number of 
Intervention 
Groups/ 
ArmsPart 1: 4 groups
Part 2: 2 groups
Duration of 
ParticipationEach participant will be in the study for up to approximately 7month s from 
the time the participant provides documented informed c onsent through the 
final contact. Participants will receive 10 doses of assigned study 
intervention ( administered Q12H ) and will be followed for 28 days after 
randomization. In addition, participants will be contacted at approximately 
7months after the last dose of study intervention .
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee s Yes
Clinical Adjudication Committee No
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this document can be found in Appendix 12.
06FSHF
07X3DY
PRODUCT: MK-4482  18
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
1.2 Schema
The study design is depicted in Figure 1.
Figure 1Study Schema and Treatment Plan
EOT =endoftreatment ; LFU=Late Follow -up Visit; N=total number of participants in each study part; n=number of 
participants per group ; Q12H=administered once every 12 hours.
aEligible participants will have laboratory -confirmed SARS -CoV -2 infection with signs/symptoms attributable to COVID -
19 for ‚â§7 days inPart 1 and ‚â§5days in Part 2 prior to randomization (Section 5.1). Calculation of the 7-/5- daysymptom 
onset window does not include the date of randomization (Section 5.1) .
bDose selection will be based on Part 1 interim analysis(es) in combination with the totality of data available across the 
MK-4482 clinical program prior to initiating Part 2 (Section 4.3.3 andSection 9.7). 
06FSHF
07X3DY
PRODUCT: MK-4482  19
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
1.3 Schedule of Activities
Study Period Screening Interv ention Follow -up Notes
Visit Number/Title 1 2 3 4 5 6 7 8 9 10
Scheduled Day 
(Window)Screening
(‚â§48hours 
before 
rand.)aDay 
1bDay 2Day 
3cDay 
4EOTDay 10 
(¬±1 
day)Day 15 
(+3 
days)Day 29 
(+3 
days)LFU 
Month 7 
(¬±1 
month )d
Type of Visit C C V/C C V/C C C C C VC = Clinic or At -home visit
V= Virtual visit (when a virtual 
visit is listed, a clinic or home visit 
is not required . Virtual visit s may 
be conducted at the investigator ‚Äôs
discretion)
Administrative Procedures
Informed Consent X
Informed Consent for FBR
(Optional)XInformed consent for FBR should 
be presented at screening, 
however, if delayed , present at 
next possible visit as outlined in 
Appendix 6.
Informed Consent for PBMC 
Collection (Optional)XOnly a subset of participants at 
selected sites
Register Study Visit in IRT X X
Inclusion/Exclusion Criteria XeXf Including review of SARS -CoV -2 
(+) local test resultsg
Participant Identification Card X XRandomization number must be 
added to card at randomization
Medical History X XIncluding day of onset of COVID -
19 signs/symptoms 
Prior/Concomitant Medication 
ReviewX X X X X X X X XIncluding COVID -19 standard of 
care therapies and supportive care
Intervention Randomization XbCOVID- 19 severity categorization 
entered in IRT at randomization 
must be based on values obtained 
on Day 1 prior to randomization
06FSHF
07X3DY
PRODUCT: MK-4482  20
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Study Period Screening Interv ention Follow -up Notes
Visit Number/Title 1 2 3 4 5 6 7 8 9 10
Scheduled Day 
(Window)Screening
(‚â§48hours 
before 
rand.)aDay 
1bDay 2Day 
3cDay 
4EOTDay 10 
(¬±1 
day)Day 15 
(+3 
days)Day 29 
(+3 
days)LFU 
Month 7 
(¬±1 
month )d
Collect/Update Secondary 
Contacts for ParticipantX X X X X
MK-4482 or Placebo 
AdministrationX X X X XAll efforts should be made to 
administer the first dose on Day 1
(randomization) ,but
administration of the first dose 
must bewithin 24 h ours of 
randomization
MK-4482 or Placebo ‚ÄìObserved 
DosingXThe morning dose at EOT will be 
observed to facilitate PK blood 
collection.
Dispense Study Intervention and 
Participant Study SuppliesX Including participant diaries
Completion of Study Medication 
DiaryX X X X X
Completion of MK -4482
Symptom Diary<================= X ==================>Completed daily from Day 1 
through Day 29. Thefirst day of
diary completion should occur 
prior to the first dose of study 
intervention (Section 8.2.5).
Reminders for MK -4482
Symptom Diary CompletionX X X X X X XFollowing EOT, reminders should 
be provided every other day 
through Day 29.
Study Staff Review and 
Collection of Participant‚Äôs Study 
DiariesX X X X XStudy Medication Diary will be 
collected after the last dose of 
study intervention .Completed 
pages of MK -4482 Symptom 
Diary will be collected at all clinic 
or at-home visits.
06FSHF
07X3DY
PRODUCT: MK-4482  21
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Study Period Screening Interv ention Follow -up Notes
Visit Number/Title 1 2 3 4 5 6 7 8 9 10
Scheduled Day 
(Window)Screening
(‚â§48hours 
before 
rand.)aDay 
1bDay 2Day 
3cDay 
4EOTDay 10 
(¬±1 
day)Day 15 
(+3 
days)Day 29 
(+3 
days)LFU 
Month 7 
(¬±1 
month )d
Functional Status Assessment X X X X X XParticipant‚Äôs ability to 
independently perform daily 
activities will be assessed.
Efficacy Procedures
NP (Parts 1 and 2) and OP (Part 1 
only) Swabs X X X X X XBoth NP and OP swabs will be 
collected in Part 1. Only NP swabs 
will be collected in Part 2.
Serum and Plasma for 
Exploratory Research X X X XResearch samples will be stored 
for testing as described in Section 
4.2.5 and Section 8.8.
Serum for Antibody Exploratory 
ResearchX X X X
Respiratory/ Oxygenation Status X X X X X X X XhSpO 2and investigator assessment 
of shortness of breath, and if 
applicable FiO 2, PaO 2and 
supplemental oxygen use.
Hospitalization ,Emergency 
Room, and Other Acute Care 
Visit StatusX X X X X XOnly hospitalization status will be 
collected at LFU (Month 7) visit.
Survival Status X X
Safety Procedures
Full Physical Examination X Including height and weight
Directed Physical Examination X X X X X X
Vital Signs X X X X X X XHeart rate, blood pressure, 
respiratory rate, temperature 
Blood Collection for Local 
Laboratory EvaluationXeLocal laboratory collection 
required unless 
chemistry/hematology results 
within 72 h prior to randomization 
are available
06FSHF
07X3DY
PRODUCT: MK-4482  22
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Study Period Screening Interv ention Follow -up Notes
Visit Number/Title 1 2 3 4 5 6 7 8 9 10
Scheduled Day 
(Window)Screening
(‚â§48hours 
before 
rand.)aDay 
1bDay 2Day 
3cDay 
4EOTDay 10 
(¬±1 
day)Day 15 
(+3 
days)Day 29 
(+3 
days)LFU 
Month 7 
(¬±1 
month )d
Blood Collection for Central 
Laboratory EvaluationX X X X X XIncluding hematology and 
chemistry 
Pregnancy Test ( WOCBP only) XeX
Confirm Contraception 
Requirements (WOCBP and male 
participants)X X X XConfirm participant compliance 
with contraception requirements 
as outlined in inclusion criteria 
and Appendix 5
AE/SAE reviewiX X X X X X X X X X
Pharmacokinetics
PK Plasma Sampling XPart 1: pre -dose;1.5 h post -dose 
Part 2: pre -dose;1.5 h post-dose 
PK PBMC SamplingjXPart 1 (PBMC Cohort Only ): 
Pre-dose, 1.5 h post -dose
AE=adverse event; ALT=alanine aminotransferase; AST=aspartate aminotransferase; COVID -19=coronavirus disease 2019; EOT=End of T reatment (day of last study intervention dose); 
FBR = future biomedical research ; hCG=human chorionic gonadotropin; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human immunodeficiency virus; LFU= Late Fo llow-Up, 
NP=nasopharyngeal; OP=oropharyngeal; PBMC=peripheral blood mononuclear cells; PK=pharmacokinetic; PSV=pregnancy status visit; rand.= randomization; RNA=ribonucleic acid; 
SAE=serious adverse event ;SARS -CoV- 2=severe acute respiratory syndrome coron avirus 2; SpO 2= oxygen saturation; WOCBP=women of childbearing potential.
aScreening and Day 1 (randomization) can be done in same session. Study assessments should not be duplicated if screening and Day 1 (randomization) are completed on the same day.
bAssessments required for COVID -19 severity categorization (Appendix 9) for IRT (vital signs, COVID -19 signs/symptoms assessment, respiratory measures, oxygen therapy, ongoing 
medical history) must be completed and documented on Day 1 prior to callin g IRT in order to randomize. All other Day 1 assessments must be completed on Day 1 prior to first dose of 
study intervention.
cDay 3 assessments should be performed on Day 3, but if circumstances do not support performance of any procedures by study staf f on Day 3, a ¬±24-hour window is allowed. 
dLFU (Month 7) visit is 7 months from the last dose of study intervention.
eThe following local laboratory results must be available for all participants from within 72 h prior to randomization to support determination of eligibility: serum creatinine, platelets, and 
absolute neutrophil count. In participants with reported history of HBV or HCV, ALT and AST must be available from within 72 h ours prior to randomization to support determination 
of eligibility . In WOCBP, a negative local pregnancy test is required within 24 hours of the first dose of study intervention per inclusion criteria. All other inclusion/exclusion criteria 
determination (eg, HIV status) can be based on participant -reported medical history, av ailable medical records, and the most recently available laboratory results for the participant (eg, 
HIV RNA VL).
fConfirm no change in eligibility based on inclusion/exclusion criteria and/or disease severity.
gIf prior results are not available, labora tory confirmation of SARS -CoV-2 infection may be performed at screening to confirm eligibility (Sections 5.1and 8.1.2 ). Results must be 
available prior to randomization.
hRespiratory/Oxygenation Status collection at the LFU visit will be limited. As LFU will be a virtual visit, SpO 2will not be measured. Use of supplemental oxygen will be collected.  
iAEs, SAEs, and other reportable safety events (eg, pregnancy) will be monitored according to Section 8.4.
jA subset of ~50 participants in Part 1 will take part in the PBMC Cohort at selected sites.
06FSHF
07X3DY
	
 	 	

	

 	
		
  
		
5 
	

	 ;&"3 "6 #"& ,5$*1$*X5
Y7 "*0
++	
<$ "1 &
*$(" ,'&"$! &"C5*"!*,C6$)(*"!5')*,# )$1$*&') $1$)/C$ )* C"2
1$*,$ '&,!$ C'"*" 1$*,9	$($ C!1&"5!  "*&)*)# )2"*
7
+
89
53 ).0'-7
+
8!$*,&)$ C2*"#.."7	$ 2')$" 6! '&*!C&"(&5 !#$'
(/)>4" 

		9>$)$ #" )"2))!'&*)$"  )*6*"1*


 #$&&$" '"27
+
8*5"*)!C&"(&&/ !"1*)",  !"'$)!!)
X>"*&!&)*C $%)$" 		Y9>$)$ '*$ C ,#(*"2'  !!)6"*&!6$!
 !1*/&$#$)!)*)# )"5)$" )*$ $##!$), #) #!$'& !2"* 6
22')$1)*5$9
)*,(,*! "27
+
8$/))"(2,&&/, !*)""!9&) ",C#");FE<$ 2')!
$ !$1$!,&=$($)#$&!$&& ;C21*!*/'",C2)$C ,<55*"=$#)&/
E
=5*$ '1*!$;C!/5 /5"=#$<  !E1 '*$)$'&$&& 6$' ' 
$ '&,!*5$*)"*/2$&,*5)$'"'3 !"*#,&)$5&"*C  !/2, ')$" X>,Z9		Y9
*$ $ '*!*$32"*5*"C*$" )"1*!$6$ )$ '*$ CC !"*
5* '"2, !*&/$ C#!$'&'" !$)$" $ !,&)X&*39 )&		Y9(,*! "2
7
+
8=) !)"=)*5,&#" */# $2))$" $ '&,!$ C , *"&"C$''"#5&$')$" 
;C$'#$' !#"**C$')*"3<)*"#(")$''"#5&$')$" !,)"/5*'"C,&(&
))C)*"$ ))$ &!#C !!*#)"&"C$' !"',&*# $2))$" X&"399)&
		YX1$39)&		YX> C9)&		YX>!#  9)&		Y9
.) !*!"2'*)*)# )"27
+
8$*5$!&/1"&1$ C ! &"'&)*)# )C,$!&$ 
'" )$ ,)"(,5!)!6$)#*C$ C!)X7
+
8*)# ) ,$!&$  &		Y
X-$#*G9)&		YX>"*&!&)*C $%)$" 		Y9# !$1$*$  )$1$*&C )
55*"1!(/).+2"*$ )*1 ", )*)# )"27
+
8 $ 5 )$ )*H,$*$ C
"5$)&$%)$" X9.9*'*$($ C
 2"*#)$" 		
Y9"2*# !$1$*2"*))*)# )"2
5)$ )6$)5 ,#" $*H,$*$ C,55&# )&"=/C &"* '$1!'" !$)$" &
#*3)$ C,)"*$%)$" (/)0,*"5 "##$$" X-$C&?94 9)&		Y94"61*
)**#$  !2"* "*&&/($"1$&(&  )$1$*& C )2 "*)*)# )"27
+
89
	 $ "1&!*,C' !$!)6$)!#" )*)!')$1$)/C$  ).."7	$ 1$)*"
22$''/C$ )'"*" 1$*, $  $#&#"!& !$C(** $*)"1$*&*$) '9
	( C *&&/2 !6&&)"&*)!)" !)$ " C "$ C'&$ $'&),!$9
55 "(?&')-.
)6+)CCI
;'<
	
 	 	

	

 	
		
  
		
)6+)CCI
;'<
	
 	 	

	

 	
		
  
		
)6+)CCI
;'<
	
 	 	@

	

 	
		
  
		
)6+)CCI
;'<
	
 	 	A

	

 	
		
  
		
; 
!"#	
A!

4/5")*&$C !6$)"(G')$1$ )(G')$1 !0 !5"$ ))(&9
2"&&"6$ C"(G')$16$&&(1&,)!$  " "5$)&$%! 5*)$'$5 )O
/*"2C
6$)7
+
89
)6+)CCI
;'<
PRODUCT: MK-4482  28
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Objectives Endpoints
Prima ry
‚Ä¢To evaluate theefficacy of MK -4482
compared to placebo as assessed by the 
percent ageof participants who are
hospitalized and/or die from randomization 
through Day 2 9.
Hypothesis : MK -4482 is superior to placebo 
as assessed by the percent ageof participants 
who are hospitalized and/or die through 
Day 2 9.‚Ä¢Hospitalization or death
‚Ä¢To evaluate the safety and tolerability of MK -
4482 compared to placebo.‚Ä¢Adverse events
‚Ä¢Adverse events leading to 
discontinuation of study 
intervention
Secondary
‚Ä¢To evaluate the efficacy of MK -4482 
compared to placebo as assessed by time to 
sustained resolution or improvement , and
time to progression of each targeted self -
reported sign /symptom of COVID -19 from 
randomization through Day 29.‚Ä¢COVID- 19signs/ symptoms
‚Ä¢To evaluate the efficacy of MK -4482 
compared to placebo as assessed by the odds 
of a more favorable response on the WHO 11-
point ordinal scale on Day 3, EOT, Day 10, 
Day 15, and Day 29.‚Ä¢WHO 11-point scale score
Tertiary/Exploratory
‚Ä¢To evaluate the efficacy of MK -4482 
compared to placebo as assessed by the 
percentage of participants who have any acute 
care visit from randomization through 
Day 29 .‚Ä¢Acute care visit
06FSHF
07X3DY
PRODUCT: MK-4482  29
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Objectives Endpoints
‚Ä¢To evaluate the efficacy of MK -4482 
compared to placebo as assessed by the 
percentage of participants who have any 
COVID- 19-related acute care visit from 
randomization through Day 29 .‚Ä¢COVID- 19-related acute care visit
‚Ä¢To measure the pharmacokinetics of NHC 
(the parent nucleoside), and NHC -TP (the 
pharmacologically- active triphosphate form) 
in plasma and PBMC collected at various 
timepoints.‚Ä¢Plasma (Part 1 and Part 2) and 
PBMC (Part 1 ) Pharmacokinetic 
concentration (eg, Ctrough)   
‚Ä¢To evaluate the antiviral activity of MK -4482 
compared to placebo as assessed by the 
change from baseline in SARS -CoV -2 RNA
titerand percent ageof participants with 
undetectable SARS -CoV -2 RNA in 
nasopharyngeal and /ororopharyngeal swabs 
separately at var ious timepoints.‚Ä¢SARS -CoV -2 RNA
‚Ä¢To evaluate the effect of MK -4482 on viral 
RNA mutation rate and detection of 
treatment -emergent sequence variants as 
assessed by comparison of gene sequencing in 
virus isolated at baseline and post-baseline in 
samples with evaluable SARS- CoV -2 RNA . ‚Ä¢Viral RNA sequences 
‚Ä¢To evaluate the antiviral activity of MK -4482 
compared to placebo as assessed by the 
percentage of participants with undetectable 
infectious SARS -CoV -2 in nasopharyng eal 
swabs at various time points .‚Ä¢Infectious SARS -CoV -2 
4 S TUDY DESIGN
4.1 Overall Design
This study (MOVe -OUT) is a Phase 2/3, randomized, placebo- controlled, double -blind, 
multi- site study to evaluate the efficacy, safety, and PK of MK -4482 (also known as 
molnupiravir [pINN] orMOV ) administered to non -hospitalized participants ‚â•18 years of 
age with laboratory- confirmed COVID- 19 and symptom onset within 5 days prior to 
randomization.
06FSHF
07X3DY
PRODUCT: MK-4482  30
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
In Part 1, participants with mild COVID -19 and at least 75% of participants overall must 
have at least 1 characteristic or underlying medical condition associated with be ing at 
increased risk for severe illness from COVID -19(Appendix 10). In addition, e nrollment of 
participants with moderate COVID- 19 will be limited to approximately 5 0%of total planned 
sample size .
In Part 2, all participants must have at least 1 charact eristic or underlying medical condition 
associated with being at increased risk for severe illness from COVID -19 (Appendix 10).
Age is a risk factor independent of other health conditions, so while there is no minimal 
enrollment for participants >60 years of age, every effort should be made to maximize 
enrollment of this age group .
Participants will receive assigned study intervention by oral administration Q12 Hfor 5 days, 
for a total of 10 doses and be followed for 28 days afte r randomization (through Day 29) .In 
addition, participants will be contacted approximately 7 months after the last dose of study 
intervention.
Part 1 ( Phase 2 - Dose Ranging )
Approximately 30 0 participants will be randomized in a 1:1:1:1 ratio (stratified per Section 
6.3.2) into 1 of the following 4 blinded treatment groups (Figure 1):
ÔÇ∑MK-4482 200 mg(n~75)
ÔÇ∑MK-4482 400 mg (n ~75)
ÔÇ∑MK-4482 800 mg (n ~75)
ÔÇ∑Placebo (n~75)
The final dose selection will be based on analysis(es) of data from this study in combination 
with the totality of data available across the MK -4482 clinical program prior to initiating 
Part2 (Section 4.3.3 and Section 9.7) .
Part 2 ( Phase 3 - Evaluation of Selected Dose)
In Part 2, ~1550 participants will be randomized in a 1:1ratio (stratified per Section 6.3.2) to 
receive either of MK -4482 800mg or placebo ( Figure 1 ).Aninterim efficacy analysi s is 
planned in Part 2 (Section 9.7).
Throughout the Study (Parts 1 and 2)
Participants may receive Sponsor -designated s tandard of c aretreatment ofCOVID- 19, as 
appropriate ,in addition to study intervention (Section 6.5). All participants will have plasma 
sample collection for PK assessments. The protocol will aim to enroll a subset of
~50participants in an optional PBMC Cohort (Part 1) at select sites with capa bility to isolate 
PBMCs.
06FSHF
07X3DY
PRODUCT: MK-4482  31
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Participants will be provided with a Study Medication Diary (dose administration will be 
recorded daily for 5 days) and a S ymptom Diary (presence/absence and severity of a solicited 
list of signs/symptoms attributable to COVID -19 will be recorded daily for 29 days). In the 
event of hospitalization, all evaluations outlined in the SoA (Section 1.3) should be 
performed as feasible (deta ils in Section 8.2.3). 
All participants will have a virtual visit approximately 7months following the last dose of 
study intervention (LFU visit) to assess survival status, current supplemental oxygen use ,and 
to document any hospitalizations , according to the SoA (Section 1.3).
The results of interim analyses will be reviewed by an independent eDMC (Parts 1 and 2)
and Sponsor siDMC (Part 1 only) (Section 9.7 and Section 10.1.4). In addition, participant
safety will be monitored by theindependent eDMC through periodic review of accumulating
data (received from an unblinded statistician) as detailed in the eDMC charter .
Specific procedures to be performed during the study, as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
Therandomized, placebo -controlled, double -blind superiority design and the selected 
endpoints of the study areconsistent with regulatory guidance and areconsidered appropriate 
for non-hospitalized adult participants with COVID -19[Food and Drug Administration 
2020] [European Commission 2020] .
The primary outcome is assessed through Day 29 (for 28 days of follow- up from 
randomization )to allow for a sufficient duration to reliably assess the safety and 
effectiveness of a 5 -day treatment course of MK -4482 . This duration is considered 
appropriate to capture important clinically relevant efficacy endpoints (eg, hospitalization, 
death ). A 28 -day follow -up period also aligns with the ACTT -1 Study Group‚Äôs evaluation of 
remdesivir for treatment of COVID -19 in hospitalized adults [Beigel, J. H., et al 2020] .
4.2.1 Rationale for Endpoints
4.2.1.1 Efficacy Endpoints
4.2.1.1.1 Primary Clinical Endpoint
The primary endpoint selected in this study ishospitalization or death. A ll-cause 
hospitalization ( ‚â•24 hours of acute care in a hospital or similar acute care facility, including 
emergency r ooms or facilities c reated to address hospitalization needs during the COVID- 19 
pandemic ) or death is intended to demonstrate the efficacy of MK -4482 relative to placebo 
using a clinically meaningful aspect of the disease that is relevant to non-hospitalized 
patients with COV ID-19. This endpoint combines key clinical outcomes of interest, aiming 
todemonstrat ethe efficacy of study intervention in reduc ingserious complications of 
COVID- 19.
06FSHF
07X3DY
PRODUCT: MK-4482  32
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
4.2.1.1.2 Secondary Endpoints
To further evaluate efficacy of MK -4482 administered to non-hospitalized participants , 
additional relevant endpoints were selected, which are based on signs/ symptoms associated 
with COVID -19 infection and other aspects of clinical progression of disease that are 
expected to improve with effective anti viral therapy: 
ÔÇ∑Time to sustained resolution or improvement , and time to progression of each
targeted self -reported sign /symptom attributable to COVID -19 (Section 9.6.1) as 
reported by the participant through Day 29.
ÔÇ∑WHO 11-point ordinal outcome scale to assess COVI D-19-associated symptom 
burden (severity and duration), hospitalization, and death through Day 2 9
(Appendix 8).
4.2.1.2 Safety Endpoints
Safety evaluations include AEcollection, physical examinations (including vital signs) ,and 
laboratory tests (hematology and chemistry) performed per the SoA (Section 1.3). AEs will 
be evaluated and assessed according to the guidelines in Section 8.4 and Appendix 3. 
Participants may be asked to return for unscheduled visits to perform additi onal safety 
monitoring.
In preclinical studies, mild hematologic toxicity was noted on Day 7 , which progressed to 
more severe pancytopenia after 14 -21 days of continuous exposure at 0.4-fold the NHC 
exposure at the 800 mg Q12H human dose of MK- 4482. These changes were fully reversible 
(Section 2.3 ). Based on available unblinded data from the clinical development program for 
MK-4482, no clinically significant abnormalities in hematological laboratory tests as a 
function of either dose or treatment have been observed. However, based on pre clinical
findings ,participants in this study will be monitored for any signs of bone marrow toxicity, 
including monitoring of CBC andplatelets after initiating study intervention. 
In preclinical studies, e levated liver enzymes were noted in ratsat 62- fold the NHC exposure 
at 800 mg Q12H and noted in dogs at 19- fold the NHC exposure at 800 mgQ12H .Based on 
available unblinded data from the clinical development program for MK -4482 , no clinically 
significant abnormalities in liver parameters as a function of either dose or treatment were 
noted . However, elevated LFTs with a DILI pattern will be considered an ECI and closely 
monitored. 
No test -article related pathology changes in the pancreas to indicate pan creatic toxicity were 
noted in nonclinical studies and lipase and amylase were not measured. Transient elevations 
of serum lipase were observed at least 3 days after last dose in the P hase 1 study; the 
incidence of these elevations was comparable between r ecipients of MK- 4482 and placebo . 
The occurrence and magnitude of these elevations did not appear to be dose related, and they 
were not associated with abdominal/gastrointestinal symptoms. However, as asymptomatic 
lipase elevations and clinical pancreatiti s have been associated with some nucleoside analogs, 
changes in amylase or lipase were considered an ECI and closely monitored in Part 1 of this 
06FSHF
07X3DY
PRODUCT: MK-4482  33
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
study and MK -4482- 001. Based on available unblinded data from the clinical development 
program for MK -4482, no clinically significant abnormalities in amylase or lipase as a 
function of either dose or treatment were noted . Thus due to the lack of preclinical findings 
and no trend noted in MK -4482 studies to date , elevated amylase, or lipase >3 Xthe upper 
limit of normal isnot considered an ECI for Part 2.
4.2.1.3 Pharmacokinetic Endpoints
Blood samples for PK assessment and concentrations of the MK- 4482 nucleoside and 
triphosphate will be collected from all participants as described in the SoA (Section 1.3) and 
Secti on 8.6. A s appropriate, PK -efficacy and PK -AE relationships for MK -4482 will also be 
evaluated. In Part 1, PBMC PK parameters (eg, Ctrough)will be estimated. In Part 2, plasma 
PK parameters (eg, C trough)will be summarized and in Parts 1 and 2, PK plasma parameters 
will be measured. PBMC PK samples will be used to evaluate the concentration of 
intracellular NHC- triphosphate, the active moiety resulting from dosing of MK -4482. 
Intracellular PBMC concentrations can help expla inthe relationship between MK -4482 dose 
and efficacy and safety.
4.2.1.4 Virology Endpoints
The study will evaluate SARS -CoV -2 RNA and infectious virus to assess the impact of 
MK-4482 on various aspects of SARS -CoV -2 viral dynamics.
Reducing SARS -CoV -2VLanderadicating the virus are essential to recovery and has 
important implications for transmission and infection control strategies. The mechanism of 
antiviral activity of MK -4482 is viral error catastrophe predicated on increasing the viral 
mutation rate beyond a biologically -tolerable threshold resulting in impairment of viral 
fitness leading to viral elimination . These e ndpoints are aimed at assess ingtheantiviral 
activity of MK -4482 as well as evaluat ingthe rate of viral mutagenesis with respect to 
MK-4482 treatment.
4.2.1.5 Future Biomedical Research
The Sponsor may provide samples , asdescribed in Section 8. 9,for which consent was 
provided during this study, to researchers including additional third parties (eg, a university 
investigator).
Such research is to address emergent questions not described in the protocol and will only be 
conducted on specimens as described in Section 8. 9. Specimens will only be provided from 
appropriately consented participants. The objective of providing the specimens for FBR is to 
explore and identify biomarkers that inform the scientific understanding of diseases and/or 
their therapeutic treatments. The overarching goal is to use such information to develop safer, 
more ef fective drugs/vaccines, and/or to ensure that participants receive the correct dose of 
the correct drug/vaccine at the correct time. The details of FBR research are presented in 
Appendix 6.
06FSHF
07X3DY
PRODUCT: MK-4482  34
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
4.2.2 Rationale for the Use of Comparator/ Placebo
This study will be pla cebo -controlled in order to avoid bias in the collection/evaluation of 
data during study conduct and to assess whether any observed effects are treatment -related or 
an impact of study participation. Participants may receive Sponsor -designated standard of 
care treatment (Section 6.5) , as appropriate, in addition to study intervention (MK- 4482 or 
matching placebo).
There arecurrently no orally available direct -acting antivirals approved for the treatment of 
COVID- 19to serve as an active comparator, therefore placebo will be used. 
4.2.3 Rationale for the Selected Participant Population
The rationale for the participant population selected for this study is as follows:
ÔÇ∑Participants with mild andmoderate COVID -19: Participants with mild and
moderate COVID- 19 (Appendix 9) are typically managed outside of the hospital and 
may benefit from administration of MK -4482 [Food and Drug Administration 2020] . 
Participants with severe and critical COVID -19 at randomization are excluded 
because they are expected to require hospitalization and would be out of scope for 
this study.
ÔÇ∑Participants at increased risk for severe illness from COVID -19: Certain 
characteristics or underlying medical conditions (Appendix 10) have been identified
that place patients at increased risk for severe illness from COVID- 19, which may 
result in hospitalization, ICU-level care , ventilatory support , or death . This study 
focus eson higher risk non -hospitalized participants who may benefit from MK -4482, 
aiming to reduce the number of participants who develop severe illness from 
COVID- 19 and need to be hospitalized or die. Thus, all participants must have at least 
1 characteristi c or underlying medical condition associated with being at increased 
risk for severe illness from COVID -19to ensure the drug is being evaluated in the 
non-hospitalized population at higher risk.
ÔÇ∑Participants with signs/symptoms attributable to COVID -19 for ‚â§5 days: Eligible
participants must have COVID -19 sign s/symptom sonset no more than 5days prior to 
randomization. SARS -CoV -2 VLs are highest early in the course of disease, present 
1-2 days prior to symptom onset, and persist for 7 -12 days in moderate cases and up 
to 2 weeks in severe cases [Cevik, M., et al 2020] . Based on the viral kinetics of 
SARS -CoV -2 and the mechanism of action of MK -4482 (inhibition of viral 
replication), study participants m ust have signs/symptoms attributable to COVID- 19 
for ‚â§5days prior to randomization; a ll efforts should be made to administer the first 
dose on Day 1 (randomization), but administration of the first dose must occur within 
24 hours of randomization .Further more, as the host inflammatory response 
predominates during later stages of disease as COVID -19 progresses, treatment with 
antiviral therapy is likely to have a greater benefit with early treatment rather than 
delayed treatment > 5days after signs /symptoms onset , especially in the non-
06FSHF
07X3DY
PRODUCT: MK-4482  35
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
hospitalized setting wherein patients are often earlier in the course of their disease 
and intervention can occur sooner than in the hospital setting.
4.2.4 Rationale for Collection of Racial , Ethnic , and Gender Identity Data
The differential effect on the safety and efficacy based on any demographic parameter, 
including race , ethnicity, or gender identity, cannot be predicted when evaluating a new 
investigational drug. Therefore, it is important to collect race ,ethnicity, and gender identity
data to ensure that there is not a differential effect based on these parameters . These data will 
also provide assurance that the results observed in the clinical study will be representative of 
the drug‚Äôs use in a broader patient populati on, including transgender people whose gender 
identities and/or expressions differ from the sex assigned to them at birth . Also, subgroup 
analyses on race and ethnicity will be performed to better understand how these parameters 
may influence clinical outc ome and toxicity.
4.2.5 Rationale for Other Exploratory Research Samples
Samples will be collected for other exploratory research. These samples may be utilized to 
perform evaluations related to SARS -CoV -2 and/or COVID- 19(including biomarkers), 
coinfections, or MK-4482 . These samples may be tested during the course of the study or 
after study closure as the field of research evolves .
Blood for exploratory research , all residual material from NP (Parts 1 and 2) and OP (Part 1 
only) swabs, and all residual materia l from blood collections areintended for testing to 
address emergent questions not described elsewhere in the protocol and may be conducted on 
specimens from all participants. The objective of collecting/retaining specimens is to perform 
testing that inform sthe scientific understanding of SARS -CoV -2 and/or COVID -19, 
coinfections , or MK -4482 . 
Exploratory research samples will not be used for human genome testing. Samples may be 
used for testing such as:
‚Ä¢Determining if antibodies to SARS -CoV -2 are present and capable of neutralizing the 
virus
‚Ä¢Measuring the quantity of infectious, replication -competent virus present in samples
‚Ä¢Assessing if participants are co infected with other respiratory pathogens 
‚Ä¢Viral genome sequencing for determination of viral genotype (Clade) and detection of 
novel treatment -emergent variants. 
Evaluating the presence of antibodies to SARS -CoV -2 and their ability to neutralize the virus 
is critical to understanding the body‚Äôs i mmune response to infection with SARS -CoV -2. 
COVID- 19 severity may be correlated with the timing and quantity of antibody production 
based on participant characteristics such as gender. Antibody -dependent enhancement of 
disease has also been identified as a potential rationale for increased disease severity in some 
06FSHF
07X3DY
PRODUCT: MK-4482  36
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
individuals [Ovsyannikova, I. G., et al 2020] . Antibody -related testing of participant samples 
may be used to evaluate if participants receiving MK -4482 or placebo have varying 
production of SARS -CoV -2 antibodies.
Molecular tests detecting viral RNA are capable of quantif ying VLs in clinical samples ; 
however, these molecular tests are incapable of quantifying infectious , replication -competent
SARS -CoV -2[Mendoza, E. J., et al 2020] . The quantity of infectious, replication- competent 
virus in participant samples may be measured via cell-based infect ionassays. One such assay 
is the plaque assay , which quantif iesviral titer (plaque forming unit) by counting the number 
of plaques formed in cell culture upon infection with serial dilutions of a virus specimen
[Mendoza, E. J., et al 2020] . Plaque assay sperformed in Vero cells will be used to assess the 
impact of MK -4482 on the presence and/or titer of replication- competent virus in NPswab 
samples .
Coinfection with other respiratory pathogens has been reported to occur to varying degrees in 
patients infected with SAR S-CoV -2 and may be as high as 50% in non- survivors [Kim, D., et 
al2020] [D'Abramo, A., et al 2020] [Wu, X., et al 2020] [Lai, C. C., et al 2020] . Participants 
enrolled may be coinfected wit h other pathogens. NHC has demonstrated broad antiviral 
activity against other RNA viruses including respiratory pathogens (eg, influenza, RSV, etc.) 
that have been observed in coinfection with SARS -CoV -2 [Lai, C. C., et al 2020] . Based on 
the potential for coinfection with other respiratory viruses, the potential impact of coinfection 
on outcomes, and the preclinical evidence of NHC antiviral activity against some of these 
pathogens, identifying participants coi nfected with other respiratory viruses may be used to 
explore the impact of MK -4482 on coinfections. 
Since initial identification of the original SARS -CoV -2 genotype, multiple viral variants of 
concern have been identified and continue to circulate worldw ide. Viral genome sequencing 
will be used to determine the SARS -CoV -2 genotype detected in study participants. 
Genotype data may be used to assess the impact of viral genotype on MK -4482 efficacy. In 
addition, viral sequence data may be used to identify tr eatment -emergent variants that could 
potentially impact vaccine or antiviral drug efficacy.
4.3 Justification for Dose
4.3.1 Rationale for Dos ing Duration
Three doses of MK- 4482 (administered every 12 hours) were sufficient to demonstrate 
efficacy in a ferret model of influenza. However, the duration of dosing of MK- 4482 required 
to achieve efficacy against SARS -CoV -2 in humans is unknown. The planned treatment 
regimen of 5 days in this study is consistent with other acute anti viral treatments such as 
oseltamivir for influenza and is supported by non clinical and clinical safety data for 
MK-4482. 
In a 28 -day toxicity study of MK -4482 at 17 mg/kg/day (0.4-fold relative to the clinical NHC 
exposure at 800 mg Q12H) administered in dogs, reversible hematology changes consistent 
with bone marrow toxicity became apparent at Day 7 with increasing severity from Day 14 
onward. Dosing of MK -4482 up to 800mg Q12H for 5.5 days has been generally well -
06FSHF
07X3DY
PRODUCT: MK-4482  37
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
tolerated by healthy participants in aPhase 1 clinical study; no cl inically meaningful trends 
have been observed for changes in clinical laboratory values, vital signs, or ECGs as a 
function of dose or treatment. Specifically, there were no clinically significant abnormalities 
observed in the hematological laboratory tests. Furthermore, unblinded data obtained from 
participants treated in the Phase 2 program indicate that MK -4482 has been generally well -
tolerated across all doses studied.
Overall, preclinical and Phase 1 and 2 clinical observations to date support a ~5 -daydosing 
duration for MK- 4482.
4.3.2 Dose Range for Part 1 (Phase 2)
The dose range planned for Part 1 was derived based on the anticipated clinically efficacious 
dose range predicted from nonclinical animal models. MK -4482 demonstrated efficacy in 
ferrets (a rel evant species for virus challenge models) against H1N1 at 7 mg/kg BID (in vitro 
data demonstrate dsimilar MK -4482 potency against H1N1 and SARS -CoV -2). The 
efficacious 7 mg/kg BID dose in ferrets scales to ~100 mg BID in humans, based on body 
surface area (assuming a 70 kg adult). This is a common scaling approach used for 
nucleosides, with some variability in the scaling of the prodrug to active triphosphate 
conversion from animals to humans.
Part 1 of the study includes evaluation of the 200mg BID dose , as it is within the efficacious 
dose range predicted from animals, and includes higher doses in order to characterize the 
dose-and exposure -response relationship for MK- 4482. The highest dose of 800 mg BID has 
a predicted steady -state mean plasma AUC 0-12 exposure of ~32 ¬µM*hr, which is 2 .4-fold 
below the mean plasma AUC 0-12exposure at the highest single dose evaluated in adults of 
1600 mg. 
4.3.3 Dose Selection for Part 2 (Phase 3)
The MK -4482 dose of 800 mg Q12H for 5 days was selected for Part 2 of this study. The 
dose selection was based on data from IA2 as well as the totality of available safety , 
virology, PK, and clinical data from the MK -4482 program.
Enrollment of hospitalized participants in Part 1 (Phase 2) of MK -4482- 001 has been 
completed. A total of 304 participants were randomized into 4 intervention groups: 
75participants in the MK -4482 200 mg group, 75 participants in the MK -4482 400 mg
group, 76 participants in the MK -4482 800 mggroup, and 78 participants in the placebo 
group. MK -4482 was generally well tolerated; the proportion of participants with AEs, drug-
related AEs, SAEs, and AEs leading to study intervention discontinuation during the 
protocol -specified AE safety follow -up period were comparable across the intervention
groups, with no apparent dose effect observed. There were no clinically significant 
differences in laboratory findings that met predetermined criteria, worsening Grade 3 or 4, in 
recipients of MK- 4482 (any dose) compared with placebo. There was a numerica lly higher 
number of AEs resulting in death in participants treated with MK -4482 (14/218, 6.4%) 
compared with placebo (2/75, 2.7%) in P001. There was no apparent dose effect based on the 
incidence of death in each of the MK -4482 groups. None of the deaths was considered 
06FSHF
07X3DY
PRODUCT: MK-4482  38
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
related to study intervention by the investigator. The eDMC noted that there was no 
clustering of specific AEs resulting in death and concluded that no safety signals were seen at 
any MK -4482 dose. The most common AE resulting in death was C OVID -19 and most 
deaths were associated with complications of COVID -19 (including pneumonia, sepsis, or 
thrombosis) or secondary bacterial infections. Most deaths occurred in participants who had 
severe COVID- 19 at baseline, were >60 years of age, had unde rlying comorbidities, and/or 
had duration of symptoms >5 days prior to randomization.
Enrollment of Part 1 (Phase 2) of this study (MK -4482- 002) has been completed. A total of 
302 participants were randomized into 4 intervention groups: 75 participants in the MK -4482 
200 mg group, 77 participants in the MK -4482 400 mg group, 76 participants in the 
MK-4482 800 mggroup, and 74 participants in the placebo group . MK-4482 was well 
tolerated in non- hospitalized participants in MK -4482- 002. The proportion of participants 
with AEs, drug -related AEs, SAEs, AEs leading to death, and AEs leading to study 
intervention discontinuation during the protocol -specified AE safety follow -up period were 
comparable across the intervention groups, with no apparent dose effect observed. No ECIs 
were reported and there were no clinically meaningful abnormalities in hematological, 
pancreatic, or hepatic parameters as a function of either dose or treatment.
The eDMC review of unblinded IA2 data from MK -4482- 001 and MK -4482 -002 concluded 
that there were no safety signals seen at any dose, and no dose -limiting toxicity was observed 
at the highest dose (800 mg). Furthermo re, MK-4482 has been generally well -tolerated in 
other studies in the MK -4482 program at all doses studied with no dose -limiting toxicity 
observed at the highest dose (800 mg).
Virology data from IA2 in the MK -4482 program (MK- 4482- 001, MK -4482 -002, and 
MK-4482- 006) show that treatme nt with MK -4482 reduces the SARS -CoV -2 VL compared 
with placebo (based on change from baseline, slope of decline, and greater proportion of 
participants with a VL below the limit of quantitation within 15 or 29 days ) in non -
hospitalized participants enrolled in MK -4482- 002 and participants with symptom onset
‚â§5days in both MK -4482- 001 and MK- 4482- 002. The exposure -response analyses for 
various virologic endpoints based on MK- 4482- 001 and MK -4482- 002suggest that the 
800mg Q12H dose provides a larger magnitude of virologic effect compared to 200 and 
400mg Q12H and is near the plateau of the dose -response curve. In addition, consistent with 
the proposed mechanism of action of MK -4482 of viral error catastrophe, the highest 
percentage of mutations in viral RNA post -treatment at Day 5 were observed in the 800 mg 
Q12H intervention group from MK -4482- 001 and MK -4482- 002.
Evaluation of the primary clinical efficacy endpoint for MK -4482- 002showed that 11 of 299 
participants were hospitalized through Day 29 (including 1 participant treated with placebo 
who died) ; ~3% of participants in the MK-4482 intervention groups were hospitalized or 
died through Day 29 (compared to ~5% in the placebo group ). All hospitalized participants 
had at least 1 risk factor for severe illness from COVID- 19 including but not limited to 
obesity (n=8), >60 years of age (n=5), and diabetes (n=5). Protocol -specified subgroup 
analyses for the primary endpoint indicated potential clinical benefit from treatment with 
MK-4482early in the course of disease (ie, symptom onset ‚â§5 days prior to the day of 
06FSHF
07X3DY
PRODUCT: MK-4482  39
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
randomization) as well as in individuals with risk factors for severe illness from COVID -19, 
including age >60 years . This trend is further supported by exposure -response ana lyses for 
the endpoint of hospitalization which suggest a trend of an increased clinical effect at 
MK-4482 800 mg Q12H dose over placebo or lower MK-4482 doses. 
Based on the totality of the observed safety profile and virologic data in the MK -4482
program, and trends in clinical efficacy in MK -4482 -002, the 800 mg Q12H dose was 
selected as the dose for further evaluation in Phase 3 . 
4.4 Beginning and End ofStudy Definition
The overall study begins when the first participant (or their legally acceptable representative) 
provides documented informed consent. The overall study ends when the last participant 
completes the last study -related contact, withdraws consent, or is lost to f ollow -up (ie, the 
participant is unable to be contacted by the investigator) .
4.4.1 Clinical Criteria f orEarly Study Termination
The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population 
as a whole is unacceptable. In addition, further recruitment in the study or at (a)particular 
study site(s) may be stopped due to insufficient compliance with the protocol, GCP, and/or 
other applicable r egulatory requirements, procedure -related problems or the number of 
discontinuations for administrative reasons is too high .Early study termination may also be 
considered after review of accumulating efficacy and safety data by the eDMC (Section 9.7) .
5 STUDY POPULATION
Male/ female non -hospitalized participants ‚â•18 year sof age with COVID- 19 will be enrolled 
in this study.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study if the participant:
Type of Participant and Disease Characteristics
1.Hasdocumentation of l aboratory- confirmed SARS -CoV -2 infection with sample 
collection ‚â§5days prior to the day of randomization .
Note: PCR is the preferred method; however, w ith evolving approaches to laboratory 
confirmation of SARS -CoV-2 infection, other molecular or antigen tests that detect viral 
RNA or protein are allowed if authorized for use in the country .Serological tests that 
detect host antibodies generated in response to recent or prior infection are not allowed.
06FSHF
07X3DY
PRODUCT: MK-4482  40
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
2.Hadinitial onset of signs/symptoms attributable to COVID -19 for ‚â§5days prior to the 
day of randomization and at least 1 of the following signs/symptom s attributable to 
COVID- 19 on the day of randomization (Appendix 9) : 
ÔÇ∑Cough
ÔÇ∑Sore throat
ÔÇ∑Nasal congestion
ÔÇ∑Runny nose
ÔÇ∑Shortness of breath or difficulty breathing with exertion
ÔÇ∑Muscle or body aches
ÔÇ∑Fatigue 
ÔÇ∑Fever > 38.0‚ó¶C
ÔÇ∑Chills
ÔÇ∑Headache
ÔÇ∑Nausea
ÔÇ∑Vomiting
ÔÇ∑Diarrhea
ÔÇ∑Loss of smell
ÔÇ∑Loss of taste
3.Has mild or moderate COVID -19(refer to Appendix 9 to det ermine disease severity at 
randomization).
4.Hasat least 1 characteristic or underlying medical condition associated with an increased 
risk of severe illness from COVID -19(refer to Appendix 10 to determine if the 
participant has a characteristic or underlying medical condition associated with an 
increased risk of severe illness from COVID- 19).
5.Is willing and able to take oral m edication. 
Demographics
6.Ismale or female ‚â•18years of age, at the time of providing informed consent.
06FSHF
07X3DY
PRODUCT: MK-4482  41
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Male Participants
7.Male participants are eligible to participate if they agree to the following during the 
intervention period and for at least 4 days after the last dose of study intervention:
‚Ä¢Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent 
on a long -term and persistent basis) and agree to remain abstinent
OR
‚Ä¢Must agree to use contraception unless confir med to be azoospermic (vasectomized or 
secondary to medical cause [Appendix 5]) as detailed below:
Agree to use a male condom plus partner use of an additional contraceptive method when 
having penile -vaginal intercourse with a WOCBP who is not currently pr egnant. Note: Men 
with a pregnant or breastfeeding partner must agree to remain abstinent from penile -vaginal 
intercourse or use a male condom during each episode of penile -vaginal penetration.
‚Ä¢Contraceptive use by men should be consistent with local regul ations regarding the 
methods of contraception for those participating in clinical studies.
Female Participants
8.A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies: 
‚Ä¢Is not a WOCBP
OR
‚Ä¢Is a WOCBP and using a contraceptive method that is highly effective (a low user 
dependency method OR a user dependent method in combination with barrier method),
or be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long -term and persistent basis), as described in Appendix 5 for at least 4 
days after the last dose of study intervention. The investigator should evaluate the 
potential for contraceptive method failure (ie, noncompliance, recently initiated) in 
relationship to the first dose of study intervention. 
‚Ä¢A WOCBP must have a negative highly sensi tive pregnancy test ( urine or serum as 
required by local regulations) within 24 hours before the first dose of study intervention.
‚Ä¢Additional requirements for pregnancy testing during and after study intervention are 
located in Section 8.3. 4.
‚Ä¢The investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.
06FSHF
07X3DY
PRODUCT: MK-4482  42
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
‚Ä¢Contraceptive use by women should be consistent with local regulations regardi ng the 
methods of contraception for those participating in clinical studies.
‚Ä¢If contraceptives are interrupted as standard of care management of COV ID-19 patients 
and resumed at a later time point, such as at hospital discharge, then abstinence must be 
practiced for the defined period of back -up contraception per the contraceptive product 
labeling. After this period, contraceptive use must adhere to Appendix 5 .
Informed Consent
9.Participant (or legally acceptable representative) has provide ddocumented informed 
consent /assent for the study. The participant may also provide consent/assent for FBR. 
However, the participant may participate in the study without participating in FBR.
Note: As outlined in the informed consent, patients can only participate in th is study if 1) 
they have chosen not to receive treatment with a SARS- CoV-2 monoclonal antibody(ies) 
and reside in the US or in other countries where SARS- CoV-2 monoclonal antibodies are 
authorized or approved, or 2) reside outside of the US in countries wh ere SARS -CoV-2 
monoclonal antibodies are not authorized or approved .
5.2 Exclusion Criteria
The p articipant must be excluded from the study if the participant:
Medical Conditions
1.Is currently hospitalized or is e xpected to need hospitalization for COVID- 19within 
48hours of randomization .
2.Is on dialysis or has reduced eGFR < 30mL/min/1.73 m2(by the MDRD equation
[Appendix 11] ).
3.Has any of the following condition s:
ÔÇ∑HIV with a recent VL>50 copies /mL (regardless of CD4 count) or an AIDS -defining 
illness in the past 6 months
Note: Participants with HIV may only be enrolled if on a stable antiretroviral therapy
regimen .
ÔÇ∑Aneutrophilic granulocyte absolute count <500/mm3
4.Has a history of HBV or HCV infection with any of the following: 
ÔÇ∑Cirrhosis 
ÔÇ∑End- stage liver disease
06FSHF
07X3DY
PRODUCT: MK-4482  43
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
ÔÇ∑Hepatocellular carcinoma
ÔÇ∑AST and/or ALT >3X upper limit of normal at screening
5.Has a platelet count < 100,000/ ¬µL or received a platelet transfusion in the 5days prior to 
randomization.
6.Has hypersensitivity or other contraindication to any of the components of the study 
interventions as determined by the investigator.
7.Has a ny condition for which, in the opinion of the investigator, participation would not be 
in the best interest of the participant or that could prevent, limit, or confound the 
protocol -specified assessments including but not limited to :
ÔÇ∑Participants who are n ot expected to survive longer than 48hours after 
randomization, or
ÔÇ∑Participants with a recent history of mechanical ventilation, or 
ÔÇ∑Participants with conditions that could limit gastrointestinal absorption of capsule 
contents .
Prior/Concomitant Therapy
8.Is taking or is anticipated to require any prohibited therapies as outlined in Section 6.5.
Prior/Concurrent Clinical Study Experience
9.Is unwilling to abstain from participating in another interventional clinical study through 
Day 29 with an investigational compound or device , including those for COVID -19
therapeutics.  
Diagnostic Assessments
Not applicable.
Other Exclusions
10.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
5.3 Lifestyle Considerations
There are no lifestyle restrictions for the study .
06FSHF
07X3DY
PRODUCT: MK-4482  44
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequen tlyrandomized in the study. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. Minimal 
information includes demography, screen failure details, eligibility criteria, and any AEs or 
SAEs meeting reporting requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who discontinues from study intervent ionOR withdraws from the stud ywill 
not be replaced.
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study participant according to 
the study protocol .
Clinical supplie s (study intervention[s] provided by the Sponsor )will be packaged to support 
enrollment . Clinical supplies will be affixed with a clinical label in accordance with 
regulatory requirement s.
6.1 Study Interventio n(s) Administered
The study intervention(s) to be used in this study are outlined inTable 1 .
06FSHF
07X3DY
PRODUCT: MK-4482  45
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Table 1 Study Intervention s
Arm 
NameArm TypeIntervention 
NameInter -
vention 
TypeDose 
Formu -
lationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationRegimen/
Treatment 
PeriodUseIMP/
NIMPSourcing
MK-
4482Experi -
mentalMK-4482 Drug Capsule 200mg Part 1: 
200mg, 
400mg, 
800mg; 
Part 2 800 mgOral Q12H 5 days 
(10 doses 
total)Experi -
mentalIMP Central
Placebo Placebo 
ComparatorPlacebo 
Matching 
MK-4482Drug Capsule 0 mg Part 1: N/A 
Part 2: N/AOral Q12H 5 days 
(10 doses 
total)Placebo IMP Central
N/A= not applicable; Q12H= every 12 hours.
The classification of Investigational Medicinal Product (IMP) and Non -Investigational Medicinal Product (NIMP) in this table is based on guidance issued by the European 
Commission and applies to countries in the European Economic Area (EEA). Country differences with respect to the definition /classification of IMP/NIMP may exist. In these 
circumstances, local legislation is followed.
06FSHF
07X3DY
PRODUCT: MK-4482  46
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
All supplies indicated in Table 1 will be provided per the "Sourcing" column depending upon 
local country operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/bat ch number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc.).
Refer to Section 8.1.8 for details regarding administration of the study intervention.
6.2 Preparation/Handling/Stora ge/Accountability
6.2.1 Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose to each participant. T he rationale for selection of doses to be used 
in this study is provided in Section 4.3.
6.2.2 Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received, and any discrepancies are 
reported and resolved before use of the study intervention .
Only participants enrolled in the study may receive study intervention, and only authorized 
site staff may supply or administer study intervention. All study interventions must be stored 
in a secure, environmentally controlle d, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
docu mented.
The study site is responsible for recording the lot number, manufacturer, and expiry date for 
any locally purchased product (if applicable) as per local guidelines unless otherwise 
instructed by the Sponsor.
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations .
06FSHF
07X3DY
PRODUCT: MK-4482  47
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
6.3 Measures to Minimize B ias: Randomization and Blinding
6.3.1 Intervention Assignment
Intervention randomization will occur centrally using an IRT system. In Part 1, there are 
4study intervention arms and participants will be assigned randomly in a 1:1:1:1 ratio to 
MK-4482 200 mg, 400 mg, 800 mg, or placebo. In Part 2, there are 2 study intervention arms 
and participants will be assigned randomly in a 1:1ratio to MK -4482 800 mg or placebo .
6.3.2 Stratification
Intervention randomization will be stratified according to the following factors:
Part 1
1. Time from symptom onset prior to the day of randomization (‚â§5 days, >5 days)
2. At increased risk of severe illness from COVID- 19 (Appendix 10) (yes, no)
Based on the viral kinetics of SARS -CoV -2 and the mechanism of action of MK -4482 , 
treatment with antiviral therapy is likely to have a greater benefit with earl iertreatment 
(‚â§5days) rather than late rtreatment (>5 days). In addition, certain characteristics or 
underlying medical conditions (Appendix 10) have been identified that pl ace patients at 
increased risk for severe illness from COVID -19, which may result in hospitalization, ICU -
level care, ventilatory support, or death. The selection of these criteria as stratification factors 
will help ensure that the treatment groups will b e well balanced within each stratum and the
study results will not be confounded by factors suspected to have a potential impact on a
participant‚Äôs response to study intervention.
Of note, at least 75% of participants overall must have at least 1 characteristic or underlying
medical condition associated with being at increased risk for severe illness from COVID -19
as defined in Appendix 10. In addition, enrollment of participants with moderate COVID -19
(Appendix 9) will be limited to 50% of total p lanned sample size.
Part 2
1. Time from symptom onset prior to the day of randomization (‚â§3 days, >3 days)
Based on updates to inclusion criterion #2 wherein theinitial onset of signs/symptoms 
attributable to COVID -19 was amended to ‚â§5days prior to the day of randomization to target 
participants earlier in their COVID -19 disease course , the time from symptom onset prior to 
the day of randomization stratification factor was amended to ‚â§3 days or >3 days .Based on 
the viral kinetics of SARS -CoV -2 and the mecha nism of action of MK -4482 , treatment with 
antiviral therapy is likely to have a greater benefit with earl iertreatment (‚â§3days) rather than 
latertreatment (> 3days).
Of note, a llparticipants must have at least 1 characteristic or underlying medical condition 
associated with being at increased risk for severe illness from COVID -19as defined in 
06FSHF
07X3DY
PRODUCT: MK-4482  48
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Appendix 10. Age is a risk factor independent of other health conditions, so while there is no 
minimal enrollment for participants >60 years of age, every effort should be made to 
maximize enrollment of this age group.
6.3.3 Blinding
A double -blinding technique with in- house blinding will be used. MK -4482 (all dose levels) 
and placebo will be pack aged identically so the blind is maintained . The participant, the 
investigator, and Sponsor personnel or delegate(s) who are involved in the study intervention
administration or clinical evaluation of the participants are unaware of the intervention 
assignments.
To allow timely completion of dose/exposure -response analyses , select Sponsor internal or 
external personnel will be unblinded while Part 1 of the study is ongoing. No personnel 
directly associated with study conduct will be unblinded (before Part 1 database lock). Before 
granting select personnel access to unblinded Part 1 data, an official memo detailing the 
unblinding procedures and listing the personnel who will have access (before database lock) 
to the unblinded data will be generated per Sponsor SOP. Once all Part 1 participants have 
completed Day 29 (ie, achieved a final status for Day 29 endpoints), the Sponsor will initiate 
database lock/unblinding procedures for this part of the study. 
In addition, a separate ,small, cross- functional unblinded team of Sponsor personnel will also 
be convened for Part 2 of the study with the purpose of supporting preparation and 
submission of applications for emergency use and/or marketing authorizations in the case of 
a positive efficacy finding noted b y the eDMC at IA4. The members of this team will not 
have access to unblinded data until an eDMC decision is reached .Additional details of the 
unblinding plan will be documented in an official memo prior to eDMC review . Sponsor 
personnel responsible for o ngoing blinded data review will remain blinded to data obtained 
from Part 2 participants until all Part 2 participants have completed Day 29 (ie, achieved a 
final status for Day 29 endpoints) except as documented in Section 9.7 ‚Äì Interim Analyses .
6.4 Study In tervention Compliance
When participants self -administer study intervention(s) at home, compliance with study 
intervention will be assessed at each visit. Compliance will be assessed by review of a study 
medication diary during the site visits and documente d in the source documents and CRF. 
A record of the number of capsules dispensed to and taken by each participant must be 
maintained and reconciled with study intervention and compliance records. Intervention start 
and stop dates, including dates for intervention delays and/or dose reductions will also be 
recorded in the CRF. Deviation(s) from the prescribed dosage regimen should be recorded in 
the CRF.
6.5 Concomitant Therapy
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed
during time periods specified by this protocol for t hose medication sor vaccination s. If there 
06FSHF
07X3DY
PRODUCT: MK-4482  49
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
is a clinical indication for any medications or vaccinations specifically prohibited, 
discontinuation from study intervention may be required. The investigator should discuss any 
questions regarding this with the Sponsor Clinical Director . The final decision on any
supportive therapy or vaccination rests with the investigator and/or the participant‚Äô s primary 
physician. However, the decisio n to continue the participant on study intervention requires 
the mutual agreement of the investigator, the Sponsor, and the participant.
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements or other specific categories of interest) that the participant is 
receiving at the time of enrollment or receives during the study must be recorded per data 
entry guidelines.
Prior and concomitant therapies listed as prohibited in Table 2are not permitted for the 
specific time frames listed. Table 2is not comprehensive, and the investigator should use 
his/her medical judgment when assessing whether a participant‚Äôs prior and concomitant 
therapy(ies) are prohibited. The Sponsor Clinical Director or designee should be contacted if 
there are any questions about a therapy not listed or regarding potential DDIs with a specific 
treatment that the participant may plan to receive. Of note, i f a participant is hospitalized 
during the study, other medications intended as treatment for COVID -19 are permitted.
Table 2 Prohibited and Allowed Therapies
COVID -19 Vaccines ÔÇ∑SARS- CoV- 2 vaccines are prohibited any time prior to randomization 
and through Day 29.
COVID -19Monoclonal 
AntibodiesÔÇ∑Monoclonal antibodies are prohibited for treatment of th e current SARS-
CoV-2 infection, including prior to randomization and through Day 29 .
Other COVID -19 
TherapeuticsÔÇ∑Sponsor -designated standard of care for treatment for COVID -19ais 
permitted (eg, corticosteroids ) but may require additional safety 
monitoring as determined by the treating clinician.
oIf guidelines for local standard of care conflict with Sponsor -
designated standard of care, site should consult with Sponsor.
oUnless designated by the Sponsor as acceptable standard of 
care for COVID -19, concomitant use of other therapies
intended as specific treatment for COVID -19 are prohibited 
from randomization through Day 29 . If aparticipant is 
hospitalized during the study, other therapies intended as 
treatment for COVID -19 are permitted .
ÔÇ∑Supportive therapies (including but not limited to anti -pyretic and anti -
inflammatory agents) to manage COVID -19 signs/symptoms are 
allowed. 
Non-COVID -19 
Investigational Agents All non-COVID -19 investigational agents including devices are prohibited 
within 30 days prior to randomization and through Day 29. 
a For a detailed list of Sponsor -approved treatments, refer to the MK-4482 -002 Sponsor -Designated Standard of Care for 
Treatment of COVID -19 or Supportive Therapies for Management of COVID -19 document.
06FSHF
07X3DY
PRODUCT: MK-4482  50
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
6.5.1 Rescue Medications and Supportive Care
Sponsor -designated standard of care for COVID- 19 is permitted.
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification of MK -4482 or placebo is allowed in this study.
6.7 Intervention After the End of the Study
There is no study -specified intervention following the end of the study.
6.8 Clinical Supplies Disclosure
The emergency unblinding call center will use the intervention/randomization schedule for 
the study to unblind participants and to unmask study intervention identity. The emergency 
unblinding call center should only be used in cases of emergency (see Section 8.1.10). In the 
event that the emergency unblinding call center is not available for a given site in this study, 
the central electronic intervention randomization system (IRT) should be used to unblind 
participants and to unmask study interve ntion identity. The Sponsor will not provide random 
code/disclosure envelopes or lists with the clinical supplies.
7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
WITHDRAWAL
7.1 Discontinuation of Study Intervention
Discontinuation of study intervention does not represent withdrawal from the study.
As certain data on clinical events beyond study intervention discontinuation may be 
important to the study, they must be collected through the participant‚Äôs last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study intervention prior to completion of the protocol -specified treatment 
period will still continue to be monitored in the study and participate in the study visits and 
procedu res as specified in Section 8.11.3, unless the participant has withdrawn from the 
study (Section 7.2).
Participants may discontinue study intervention at any time for any reason or be d iscontinued 
from the study intervention at the discretion of the investigator should any untoward effect 
occur. In addition, a participant may be discontinued from study intervention by the 
investigator or the Sponsor if study intervention is inappropriate, the study plan is violated, or 
for administrative and/or other safety reasons.
A participant must be discontinued from study intervention but continue to be monitored in 
the study for any of the following reasons:
‚Ä¢The participant or participant‚Äôs legally acceptable representative requests to discontinue 
study interven tion.
06FSHF
07X3DY
PRODUCT: MK-4482  51
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
‚Ä¢The participant has a medical condition or personal circumstance which, in the opinion of 
the investigator and/or Sponsor, place sthe participant at unnecessary risk from continued 
administration of study intervention.
‚Ä¢An elevated AST or ALT lab valu e that is ‚â• 3X the upper limit of normal and an elevated 
total bilirubin lab value that is ‚â• 2X the upper limit of normal and, at the same time, an 
alkaline phosphatase lab value that is < 2X the upper limit of normal, as determined by 
way of protocol -specifi ed laboratory testing or unscheduled laboratory testing .
‚Ä¢The participant has a ny platelet count of <50,000/¬µL , as determined by way of protocol -
specified laboratory testing or unscheduled laboratory testing .
‚Ä¢The participant is no longer able to take oral m edication or becomes intubated prior to 
completion of study intervention.
‚Ä¢A female participant becomes pregnant.
For participants who are discontinued from study intervention but continue to be monitored 
in the study, all visits and procedures, as outlined in the SoA, should be completed.
Discontinuation from study intervention is ‚Äúpermanent.‚Äù Once a participant is discontinued
from study intervention, they shall not be allowe d to restart study intervention .
If a participant discontinues from study intervention early for any reason (ie, prior to the 9th
or 10thdose), then plasma samples for PK and blood samples for PBMCs will not be 
collected for that participant (Section 8.6.1 and Section 8.6.2).
7.2 Participant Withdrawal From the Study
A participant must be withdrawn from the study if the participant or participant‚Äôs legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Both survival and hospitalization status at Day 29 and LFU arerequired for all randomized 
participants and should still be reported for participants who withdraw fr om the study where 
permitted by local guidelines. Site personnel should attempt to obtain information regarding 
vital status (including date last known to be alive, hospitalization, date of death, primary 
cause of death, and COVID -19 contribution to death) as outlined in Section 8.2.4.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific details regarding withdrawal from FBR, are outlined in Section
8.11.3 and Section 8.1.9.1 . The procedures to be performed should a participant repeatedly 
fail to return for scheduled visits and/or if the study site is unable to contact the participant 
are outlined in Section 7.3.
06FSHF
07X3DY
PRODUCT: MK-4482  52
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
7.3 Lost t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:
‚Ä¢The site must attempt to contact the participant and reschedule the missed visit. If the 
participant is contacted, the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
‚Ä¢The investigator or designee must make every effort to regain contact with the participant 
at each missed visit (eg, telephone calls and/or a certified letter to th e participant‚Äôs last 
known mailing address or locally equivalent methods). These contact attempts should be 
documented in the participant‚Äôs medical record.
8 STUDY ASSESSMENTS AND PROCEDURES
‚Ä¢Study procedures and their timing are summarized in the SoA.
‚Ä¢Adher ence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
‚Ä¢The investigator is responsible for ensuring that procedures are conducted by 
appropriately qualified (by education, training, and experience) staff. Delegation of study 
site personnel responsibilities will be docu mented in the Investigator Trial File Binder (or 
equivalent).
‚Ä¢All study- related medica l decisions must be made by an investigator who is a qualified 
physician.
‚Ä¢All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record re asons for 
screening failure, as applicable.
‚Ä¢Procedures conducted as part of the participant‚Äôs routine clinical management (eg, blood 
count) and obtained before signing of ICF may be utilized for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
‚Ä¢Additional evaluations/testing may be deemed necessary by the investigator and or the 
Sponsor for reasons related to participant safety. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those regulations.
The maximum amount of blood collected from each participant over the duration of the study 
will not exceed approximately 140mLfor participants in the PBMC Cohort or 
approximately 108mLfor all other participants (Appendix 2 , Table 12).
06FSHF
07X3DY
PRODUCT: MK-4482  53
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Repeat or unscheduled samples may be taken for safety reasons or due to technical issues 
with the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant (or their legally 
acceptable representative )prior to participating in thisclinical study or FBR .If there are 
changes to the participant‚Äôs status during the study (eg, health or age of majority 
requirements), the investigator or medically qualified designee must ensure the appropriate 
documented informed consent is in place .
For country -specific requ irements see Appendix 7.
8.1.1.1 General Informed Consent
Informed consent given by the participant or their legally acceptable representative must be 
documented on a consent form. The form must include the trial protocol number, trial 
protocol title, dated signature, and agreement of the participant (or their legally acceptable 
representative) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB/IEC‚Äôs approval/favorable opinion in advance of use. The 
participant or their legally a cceptable representative should be informed in a timely manner if 
new information becomes available that may be relevant to the participant‚Äôs willingness to 
continue participation in the study. The communication of this information will be provided 
and doc umented via a revised consent form or addendum to the original consent form that 
captures the participant‚Äôs or the participant‚Äôs legally acceptable representative‚Äôs dated 
signature.
Specifics about the study and the study population are to be included in t he study informed 
consent form.
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements.
8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically qualified desi gnee will explain the FBR consent to the 
participant, or the participant‚Äôs legally acceptable representative, answer all of his/her 
questions, and obtain documented informed consent before performing any procedure related 
to FBR. A copy of the informed con sent will be given to the participant before performing 
any procedure related to FBR .
06FSHF
07X3DY
PRODUCT: MK-4482  54
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
8.1.1.3 Consent for PBMC Cohort Blood Sample Collection
The investigator or medically qualified designee will explain the PBMC Cohort blood sample 
collection to the participant a nd/or the participant‚Äôs legally acceptable representative, answer 
all of their questions, and obtain documented informed consent before performing any 
procedure related to the PBMC Cohort blood sample collection. After applicable consent is 
obtained, these participants will have additional PBMC PK blood sample collection as 
specified in the SoA (Section 1.3) and Section 8.6.2. A copy of the signed informed consent 
will be given to the participant and/or participant‚Äôs legally acceptable representative.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator ,who is a qualified 
physician, to ensure that the participant qualifies for the study.
The SARS -CoV -2 test result must be reviewed for participant eligibility and data entered into 
the eCRF including date specimen collected, sample type (eg, NP swab, OP swab, 
midturbinate swab, saliva, etc. ), test method (eg ,RT-PCR) and result (positive result is 
requir ed). If prior results are not available, laboratory confirmation of SARS -CoV -2 infection 
may be performed at screening to confirm eligibility. Results must be available prior to 
randomization.
Assessments required for COVID- 19severity categorization (Appe ndix 9) for IRT (vital 
signs, COVID -19 signs/symptoms assessment, respiratory measures, oxygen therapy, 
ongoing medical history) must be completed and documented on Day 1 prior to calling IRT 
in order to randomize. All other Day 1 assessments must be compl eted on Day 1 prior to first 
dose of study interventio n.
The following local laboratory results must be available for all participants from within 
72hours prior to randomization : serum creatinine, platelets, and absolute neutrophil count. In 
participants with reported history of HBV or HCV, ALT and AST must be available from 
within 72 hours prior to randomization to support determination of eligibility. In WOCBP, a 
negative local urine or serum pregnancy test is required within 24 hours of the first dose o f 
study intervention per inclusion criteria.  
All other inclusion/exclusion criteria determination (eg, HIV status) can be based on 
participant- reported medical history, available medical records, and the most recently 
available laboratory results for the participant (eg, HIV RNA VL ). 
8.1.3 Participant Identification Ca rd
All participants will be given a participant identification card identifying them as participants 
in a research study. The card will contain study site contact information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides documented informed consent. At the time of intervention
06FSHF
07X3DY
PRODUCT: MK-4482  55
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
randomization, site personnel will add the treatment /randomization number to the participant 
identification card.
The participant identification card also contains contact information for the emergency 
unblinding call center so that a healthca re provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical History
A medical history will be obtained by the investigator or qualified designee. Participants will 
be asked to provide a ny background or concomitant conditions, drug allergies and/or 
surgeries within the last 12 months. In addition, history of smoking (tobacc o or marijuana), 
including use of vaping devices, will be collected. Medical history for the following 
conditions will be collected separately on the Medical History Pre -Specified Conditions 
eCRF: chronic kidney disease, chronic obstructive pulmonary disea se, immunocompromised
state from solid organ transplant (Part 1 only) , obesity, active cancer (excluding minor 
cancers not associated with immunosuppression or significant morbidity/mortality) , 
congestive cardiac failure, coronary artery disease, cardiomyo pathies, sickle cell disease
(Part 1 only) ,and diabetes mellitus (Appendix 10) .Any oxygen therapy needs in the 7 days 
prior to symptom onset and through randomization will be reported in the oxygen therapy 
eCRF with flow rate reported in L/min. Reporting will include supplemental oxygen 
requirements during pre -morbid/pre -COVID- 19, between the onset of COVID -19 
signs/ symptoms and study randomization, andany changes to oxygen therapy needs during 
the study treatment and follow -up periods .
8.1.5 Prior and Concomitant Medications Revi ew
8.1.5.1 Prior Medications
The investigator or qualified designee will review prior medication use and record prior 
medication staken by the participant w ithin 30 days before first dose of study intervention.
Allprior therapeutics/vaccines for COVID -19 regardless of timing, must be recorded.
8.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication s, if any, taken by the 
partici pant during the study. Allconcomitant therapeutics/vaccines for COVID -19,including 
all supportive therapies ( eg,anti-pyretic and anti -inflammatory agents) to manage COVID -19 
signs/symptoms ,must be reported.
8.1.6 Assignment of Screening Numb er
All consented participants will be given a unique screening number that will be used to 
identify the participant for all procedures that occur prior to randomization . Each participant 
will be assigned only 1 screening number. Screening numbers must not be re -used for 
different participants.
06FSHF
07X3DY
PRODUCT: MK-4482  56
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Participants may be rescreened. Specific details on the screening/ rescreening visit 
requirements are provided in Section 8.11. 2.1.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly alloc ated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment randomization. Once a 
treatment /randomization number is assigned to a participant, it can nev er be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
Study intervention will be provided as per Table 1and dispensed through the IRT system at 
the Day 1 (randomization) visit. All efforts should be made to administer the first dose on 
Day 1 (randomization), but administration of the first dose must occur within 24 hours of 
randomization. If administered on the next calendar day following randomization, the day of 
administration of the first dose of study intervention in this case would be considered Day 2 .
Study intervention and the S tudy Medication D iary will be dispensed to the participant 
according to the p harmacy manual for at home administration. Study intervention will be 
self-administered by the participant Q12H at approximately the same times each day. 
8.1.8.1 Timing of Dose Administration
Participants wil l take the appropriate number of capsule sof study intervention (as described 
in the study intervention administration instructions) Q12H (¬±2hours) for 10 doses . Study 
intervention can be administered without regard to food . Refer to Section 8.6.1 regardi ng PK 
collection. 
‚Ä¢For participants that begin dosing in the morning on Day 1, the EOT visit will occur on 
Day 5. PK specimens will be collected at the EOT visit in association with the 9thdose, 
and the final 10thdose will occur in the evening on Day 5 .
‚Ä¢For participants that begin dosing in the evening on Day 1, the EOT visit will occur on 
Day 6. PK specimens will be collected at the EOT visit in association with the 10thdose 
on Day 6. 
As outlined in the SoA, all efforts should be made to administer the first dose on Day 1 
(randomization), but administration of the first dose must occur within 24 hours of 
randomization; therefore it is possible that dosing may not begin until Day 2.
‚Ä¢Forparticipants that begin do sing in the morning on Day 2, the EOT visit will occur on 
Day 6. PK specimens will be collected at the EOT visit in association with the 9thdose, 
and the final 10thdose will occur in the evening on Day 6 .
06FSHF
07X3DY
PRODUCT: MK-4482  57
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
‚Ä¢For participants that begin dosing in the evening on Day 2, the EOT visit will occur on 
Day 7. PK specimens will be collected at the EOT visit in association with the 10thdose 
on Day 7.
If the EOT visit occurs on Day 6, no additional visit is required on Day 5. And if the EOT 
visit occurs on Day 7, no additional visits are required on Day 5 or Day 6.
The administration of the morning dose on theEOT visit will be observed by site
staff/delegate and should be aligned with the timing of blood collection for PK analyses at 
EOT (SoA, Section 1.3).
For all doses , the timing of dose administration should be recorded in the Study Medication 
Diary.
If a participant misses a dose of the study intervention , then th e following guidance should be 
followed: 
‚Ä¢If ‚â§10hours from the time the missed dose should have been taken, the missed dose 
should be taken, and the normal dosing schedule (ie, Q12H) resumed.
‚Ä¢If >10 hours from the time the missed dose should have been tak en, the missed dose 
should be skipped, and the normal dosing schedule (ie, Q12H) resumed. The participant 
should not double the next dose to compensate for what has been missed .
‚Ä¢In the event of an out of window dose during the treatment period, the EOT vis it may 
need to be rescheduled to accommodate collection of PK samples in association with the 
9thor 10thdose. The site should communicate with the participant during the treatment 
period to discuss if any changes to the dosing schedule occurred , which might affect the 
timing of the 9thor 10thdose and thus warrant a change to the EOT visit.
If a participant's renal function deteriorates requiring dialysis during the study intervention, 
the Sponsor will not require the discontinuation of the study intervention; administration of 
the study intervention may continue at the discretion of the investigator. For participants who 
require continuous dialysis, study intervention should continue to be administered Q12H with 
no change to the timing of administration. F or participants who require intermittent dialysis, 
study intervention should continue to be administered Q12H with doses administered 4 to 
6 hours prior to dialysis where possible .  
8.1.9 Discontinuation and Withdrawal
Participants who discontinue stu dy intervention prior to completion of the treatment period
should be encouraged to continue to be followed for all remaining study visits after EOT as 
outlined in Section 8.11.3.
Participants who withdraw from the study should be encouraged to complete al l applicable 
activities scheduled for the Day 29 visit (or the EOT visit if withdrawing prior to completion 
of the treatment period; Section 8.11. 3)at the time of withdrawal. Any AEs that are present 
06FSHF
07X3DY
PRODUCT: MK-4482  58
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
at the time of withdrawal should be followed in accordance with the safety requirements 
outlined in Section 8.4.
Survival status at Day 29 is required for all randomized participants and should still be 
reported for participants who withdraw from the study where permitted by local guidelines.
8.1.9.1 Withdrawal From Future Biomedical Research
Participants may withdraw their consent for FBR. Participants may withdraw consent at any 
time by contacting the study investigator. If medical records for the study are still available, 
the investigator will contact the Sponsor using the designated mailbox 
(clinical.specimen.management@merck.com). Subsequently, the participant‚Äôs consent for 
FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming 
the withdrawal. It is the responsibility o f the investigator to inform the participant of 
completion of withdrawal. Any analyses in progress at the time of request for withdrawal or 
already performed before the request being received by the Sponsor will continue to be used 
as part of the overall r esearch study data and results. No new analyses would be generated 
after the request is received.
If the medical records for the study are no longer available (eg, if the investigator is no longer 
required by regulatory authorities to retain the study records) or the specimens have been 
completely anonymized, there will no longer be a link between the participant‚Äôs personal 
information and their specimens. In this situation, the request for specimen withdrawal 
cannot be processed.
8.1.10 Participant Blinding/Unbli nding
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the investigator or medically qualified designee (consist ent 
with local requirements) needs to identify the intervention used by a participant and/or the 
dosage administered , he/she will contact the emergency unblinding call center by telephone 
and make a request for emergency unblinding. As requested by the inv estigator or medically 
qualified designee, the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor. Before contacting the emergency 
unblinding call center to request unblinding of a partici pant‚Äôs intervention assignment, the 
investigator who is a qualified physician should make reasonable attempts to enter the 
toxicity grade of the AEs observed, the relation to study intervention, the reason thereof , etc, 
in the medical record. If it is not possible to record this assessment in the medical record 
before the unblinding, the unblinding should not be delayed.
If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and 
person performing the unblinding) must be docum ented promptly, and the Sponsor Clinical 
Director notified as soon as possible.
06FSHF
07X3DY
PRODUCT: MK-4482  59
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Once an emergency unblinding has taken place, the investigator, site personnel, and Sponsor 
personnel may be unblinded so that the appropriate follow -up medical care can be pro vided 
to the participant.
Participants whose treatment assignment has been unblinded by the investigator or medically 
qualified designee and/or nonstudy treating physician should continue to be monitored in the 
study.
8.1.11 Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study site .
8.1.12 Collect/Update Secondary Contact Informatio n
Sites will capture secondary contact information for 2individuals that the site can contact if 
the participant cannot be reached (eg, spouse, friend, neighbor, etc.). Sites will also request 
health care provider contact information and a few hospitals th at the participant is likely to go 
to if they get sick. Contact information for secondary contacts or health care provider will not 
be recorded on any eCRF. If participants cannot be reached after 2attempts 24 hours apart, 
then their listed secondary conta ct person(s) or healthcare provider will be contacted. At
study entry only, sites will record the participant‚Äôs home address in site records (it will not be 
reported on the eCRF).
Secondary contact information will be reviewed and updated according to the SoA
(Section 1.3). 
8.1.13 Participant Study Supplies
On Day 1 of the study, participants will receive bottle sof study intervention along with study 
supplies, including:
‚Ä¢Copy of informed consent
‚Ä¢Information about the study
‚Ä¢Instructions on study procedures and h ow to take study intervention
‚Ä¢Pocket/wallet card with site staff contact information
‚Ä¢Instructions on what to do if participants have worsening symptoms/become hospitalized
‚Ä¢Study Medication D iary (see Section 8.1.14) 
06FSHF
07X3DY
PRODUCT: MK-4482  60
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
‚Ä¢Symptom Diary (see Section 8. 2.5)
8.1.14 Study Medication Diary
A paper Study Medication Diary will be provided for documentation of doses of study 
intervention and assessment of compliance. Participants should complete the Study 
Medication D iary for each dose taken. In the event that the participant is (in the judgement of 
the investigator) unable to complete the diary, information regarding study intervention
administration may be recorded by an LAR or other close contact who witnesses 
administration of the study int ervention.
The Study Medication Di ary will be reviewed in conjunction with capsule counts by study 
staff with each participant at the visits described in the SoA, Section 1.3, to ensure 
compliance with completion and consistency with capsule counts . Capsul e counts will be 
performed by study staff (expected versus actual) for each study intervention bottle according 
to the Pharmacy Manual. 
The Study Medication Diary will be collected as soon as possible after the last dose (ie, 10th
dose) of study intervent ion. Ifthe EOT visit is performed prior to the last dose of study 
intervention, the Study Medication Diary should be collected no later than the Day 10 visit.
The study intervention data as recorded in the participant‚Äôs Study Medication Diary will be
entered in the eCRF .
In the event of hospitalization, the Study Medication Diary will be completed by the 
participant as feasible. In the event that the participant is unable to complete the diary during 
hospitalization, the individual administering the s tudy intervention (eg, study or nonstudy 
staff) will collect information corresponding to study intervention administration in the 
participant‚Äôs Study Medication Diary or other source notes (documentation should be 
maintained as part of participant records at the site) . 
8.2 Efficacy Assessmen ts
8.2.1 Nasopharyngeal and Or opharyngeal S wabs 
NP (Parts 1 and 2) and OP (Part 1 only) swabs will be collected at various timepoints as 
outlined in the SoA (Section 1.3) forqualitative and quantitative SARS -CoV -2 RT -PCR 
testing , detection of infectious SARS -CoV -2,and SARS -CoV -2 genome sequencing. At 
study entry (Day 1 ), the sample sshould be collected prior to the first dose of study 
intervention. Additional information, including instructions for swab collection, storag e,and 
shipping, can be found in the laboratory manual.
8.2.2 Respiratory/Oxygenation Status
SpO 2will be measured via pulse oximetry (SoA, Section 1.3) after the participant has been at 
rest for at least 5 minutes . The first recording will be on Day 1 prior to the first dose of study 
intervention and then at each in- person visit through Study Day 29. In addition, 
investigator /designee assessment of shortness of breath at rest and with exertion will be 
06FSHF
07X3DY
PRODUCT: MK-4482  61
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
performed atrandomization prior to the first dose of study intervention and then at each in-
person visit through Study Day 29. FiO 2, PaO 2,and supplemental oxygen useif applicable
should be reported.
Use of supplemental oxygen, including type (eg, oxygen from a conventional regulator or 
high-flow heated and humidified devi ce, non- invasive mechanical ventilation, invasive 
mechanical ventilation, ECMO) and flow rate (L/min) will be recorded on the approp riate 
eCRF. If applicable, supplemental oxygen requirements pre -morbid/pre -COVID- 19and
between the onset of COVID -19 signs and symptoms and study randomization will be 
recorded (Section 8.1.4).
New or worsening shortness of breath or difficulty breathing should be reported to the site 
clinician and referral for medical attention considered.
Note: Respiratory/Oxygenation Status collection at the LFU visit will be limited. As LFU 
will be a virtual visit, SpO 2will not be measured. Use of supplemental oxygen will be 
collected.
8.2.3 Hospitalization
Hospitalization status will be assessed as outlined in the S oA(Section 1.3) . Hospitalization is 
defined as ‚â•24 hours of acute care in a hospital or similar acute care facility, including 
emergency rooms or facilities created to address hospitalization needs during the COVID- 19 
pandemic. The date and time of hospital admission, date and time of discharge , and primary 
reason for hospitalization (including if the admission is related to COVID -19)will be 
recorded. The Sponsor must be notified within 24 hours of site‚Äôs awareness of a participant‚Äôs 
hospitalization in accordance with the guidance outlined in Section 8.4. 6.
Participants who report worsening illness from any cause during the study may be referred to 
their healthcare provider or a medical facility. Such instances will be recorded at the time of 
the notification, and during follow -up to assess study endpoints, i e, hospitalization or death.
Acute care visits must also be documented and recorded on the eCRF. Acute care visits are 
defined as any hospitalization (any amount of time in a hospital or similar acute care facility, 
including emergency rooms or facilities created to address hospitalization needs during the 
COVID- 19 pandemic) or emergency room visit or any other acute care visit (including an 
urgent care visit or visit with any healthcare provider for acute care needs) from 
randomization through Day 29 . The date and time of the acute care visit , and primary reason 
for acute care visit (including if the visit is related to COVID -19)will be recorded.
For any participants who become hospitaliz ed during the study, all study procedures outlined 
in the SoA (Section 1.3), including study intervention administration (if applicable) , should 
be continued .If the hospitalized participant has not completed study intervention and is
unable to swallow the capsules or is intub ated during hospitalization, then study intervention
should be discontinued (Section 7.1). If access to the participant by study staff is not feasible
while in hospital , use of a home healthcare professional (eg, through a home healthcare 
vendor) to perfor m inpatient participant visits according to the SoA (Section 1.3) should be 
06FSHF
07X3DY
PRODUCT: MK-4482  62
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
considered. Given the frequency of study intervention administration, it is recognized that 
use of non study personnel may be necessary for this procedure. In such cases, documentat ion 
of these responsibilities and source documentation of study intervention administration must 
be maintained in the site's source documentation as appropriate. If in- person visits are not 
permitted by the institution in which the participant is hospitali zed, a virtual visit (eg ,
telehealth, telephone) may be performed to collect data that does not require in -person 
collection. Every attempt should be made to obtain equivalent data from hospital records. In 
addition to information regarding hospitalization details, available pertinent information will 
be collected, including assessment of COVID -19 symptoms (eg, via MK -4482 Symptom 
Diary or Sponsor -provided interview script, if completed), vital signs, supplemental 
oxygenation use, ventilation procedures, co ncomitant medications, and adverse events, 
including death. In addition, every effort should also be made for a visit to be scheduled after 
discharge from the hospital, providing that the visit is within 28 days of initiation of dosing. 
8.2.4 Survival Status
Survival status (ie, whether the participant is alive or dead) will be assessed per the SoA 
(Section 1.3) .
Site personnel should attempt to obtain information regarding vital status (including date last 
known to be alive, hospitalization, date of death, primary cause of death, and COVID -19 
contribution to death ) from the participant or other sources (eg, family members, other 
designated secondary contacts, hospital the participant stated they would most likely go to, 
clinic/hospital/medical records, and local or national databases), per the SoA ( Section 1.3).
Information about death should be entered in the eCRF within 24hours of a site becoming 
aware of a death.
8.2.5 MK-4482 Symptom Diary
COVID- 19 signs/symptoms will be reported daily by the participant using apaper MK-4482
Symptom Diary on Days 1 to 29. Targeted symptoms assessed in the diary include cough, 
sore t hroat, nasal congestion (stuffy nose), runny nose, shortness of breath or difficulty 
breathing, muscle or body aches, fatigue (tiredness) , feeling hot or feverish, chills, headache, 
nausea, vomiting ,diarrhea , loss of taste and loss of smell . If the partic ipant is able to 
comprehend the diary questions ( in the judgement of the investigator ) but is unable to record 
their responses on the diary on their own per investigator discretion, collection of COVID- 19 
signs/ symptom data by study staff via an in- person or virtual (eg, telephone) participant 
interview using a Sponsor -provided interviewer script should be implemented.
On Day 1 (the same day as randomization) ,participants will complete the MK -4482
Symptom Diary prior to the first dose of study treatment. Completion of the Symptom Diary
will be observed at the site or in- home visit and documented, including time of participant 
completion ,by study staff/ home healthcare professional. Following Day 1, participants 
should complete the diary dailyat approximately the same time every day through Day 29 , 
recording and rating each symptom at its worst (reported as none, mild, moderate, or severe) 
during the prior 24 hours. 
06FSHF
07X3DY
PRODUCT: MK-4482  63
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
In the event of hospitalization, the MK -4482 Symptom Diary should be comple ted during 
hospitalization if possible. I f the participant is unable to record their responses on the diary 
on their own, theSponsor -provided interviewer script should be implemented by study staff .
Completion of the diary should be resumed by the participant after discharge per SoA, 
Section 1.3.
The MK -4482 Symptom Diary will be reviewed by study staff with each participant at the 
visits described in the SoA (Section 1.3) to ensure compliance with completion .To further 
support compliance with completion by the participant, the study staff should provide 
participants with r egular telephone or other reminders (eg, email, text messages) regarding 
diary completion. Following the EOT visit, these reminders should be provided every other 
day through Day 29. The MK -4482 Symptom Diary will be collected per the SoA, Section 
1.3, and the diary data will be recorded in the eCRF. 
8.2.6 Functional Status Assessments
Functional status assessments will be performed at all in -clinic or at- home visits per the SoA 
(Section 1.3). The p articipant‚Äô s ability to independently perform daily activities with minimal 
or no symptoms will be assessed and evaluated at the discretion of investigator/designee.
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided below . The total amount of blood to be drawn over the course of the study (from 
pre-study to post -study visits), including approximate blood volumes drawn by visit and by 
sample type per par ticipant, can be found in Appendix 2 , Table 11.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination will be conducted at the screening visit by a nurse or other 
qualified healthcare provider. Height and weight will also be collected and recorded. A nurse 
or other qualified healthcare provider will also conduct d irected physical exa mination
targeted at the participant‚Äôs symptoms/complaints at all other in -person visits (in-clinic or at-
home). Details of the physical examinations will be provided to an investigator or medically 
qualified designee (consistent with local requir ements) for review and assessment per 
institutional standard .
8.3.2 Vital Signs
Body temperature, heart rate, respiratory rate, and blood pressure will be assessed.
Vital sign measurements should be preceded by at least 5 minutes of rest for the participant 
in aquiet setting without distractions.
06FSHF
07X3DY
PRODUCT: MK-4482  64
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
8.3.3 Clinical Safety Laboratory Assessments
Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
‚Ä¢The investigator or medically qualified designee (consist ent with local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinic ally significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless 
judged by the investigator to be more severe than expected for the participant's condition.
‚Ä¢All protocol -required laboratory assessments, as defined in Appendix 2 , must be 
conducted in accordance with the laboratory manual and the SoA .
‚Ä¢If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution‚Äôs local laboratory require a change in study participant management or are 
considered clinically significant by the investigator (eg, SAE or AE), then the results 
must be recorded in the appropriate CRF (eg, SLAB).
‚Ä¢For any laboratory tests with values considered clinically significantly abnormal duri ng 
participation in the study or within 14days after the last dose of study intervention, every 
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by the inv estigator .
8.3.4 Pregnancy Testing
‚Ä¢Pregnancy testing:
Pregnancy testing requirements for study inclusion are described in Section 5.1.
Pregnancy testing should be conducted at screening (serum or urine )andon Day 29
(serum) ,approximately 24days after the last dose of study intervention.
Additional serum or urine pregnancy tests may be performed, as determined necessary by the 
investigator or required by local regulation, to establish the absence of pregnancy at any time 
during the subject's participation in th e study.
8.4 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3 .
Adverse events, SAEs, and other reportable safety events will be reported by the participant 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
06FSHF
07X3DY
PRODUCT: MK-4482  65
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
The investigator and any designees are responsible for detectin g, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality .
8.4.1 Time Period and Frequency for Collecting A E, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the participant provides 
documented informed consent but before intervention randomization must be reported by the 
investigator if the participant is receiving placebo run-in or other run -in treatment , if the 
event cause sthe participant to be excluded from the study, or is the result of a protocol -
specified intervention, including but not limited to washout or discontinuation of usual 
therapy, diet, or a procedure.
From the time of intervention randomization through 14 days following cessation of study 
intervention, all AEs, SAEs, and other reportable safety events must be reported by the 
investigator.
Additionally, any SAE brought to the attention of an investigator at any time outside of the 
time period specified in the previous paragraph must be reported immediately to the Sponsor 
if the event is considered related to study intervention.
Investigators are not obligated to actively seek AE sor SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and he/sh e 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3 .
Exception: A positive pregnancy test at the time of initial screening is not a reportable event 
unless the participant has received study intervention.
06FSHF
07X3DY
PRODUCT: MK-4482  66
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Table 3 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of Event Reporting Time Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol -specified 
Follow -up PeriodReporting Time 
Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame to 
Report Event and 
Follow -up 
Information to 
Sponsor:
NSAE Report if:
-due to protocol -specified 
intervention
-causes exclusion
-participant is receiving 
placebo run -in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -specified 
intervention
-causes exclusio n
-participant is receiving 
placebo run -in or other 
run-in treatmentReport all Report if:
-drug/vaccine 
related.
(Follow ongoing to 
outcome)Within 24 hours of 
learning of event
Pregnancy/
Lactation 
ExposureReport if:
-participant has been 
exposed to any protocol -
specified intervention (eg, 
procedure, washout or 
run-in treatment including 
placebo run -in)
Exception: A positive 
pregnancy test at the time 
of initial screening is not a 
reportable event.Report all Previously reported 
‚ÄìFollow t o 
completion/terminati
on; report outcomeWithin 24 hours of 
learning of event
ECI(require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-Potential DILI
-Require regulatory 
reportingNot required Within 24 hours of 
learning of event
ECI (d o not 
require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs and 
those not requiring 
regulatory reportingNot required Within 5 calendar 
days of learning of 
event
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 calendar 
days of learning of 
event
(unless serious)
Overdose Report if:
-receiving placebo run -in 
or other run -in medication Report all Not required Within 5 calendar 
days of learning of 
event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse 
event
06FSHF
07X3DY
PRODUCT: MK-4482  67
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make e very attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by the investig ator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safety of participants and the 
safety of a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country -specific regulatory requirements and global laws and 
regulations relating to safet y reporting to regulatory authorities, IRB/IECs, and investigators.
Investigator safety reports must be prepared for SUSAR saccording to local regulatory 
requirements and Sponsor policy and forwarded to investigators as necessary.
An investigator who recei ves an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee), inc luding the pregnancy of a male participant‚Äôs female 
partner, that occurs during the study are reportable to the Sponsor as described in Section 
8.4.1.
All reported pregnancies must be followed to the completion/termination of the pregnancy.
Any pregnancy complication will be reported as an AE or SAE. 
The medical reason (example: maternal health or fetal disease) for an elective termination of 
a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born 
06FSHF
07X3DY
PRODUCT: MK-4482  68
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
with severe abnormalitie s/congenital anomalies that lead to an elective termination of a 
pregnancy will be reported as an SAE for the fetus. 
Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth 
must be reported as serious events (Important Medical Events). If the pregnancy continues to 
term, the outcome (health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Certain ef ficacy endpoints including hospitalizations andmortality must be collected 
throughout the study (ie, during both treatment and follow -up). From the time of 
randomization through 14 days following cessation of study intervention, these events must 
be reported as described in Section 8.4.1. New hospitalizations and/or deaths that occur after 
14 days following cessation of treatment must continue to be assessed for seriousness and 
causality. However, they must only be reported to the Sponsor within 24 hours as new SAEs 
ifthere is evidence to suggest a causal relationship between the study intervention and the 
SAE .
8.4.7 Events of Clinical Interest
Selected serious and nonserious AEs are also known as ECIs and must be reported to the 
Sponsor.
Events of clinical interest for this study include:
1.An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by way of protocol -specified laboratory 
testing or unscheduled laboratory testing.*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require 
an additional evaluation for an underlying etiology. The study site guidance for 
assessment and follow -up of these criteria can be found in the Investigator Study File 
Binder (or equivalent).
2.Any postbaseline platelet value <50 ,000/ŒºL, as determined by protocol -specified and/or 
unscheduled laboratory testing.
8.5 Treatment of Overdose
In this study, an overdose is the receipt of any number of capsules greater than the number of 
capsules to be taken as outlined in the pharmacy manual.
No specific information is available on the treatment of overdose.
06FSHF
07X3DY
PRODUCT: MK-4482  69
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Sponsor Clinical Director based on the clinical evaluation of the 
participant.
8.6 Pharmacokinetics
8.6.1 Blood Collection for Measurement of NHC in Plasma
At the EOT visit, venous blood sa mples will be collected from all participants for the 
measurement of NHC concentrations in plasma ( Table 4).
The timing of the morning dose on the EOT visit should be al igned with the timing of blood 
collection for PK analyses at EOT (Section 1.3 and Section 8.1.8.1). The EOT morning dose 
will be observed at the site or in- home visit and recorded by study staff/visiting nurse. 
Sample collection, storage, and shipment inst ructions for plasma samples will be provided in 
a laboratory manual. 
Table 4 Plasma Sample Collection Schedule for NHC Concentrations
Study Part Plasma Sample Collection Time Points (Window)
Part 1 and Part 2 ÔÇ∑1 sample pre -dosea
ÔÇ∑1 sample 1.5 hours post -dose (¬±30 min)
aPre-dose sample should be collected within 2 hours of dosing.
If a participant discontinues from study intervention early for any reason (ie, prior to the 9th
or 10thdose), then plasma samples for PK will not be c ollected for that participant.
8.6.2 Blood Collection for Measurement of NHC -TPin PBMC
At the EOT visit, venous blood samples will be collected from participants in the PBMC 
Cohort in Part 1 for the measurement of NHC -TP concentrations in PBMCs. 
Two blood samples for PBMCs will be collected at each of the following timepoints on the 
EOT visit during Part 1 only: 
‚Ä¢2 tubes pre-dose
‚Ä¢2 tubes post-dose at 1.5 hours (¬± 30 min)
Pre-dose sample should be collected within 2 hours of dosing. The timing of blood collec tion 
will be aligned with the timing of dose administration as outlined in Section 8.1.8.1. Sample 
collection, storage, and shipment instructions for PBMC samples will be provided in a 
separate manual.
If a participant discontinue sfrom study intervention early for any reason (ie, prior to the 9th
or 10thdose), then blood samples for PBMCs will not be collected for that participant.
06FSHF
07X3DY
PRODUCT: MK-4482  70
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
8.7 Pharmacodynamics
The virologic, clinical efficacy, and clinical safety endpoints (Section 3) will be used to 
evaluate any pharmacokinetic/pharmacodynamic relationships for MK -4482 . For assessment 
of antiviral activity of MK -4482 at each study dose, baseline, and post -dose virologic 
information (eg, viral RNA) at pre -specified timepoints (Section 1.3 ,SoA) will be measured. 
For each participant, the baseline measurement is defined as the measurement obtained pre -
dose on the first day of dosing.
8.8 Exploratory Research Samples
Collection of samples for other exploratory research is also part of this study. These samples 
may be utilized to perform evaluations related to SARS -CoV -2 and/or COVID -19, 
coinfections , or MK -4482 as described in Section 4.2.5. These samples may be tested during 
the course of the study or after study closure as the field of res earch evolves. 
Serum and plasma samples for exploratory research will be collected from all participants as 
specified in the SoA (Section 1.3) for exploratory research; in addition, residual material 
from NP/OP swabs and other previously collected blood s amples may also be used. Sample 
collection, storage, and shipment instructions for the exploratory research samples will be in 
the laboratory manual.
8.9 Future Biomedical Research Sample Collection
If the participant provides document informed consent, the fo llowing specimens may be used 
for exploratory research and/or FBR as outlined in Sections 8.8 and 4.2.1.5, respectively :
‚Ä¢Unused isolates from N Pswabs (Part 2 only)
‚Ä¢Unused serum and plasma from serum and plasma for exploratory research (Part 2 only)
‚Ä¢Unused serum from serum for antibody exploratory research (Part 2 only)
8.10 Medical Resource Utilization and Health Economics
Sites are to collect hospitalization status and discharge data , including acute care visit status,
per the SoA (Section 1.3) and Section 8.2.3 . 
8.11 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8. 
06FSHF
07X3DY
PRODUCT: MK-4482  71
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
8.11.1 Infection Prevention Procedures
Each site will follow their institution alprocedures and/or local requi rements to protect study 
staff and other patients from infectious exposure to SARS -CoV -2. These procedures may 
include but are not limited to:
‚Ä¢Provision of PPE to site staff, participants, and LARs
‚Ä¢Performing at -home and/or virtual visits (as allowed per the SoA)
‚Ä¢Designating special entry points for study participants for clinic visits 
8.11.2 Types of Study Visits
8.11.2.1 Screening /Rescreening Visits
Screening
Screening will occur ‚â§ 48hours prior to study intervention randomization. Prior to 
randomization, potential participants will be evaluated to determine that they fulfill the entry 
requirements as set forth in Section 5. Participants are expected to enroll as soon as possible 
after eligibility is confirmed.
Rescreening
If the screening window has been exceeded, participants are allowed to rescreen 1 time if the 
participant still meets all the inclusion and none of the exclusion criteria at the time of 
rescreening. Once a participan t has started the rescreening process, a new screening period 
(ie, an additional 48 hour window) will begin, during which time screening procedures will 
be repeated.
The following assessments must be repeated for participants who are rescreened:
‚Ä¢Vital signs and full physical exam ination
‚Ä¢Review medical history and prior/concomitant medications for new information
‚Ä¢Local laboratory assessments for inclusion/exclusion (results within 72 h ours prior to 
randomization may be used for eligibility)
‚Ä¢Urine or serum Œ≤- hCG (pregnancy testing for WOCBP) 
‚Ä¢Review of AEs
If the informed consent form has been updated, participants should be reconsented before 
rescreening. If no updates have been made, the informed consent from the original screening 
period should be reviewed with the participant and a verbal reconsent to co ntinue in the study
should be documented. 
06FSHF
07X3DY
PRODUCT: MK-4482  72
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
8.11.2.2 Clinic or At -Home Visit s
In lieu of a participant travelling to the study site, an at- home visit by a healthcare provider 
(eg, home healthcare company or visiting nurse, etc.) may be appropriate to perform study 
assessments and procedures per the SoA ( Section 1.3) (where available and when permitted 
by local regulations and IRB/IEC). For any visit conducted at home, the investigator/site 
personnel may also contact the participant virtually (on the same day) , Sectio n 8.11.2 .3,to 
conduct/confirm study procedures/assessments (eg, perform an investigator AE assessment).
Refer to the procedure manual and/or the Investigator Trial File Binder (or equivalent) for 
additional details. 
8.11.2.3 Virtual Visit s
The investigator or des ignee may conduct the Day 2 and Day 4 visits with the participant 
virtually (eg, by telehealth, telephone, webcast, videoconference, etc.). Identity of each 
participant should be confirmed according to institutional procedures and/or local guidelines
prior to conduct of virtual visits. Virtual visits will consist of concomitant medication and 
AE/SAE collection only. When a virtual visit is listed in the SoA, a clinic or home visit is not 
required . Virtual visits may be conducted at the i nvestigator ‚Äôsdiscre tion.
8.11.3 Participants Who Discontinue or Withdraw
Participants who discontinue study intervention prior to completion of the treatment period 
should complete the activities for the EOT visit at the time of discontinuing study 
intervention. B lood samples for PK will not be collected for participants who discontinue 
study intervention prior to their 9thor 10thdose. The participant should then be encour aged to 
complete all the remaining subsequent study visits after EOT as outlined in the SoA 
(Section1.3). In the event that an active condition requires ongoing monitoring (eg, abnormal 
laboratory results, AEs, or progression of COVID -19 signs/symptoms), unscheduled visit(s) 
may be performed prior to the next study visit on Day 10.
Participants who withdraw from the study prior to completion of the treatment period should 
complete the activities for the EOT visit at the time of withdrawal. Blood samples for PK
will not be collected for participants who discontinue from study prior to their 9thor 10thdose 
of study intervention. Participants who withdraw from the study after completion of the 
treatment period should be encouraged to complete all applicable activities scheduled for the 
Day 29 visit at the time of withdrawal. This visit should be conducted at the clinic or as a 
home visit if possible. If circumstances do not support an in- person visit, a virtual visit may 
be used; in this case, laboratory or other in -person measures would not be collected. Return 
of participant diaries and reconciliation of any study intervention should be coordinated if
relevant. Any AEs that are present at the time of withdrawal should be followed in 
accordance with the safet y requirements outlined in Section 8.4.
Both survival and hospitalization status at Day 29 are required for all randomized 
participants and should still be reported for participants who withdraw from the study where 
permitted by local guidelines.
06FSHF
07X3DY
PRODUCT: MK-4482  73
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
8.11.4 Late Follow -up(7 Month) Visit
A virtual visit (eg, by telephone, webcast, videoconference, etc.) will be conducted at 
7months (¬±1 month ) after the last dose of study intervention for all participants. Information 
regarding survival status, current supplemental oxygen use, and any hospitalizations that 
occurred since last contact will be collected according to the SoA (Section 1.3). 
9 STATISTICAL ANALYSIS PLAN
This section outlines the stati stical analysis strategy and procedures for the study. If, after the 
study has begun, but prior to any unblinding/final database lock, changes are made to the 
primary hypothesis, or the statistical methods related to this hypothes is, then the protocol will
be amended (consistent with ICH Guideline E -9). Changes to exploratory or other non -
confirmatory analyses made after the protocol has been finalized, but prior to 
unblinding/final database lock, will be documented in a sSAP and referenced in the CSR for 
the study. Post hoc exploratory analyses will be clearly identified in the CSR. Other planned 
analyses (ie, those specific to the analysis of PK data, medical resource utilization outcomes, 
and r esearch plasma samples) are beyond the scope of this document or will be documented 
in separate analysis plans.  
9.1 Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below; the comprehensive plan 
is provided in Section 9.2 to Section 9.12.  
Study Design Overview A Phase 2/3, Randomized, Placebo- Controlled, Double -Blind 
Clinical Study to Evaluate the Efficacy, Safety, and 
Pharmacokinetics of MK -4482 in Non -Hospitalized Adults with 
COVID -19.
Treatment Assignment Part 1:Approximately 300 participants will be randomized in a 
1:1:1:1 ratio (stratified perSection 6.3.2a) to receive 1 of the 
following 4 study interventions, Q12H for 5 days.
ÔÇ∑MK-4482 200 mg (n~ 75)
ÔÇ∑MK-4482 400 mg (n~ 75)
ÔÇ∑MK-4482 800 mg (n~ 75)
ÔÇ∑Placebo (n~ 75)
Part 2: A total of approximately 1550 participants will be 
randomized in a 1:1ratio (stratified per Section 6.3.2) to receive 
either MK -4482 800mgor placebo Q12H for 5 days.
Analysis Populations Efficacy : MITT(Parts 1 and 2 separately)
Safety : APaT (Parts 1 and 2 combined)
06FSHF
07X3DY
PRODUCT: MK-4482  74
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Primary Endpoints Efficacy : Proportion of participants with hospitalization or death 
by Day 2 9.
Safety : Number of participants with AEs, and discontinuing study 
intervention due to AEs
Key Secondary Endpoints ‚Ä¢Time to sustained resolution or improvement , and time to 
progression of eachtargeted self- reported sign/ symptom of 
COVID -19 through Day 2 9
‚Ä¢Odds of a more favorable response on the WHO 11-point 
ordinal scale on Day 3, EOT , Day 10, Day 15,and Day 29
Statistical Methods for Key 
Efficacy AnalysesFor the evaluation of the primary hypothesis, superiority of 
MK-4482 compared to placebo with respect to the percentage of 
participants with hospitalization or death by Day 2 9will be 
calculated using the stratified Miettinen and Nurminen method 
[Miettinen, O. 1985] .
Statistical Methods for Key 
Safety AnalysesP-values (Tier 1 endpoints) and 95% CIs (Tier 1 and Tier 2 
endpoints) will be provided for between -treatment differences in 
the percentage of participants with AEs; these analyses will be 
performed using the unstratified Miettinen and Nurminen method
[Miettinen, O. 1985] .
Interim Analyses IA1 ‚ÄìPart 1 Dose Evaluation
This IA will be used to review data to inform dose selection 
models and analyses.
IA2‚ÄìPart 1bDose Selection
This IA will be used to evaluate the dose/exposure -response to 
select the dose for Phase 3 .
IA3 ‚ÄìPart 2 Sample Size Re -estimation
This IA will be an unblinded sample size re- assessment. The 
conditional power approach will be em ployed in which the overall 
sample size can be adjusted upwards if the interim result is 
sufficiently promising without inflation of the type I error. 
IA4 ‚ÄìPart 2 Futility/Early Efficacy
The purpose of this IA is to allow for early stopping in the case of 
futility and to allow for the initiation of marketing authorization 
applications in the case of a positive efficacy finding. 
Additional details about interim analyses are in Section 9.7.
Multiplicity There are no adjustments for multiplicity other than the type I error 
control for interim analyses described in Section 9.7.
06FSHF
07X3DY
PRODUCT: MK-4482  75
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Sample Size and Power The total sample size for the primary efficacy assessment (Part 2) 
will be ~1550 participants (~775for MK -4482 800 mg and~775
for the placebo group). The study has overall power of 97% to 
demonstrate the superiority of MK -4482 over placebo at an 
overall one -sided, 2. 5% alpha level, if the underlying treatment 
difference (MK -4482 minus placebo) in the percentage of 
participants who are hospitalized and/or die through Day 29 
is -6percentage points.  
Additional details and assumptions for sample size and power 
calculation are in Section 9.9. 
aStratification in Part 1 included: 1) Time from symptom onset prior to the day of randomization 
(‚â§5 days, >5 days) ; and 2) At increased risk of severe illness from COVID -19 (Appendix 10) (yes, 
no)
9.2 Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the S ponsor or designee .
This study has 2 distinct parts: Part 1 (Phase 2) and Part 2 (Phase 3). Part 2 will not be 
initiated until Part 1 is completed, the data have been analyzed ,and a dose for Part 2 is
determined. Once all Part 1 participants have completed Day 29 ( ie,achiev ed a final status 
for Day 29 endpoints), the Sponsor will initiate database lock/unblinding procedures for this 
part of the study. Internal blinding will be maintained for Part 2 participants until all Part 2 
participants have completed Day 29 ( ie,achieve d a final status for Day 29 endpoints) except 
as documented in S ection 9.7. For both parts of the study, Day 1 through Day 29 will be 
conducted as a double -blind study under in -house blinding procedures. The official, final 
database for Day 1 through Day 29 will not be unblinded within each part until 
medical/scientific review has been performed, protocol deviations have been identified, and 
data have been declared final and complete. The clinical database and Sponsor personnel 
directly involved in the analysis and reporting of Day 1 through Day 29 will become 
unblinded at the time of the analyses of Part1 and Part 2data at Day 29, although study 
participants and site personnel will remain blinded until LFU. Results from after Day 29 
through the LFU visit may be presented separately.
PK data may be unblinded early for the purpose of preparing a population PK model. If this 
occurs, a separate team from the protocol team will be unblinded for the purpose of preparing 
the PK model. Efficacy and safety data wil l not be unblinded for the purpose of preparing the 
PK model. D ata or results from IA1, IA2, IA3 , IA4 will not be shared with the protocol team 
before unblinding of the Sponsor for the relevant part of the study .
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study treatment assignment .
Blinding issues related to the planned interim analyses are described in Section 9.7 .
06FSHF
07X3DY
PRODUCT: MK-4482  76
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
9.3 Hypotheses/Estimation
Objectives and hypotheses of the study are stated in Section 3.
9.4 Analysis Endpoints
Efficacy and safety endpoints that will be evaluated for within -and/or between -treatment 
differences are listed below.
9.4.1 Efficacy/Pharmacokinetics Endpoints
9.4.1.1 Efficacy Endpoints
Primary:
ÔÇ∑Proportion of participants with either hospitalizati on(‚â•24 hours of acute care in a 
hospital or similar acute care facility, including e mergency rooms or facilities created 
to address hospitalization needs during the COVID- 19 pandemic ) or death by Day 29.
Secondary:
ÔÇ∑Time to sustained resolution or improvement of each targeted self -reported 
sign/symptom present at randomization (ie, Day 1 ), defined as the number of days 
from randomization to the first of 3 consecutive days when resolution or 
improvement is demonstrated for each targete d self -reported sign/symptom .
Participants who meet criteria for sustained resolution or improvement after 
3consecutive days must not relapse by Day 29 (ie, have 2 or more consecutive days 
of each self -reported sign/symptom returning to the baseline sever ity or worse than 
baseline severity after the criteria for sustained resolution or improvement are met).
Resolution or improvement is defined as follows:
oA symptom reported at randomization as Mild and is subsequently reported as 
None
oA symptom reported at randomization as Moderate and is subsequently 
reported as Mild or None,
oA symptom reported at randomization as Severe and is subsequently reported 
as Moderate, Mild or None
oA symptom repor ted at randomization as Yes and is subsequently reported as 
No
NOTE: Participants without a symptom reported at randomization will not be 
included in the analysis
ÔÇ∑Time to progression of the targeted self -reported signs/symptoms present at 
randomization, de fined as the number of days from randomization to the first of 
06FSHF
07X3DY
PRODUCT: MK-4482  77
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
2consecutive dayswhen the targeted self -reported signs/symptoms worsen . 
Worsening is defined as follows:
oA symptom reported at randomization as None or No and is subsequently 
reported as Mild/Moderate/Severe or Yes, respectively
oA symptom reported as Mild at randomization and is subsequently reported as 
Moderate or Severe
oA symptom reported as Moderate at randomization and is subsequently 
reported as Severe
NOTE: Participants with symptoms reported at randomization as Severe will 
not be included in the analysis
ÔÇ∑Odds of a more favorable response on the WHO 11-point ordinal scale on Day 3, 
EOT, Day 10, Day 15,and Day 29. This scale provides a m easure of illness severity 
across a range from 0 (not infected) to 10 (dead).  
Note: Relevant data ( ie,central laboratory SARS -CoV -2 RNA results, supplemental 
oxygen use and methods, oxygen saturation, dialysis and vasopressor use, vital status,
and inve stigator assessment of the participant‚Äôs ability to independently perform daily 
activities with minimal or no symptoms )to support determination of t he WHO 11-
point ordinal score will be collected in eCRFs.
Exploratory : 
ÔÇ∑Percentage of participants who have any acute care visit. Acute care visit is defined as 
any hospitalization (any amount of time in a hospital or similar acute care facility, 
including emergency rooms or facilities created to address hospitalization needs 
during the COV ID-19 pandemic ) oremergency room visit or any other acute care 
visit (including an urgent care visit or visit with a nyhealthcare provider for acute care 
needs) from randomization through Day 29
ÔÇ∑Percentage of participants who have any COVID -19-related acute care visit. Acute 
care visit is defined as any hospitalization (any amount of time in a hospital or similar 
acute care facility, including emergency rooms or facilities created to address 
hospitalization needs during the COVID- 19 pandemic ) or emergency room visit or 
any other acute care visit (including an urgent care visit or visit with any healthcare 
provider for acute care needs) from randomization through Day 29
ÔÇ∑Change from baseline in SARS -CoV -2 RNA titer in nasopharyngeal and 
oropharyngeal swabs se parately at various timepoints 
ÔÇ∑Percent ageof participants with undetectable SARS -CoV -2 RNA in nasopharyngeal 
and oropharyngeal swabs separately at various timepoints
06FSHF
07X3DY
PRODUCT: MK-4482  78
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
ÔÇ∑Viral RNA mutation rate and detection of treatment- emergent sequence variants as 
assessed by comparison of baseline and post -baseline virus sequencing
ÔÇ∑Percentage of participants with undetectable infectious SARS -CoV -2 in 
nasopharyng eal swabs onDay 3, EOT, Day 10, Day 15, and Day 29.
In addition to the endpoints listed above, s urvival, supplemental oxygen use, and 
hospitalization status at the LFU visit (Month 7) will also be summarized.
9.4.1.2 Pharmacokinetics Endpoints
Pharmacokinetics endpoints are exploratory endpoints in this study: 
ÔÇ∑Pharmacokinetic parameters ( eg,Ctrough) (Part s 1and 2 )
9.4.2 Safety Endpoints
A description of safety measures is contained in Section 8.3 and Section 8.4. The analysis of 
safety results is d escribed in Section 9.6.2.
The safety analysis endpoints include: 
ÔÇ∑The proportion of: 1) participants with at least 1 AE; 2) participants with at least 
1drug-related AE; 3) participants with at least 1 SAE; 4 ) participants with at least 
1serious and drug -related AE; 5)participants who discontinued study intervention 
due to AE; 6) participants who discontinued study intervention due to a drug -related 
AE; and 7 ) participants with AE(s) leading to death. The AE reporting period is from 
the time of randomization through 14 days following cessation of treatment. 
Additional reporting periods will be used as appropriate (eg, throughout the study for 
SAE). 
ÔÇ∑Events of Clinical Interest specified in Section 8.4.7 .
Predefined Limits of Change (PDLC) in Laboratory Parameters
For the summaries of laboratory tests, participants must have both a baseline and post -
randomization on-treatment measurement to be included. Participants‚Äô laboratory values 
(based on their most abnormal laboratory test values, in the direction of interest, while on 
study intervention) will be classified as to whether or not they fall outside of the PDLC and 
are worse in grade ( ie,more abnormal in the direction of interest) than at baseline. The
criteria will be adapted from the DAIDS table for Grading the Severity of Adult and Pediatric 
Adverse Events, J UL2017, version 2.1. A listing of the participants who meet the criteria 
will also be provided.
06FSHF
07X3DY
PRODUCT: MK-4482  79
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
9.5 Analysis Populations
9.5.1 Efficacy Analysis Populat ions
The MITTpopulation will serve as the primary population for the analysis of efficacy data 
for both parts of this study. The M ITT population consists of all randomized participants who 
received at least 1 dose of study intervention .Part 1 (Phase 2) and Part 2 (Phase 3) of the 
study will be analyzed separately for efficacy endpoints. Therefore, the MITT population for 
Part 2 will not include Part 1 participants, and vice versa .
A supportive analysis using the Per -Protocol population will be performed for the primary 
efficacy endpoint(s) for Part 2. The Per -Protocol population excludes participants due to 
deviations from the protocol that may substantially affect the results of the pr imary efficacy 
endpoint. 
The final determination on protocol deviations, and thereby the composition of the Per -
Protocol population ,will be made prior to the final unblinding of the database and will be 
documented in a separate memo.
Participants will be included in the treatment group to which they are randomized for the 
analysis of efficacy data using both the MITT and Per- Protocol populations.
9.5.2 Safety Analysis Populations
Safety a nalyses will be conducted in the APaT population, which consists of all ra ndomized 
participants who received at least 1dose of study treatment. Participants will be included in 
the treatment group corresponding to the study treatment they actually received for the 
analysis of safety data using the APaT population. This will be the treatment group to which 
they are randomized except for participants who take incorrect study treatment for the entire 
treatment period; such participants will be included in the treatment group corresponding to 
the study treatment actually received. P art 1 (Phase 2) and Part 2 (Phase 3) of the study will 
be combined for the final analysis of safety endpoints. The data presentations will focus on 
the selected dose group for MK -4482 and placebo.
At least 1 laboratory value or vital sign obtained subsequent to at least 1 dose of study 
treatment is required for inclusion in the analysis of the respective safety parameter. To 
assess change from baseline, a baseline measurement is also required.
9.6 Statistical Met hods
This section describes the statistical methods that address the primary and secondary 
objectives as well as a key exploratory objective for viral RNA endpoints. Methods related to 
other exploratory objectives will be described in the sSAP. Methods re lated to PK analysis 
and PK/PD modeling will be described in a separate modeling and simulation plan authored 
by QP2. Methods related to dose -response analysi susing MCP -MOD will be described in a 
separate dose -response analyses plan. Methods related to analyses of biomarkers and other 
exploratory samples will be described separately.
06FSHF
07X3DY
PRODUCT: MK-4482  80
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Efficacy results that will be deemed to be statistically significant after consideration of the 
type I error control for interim analyses are discussed in Section 9.7. There are no 
adjustments for multiplicity. Statistical testing and inference for safety analyses are described 
in Section 9.6.2.
9.6.1 Statistical Methods for Efficacy Analyses
For the evaluation of the primary hypothesis, superiority of MK -4482 compared to placebo 
with respect to the percentage of participants with either hospitalization or death by Day 2 9
will be assessed using the stratified Miettinen and Nurminen method [Miettinen, O. 1985] . 
Superiority will be concluded based on p- value boundaries as desc ribed in Section 9.7. 
Stratification factors includ e the stratification factors specified in Section 6.3.2. Geographic
region will not be used as a stratification factor in the primary analyses , but it may be 
considered as an additional stratification factor of the stratified Miettinen and Nurminen 
method for sensitivity analysis if it does not cause sparse data issues .The number of regions
along with the specific countries contained within eac h region will be described inthe sSAP.
Every effort will be made to ascertain hospitalization and survival status for all participants. 
For the primary analysis of this endpoint in the MITT population, unknown Day 29 survival 
status will be treated as fai lure,and early withdrawal from the study with known Day 29 
survival status as alive but unknown Day 29 hospitalization status will not be treated as 
failure. A sensitivity analysis treating both unknown Day 29 survival status and early 
withdrawal from the study with known Day 29 survival status as alive but unknown Day 29 
hospitalization status as failure will also be p rovided .
A sensitivity analysis for the primary endpoint will be conducted that includes only 
COVID- 19 related hospitalizations or death by Day 29 in the MITT population. This 
treatment comparison will be assessed using the stratified Miettinen and Nurminen method as 
described above. An a dditional sensitivity analysis excluding hospitalizations that occur early 
in the course of the study ( ie, within a certain time from randomization )will also be 
performed. Details will be specified in the sSAP. 
Two additional sensitivity analyses will be performed using the endpoints of time to 
hospitalization/death and time to COVID-related hospitalization /death. These analyses will 
be performed in the MITT population. The stratified log -rank test will be used for the 
comparison of MK -4482 with placebo for the se 2endpoints . Stratification factors will be the 
same as those used fo r the primary endpoint. Hazard ratios will be based on the stratified Cox 
Proportional Hazards regression model . The Efron approximation will be used for handling 
ties. Hazard ratios less than 1 indicate a benefit for MK -4482. C ensoring rules for the se
analyses will be specified in the sSAP.
Time to sustained resolution or improvement and time to progression of each targeted self -
reported sign/symptom of COVID- 19 will be summarized using data collected from a 
15-item daily paper symptom diary completed by participants (Section 8.2.5) .The 
distribution of time to sustained resolution or improvement and time to progression of each
sign/symptom will be analyzed using the same method for the time to hospitalization or death 
endpoint, ie, the s tratified log -rank test will be used for the comparison of MK -4482 with 
06FSHF
07X3DY
PRODUCT: MK-4482  81
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
placebo and the Cox proportional hazard model will be used to estimate the hazard ratio.
Descriptive statistics and Kaplan -Meier plots will also be provided .
The proportion of participants with each sign/symptom will be summarized by severity (or 
presence/absence for loss of taste and loss of smell) for each treatment group at Day 1, 
Day 3, EOT, Day 10, Day 15, and Day 29.
Thesesummaries above will include co mparison of each individual sign/symptom. Missing 
symptom diary data will be imputed using LOCF method. Additional details will be specified
in the sSAP. 
The viral RNA endpoints at earlier time points (Day 3 and EOT) will be important for the 
dose selecti on decision from Part 1 of the study. Change from baseline in SARS -CoV -2 RNA 
titer, calculated as log 10(post) minus log 10(baseline), as measured by quantitative RT- PCR 
of samples from NP (Parts 1 and 2) and OP (Part 1 only) swabs will be summarized 
separately by treatment group and time point. The DAO approach will be used to handle 
missing data for these summary statistics. In addition to summary statistics, treatment 
differences in change in SA RS-CoV -2 RNA titer from baseline over time w ill be estimated 
using longitudinal models. Graphical presentations of the change from baseline will be 
presented and the impact of baseline viral RNA level will be explored using subgroup 
analyses (defined by level of baseline viral RNA) and analyses/summ aries that exclude 
participants with low baseline levels (eg, viral RNA <106copies/mL).
Percentage of participant s with undetectable viral RNA (below limit of detection) as 
measured by qualitative RT- PCR of samples from NP (Parts 1 and 2) and OP (Part 1 o nly) 
swabs will be summarized separately by treatment group and time point. Between -treatment 
differences and 95% CI s will be estimated using the stratified Miettinen and Nurminen 
method [Miettinen, O. 1985] .  
WHO 11-point ordinal scale score will be analyzed using the cumulative logits function and 
the proportional odds model as described by McCullagh [McCullagh, P. 1980] . This 
methodology provides an estimate of the common odds ratio for assessing differences 
between treatment groups. In addition to a term for treatment group, the model will include 
terms for the stratifi cation factors specified Section 6.3.2. The WHO 11 -point ordinal scale 
will be determined based o n relevant data collected in eCRFs.
A detailed analysis strategy for key efficacy endpoints is listed in Table 5 .
06FSHF
07X3DY
PRODUCT: MK-4482  82
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Table 5 Analysis Strategy for Key Efficacy Endpoints
Endpoint/Variable
(Description, Time point)Primary vs. 
Supportive 
ApproachaStatistical MethodbAnalysis 
Populati onMissing 
Data 
Approach
Primary
Proportion of participants 
with either hospitalization 
or death by Day 2 9P Stratified Miettinen and 
NurminencMITT As 
described 
in 9.6.1
Proportion of participants 
with either h ospitalization 
or death by Day 2 9S Stratified Miettinen and 
NurminencPP Observed 
data only
Proportion of participants 
with either COVID -
related h ospitalization or 
death by Day 2 9S Stratified Miettinen and 
NurminencMITT M=Fd
Proportion of participants 
with either COVID-
related h ospitalization or 
death by Day 2 9S Stratified Miettinen and 
NurminencPP Observed 
data only
Time to hospitalization or 
death by Day 29S Stratified log -rank teste;
Stratified Cox proportional 
hazard regressionfMITT, PP Model -
based with 
censoring
Time to COVID -related 
hospitalization or death by 
Day 29S Stratified log -rank teste;
Stratified Cox proportional 
hazard regressionfMITT, PP Model -
based with 
censoring
Secondary
Time to sustained 
resolution or improvement 
ofeach targeted self-
reported sign/symptoms of 
COVID -19P (MITT)
S(PP)Stratified log -rank teste;
Stratified Cox proportional 
hazard regressionfMITT
PPModel -
based with 
censoring
Time to progression of 
each targeted self- reported 
sign/symptom of COVID -
19P (MITT)
S(PP)Stratified log -rank teste;
Stratified Cox proportional 
hazard regressionfMITT
PPModel -
based with 
censoring
Odds of a more favorable 
response on the WHO 11 -
point ordinal scale on Day 
3, EOT, Day 10, Day 15,
and Day 29P (MITT)
S(PP)Proportional odds modelgMITT
PPModel -
based
EOT= end of treatment; F= failure; M= missing; MITT= modified intent -to-treat; PP= per- protocol; WHO= World 
Health Organization. 
aP=Primary approach; S=Supportive approach.
bStatistical models are described in further detail below:
cMiettinen and Nurminen method stratified by the factors specified in Section 6.3. 2.  
dÔÄ†ÔÄ†ÔÄ†ÔÄ†ÔÄ†M=F is Missing equal s toFailure 
eThe stratified log -rank test includes stratification factors specified in Section 6.3.2
fStratified Cox Proportional Hazards regression includes terms for treatment, stratification factors specified in 
Section 6.3.2 
gProportional odds model includes terms for treatment and stratification factors specified in Section 6.3.2.   
06FSHF
07X3DY
PRODUCT: MK-4482  83
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
9.6.2 Statistical Met hods for Safety Analyses
Safety and tolerability will be assessed by clinical review of all relevant parameters including 
AEs, laboratory values and vital signs.
The analysis of safety results will follow a tiered approach as shown in Table 6. The tiers 
differ with respect to the analyses that will be performed. For this protocol, only ECIs are 
considered Tier 1 events. AEs (specific terms as well as syste m organ class terms) and events 
thatmeet PDLC sin laboratory values or vital signs will be classified as belonging to "Tier 2" 
or "Tier 3" based on the number of events observed.  
Tier 1 Events
Safety parameters or AEs of special interest that are identified a priori constitute ‚ÄúTier 1‚Äù 
safety endpoints that will be subject to inferent ial testing for statistical significance with 
p-values and 95% CIs to be provided for between- treatment differences in the proportion of 
participants with events ; these analyses will be performed using the unstratified Miettinen
and Nurminen method [Miettinen, O. 1985] , an unconditional, asymptotic method. Since the 
stratification factors are not considered to be related to safety endpoints, they will not be 
included as stratification factors in the safety analys es.
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% CI sprovided for differences 
in the proportion of participants with events (also via the M iettinen and Nurminen method 
[Miettinen, O. 1985] ).
Membership in Tier 2 requires that at least 4 participants in at least one treatment group 
exhibit the event . The threshold of at least 4 events was chosen because the 95% CI for the 
between -group difference in percent incidence will always include zero when treatment 
groups of equal size each have less than 4 events and thus would add little to the 
interpretation of potentially meaningful differences. Because many 95% CIsmay be provided 
without adjustment for multiplicity, the CIs should be regarded as a helpful descriptive 
measure to be used in review, not a formal method for assessing the statistical significance of 
the between -group differences in AEs and predefined limits of change.
In addition to individual events that occur in 4 or more participants in any treatment group, 
the broad AE categories consisting of the proportion of participants with any AE, a drug -
related AE, a serious AE, an AE which is both drug -related and serious, and discontinuation 
due to an AE will be considered Tier 2 endpoints. 
Tier 3 Events
Safety endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only point 
estimates by treatment group are provided for Tier 3 safety parameters .
06FSHF
07X3DY
PRODUCT: MK-4482  84
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Continuous Safety Measures 
For continuous measures such as changes from baseline in laboratory and vital signs 
parameters, s ummary statistics for baseline, on -treatment, and change from baseline values 
will be provided by treatment group in table format. In addition, summary statistics for the 
difference between treatment groups will also be provided.
Table 6 Analysis Strategy for Safety Parameters
Safety TierSafety Endpointa p-value95% CI for 
Treatment 
ComparisonDescriptive 
Statistics
Tier 1ECIsX X X
Tier 2 Any AE X X
Any Serious AE X X
Any Drug -Related AE X X
Any Serious and Drug -Related AE X X
Discontinuation due to AE X X
Discontinuation due to Drug -Related AE X X
Specific AEs bySOCs and PT (incidence ‚â•4 
participants in at least 1of the treatment groups)
PDLCsb(incidence ‚â•4 participants in at least 1of 
the treatment groups)X
XX
X
Tier 3 Specific AEs bySOC and PT (incidence ,<4 
participants in each of the treatment groups)
PDLCsb(incidence <4 participants in each of the 
treatment groups)
Change from Baseline Results (Labs, Vital Signs)X
X
X
AE=adverse event; CI=confidence interval; ECI=event of clinical interest; PT=preferred term; SOC=s ystem organ class; 
PDLC= pre-defined l imit of change; X=results will be provided.
aAdverse Event references refer to both Clinical and Laboratory AEs.
bIncludes only those endpoints not pre -specified as Tier 1 or not already pre -specified as Tier -2 endpo ints. 
9.6.3 Demographic and Baseline Characteristics
The comparability of the treatment groups for each relevant demographic and baseline 
characteristic will be assessed by the use of tables and/or graphs. No statistical hypothesis 
tests will be performed on these characteristics. The number and percentage o f participants 
screened and randomized a nd the primary reasons for screening failure and discontinuation 
will be displayed. Demographic variables ,baseline characteristics, and prior and concomitant 
therapies will be summarized by treatment either by descr iptive statistics or categorical 
tables.
9.7 Interim Analyses
An eDMC and Sponsor siDMC will review results of interim analyses of this study and will 
make recommendations for any actions to the Sponsor Executive Oversight Committee 
(Table 7 ). Recommendations by the eDMC include possible discontinuation of the study or 
06FSHF
07X3DY
PRODUCT: MK-4482  85
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
modifications to the protocol to protect the safety of participants , review of conditional 
power for pote ntial increase to sample size, and actions resulting from the crossing of an 
efficacy or futility boundary in Phase 3. In addition to the eDMC, the Sponsor siDMC will 
review unblinded data from Phase 2 for purposes of approving the proposed MK -4482 dose 
toadvance into Phase 3.
The eDMC will be supported by an unblinded statistician who will provide treatment- level 
results from the interim analyses. The unblinded statistician will not be involved in any 
discussions regarding modifications to the protocol, s tatistical methods, identification of 
protocol deviations, or data validation efforts after the interim analyses. In addition, there 
will be a small, cross -functional unblinded team of Sponsor personnel or delegates who will 
perform the exposure -response a nd dose -response modeling and other analyses that will be 
used to inform the dose selection decision process and the siDMC review. 
Aseparate ,small, cross -functional unblinded team of Sponsor personnel will also be 
convened for Part 2 of the study with t he purpose of supporting preparation and submission 
ofapplications for emergency use and/or marketing authorization in the case of a positive 
efficacy finding noted by the eDMC at IA4 .The members of this team will not have access 
to unblinded data until a neDMC decision is reached.
Membership on these cross -functional unblinded team swill be documented in an unblinding 
plan and the details of the planned analyses will be outlined in the MAP document prior to 
initiation of the analyses. Sponsor personnel responsible for ongoing blinded data review and 
preparation of the final study report will not be included on the cross -functional unblinded 
team.
Following any decision to terminate or modify the protocol, the executive committee of the 
Sponsor (and potentially other limited Sponsor personnel) may be unblinded to results at the 
treatment level in order to act on these recommendations. The extent to which individuals are 
unblinded with respect to results of interim analyses will be documented in a sepa rate 
unblinding memo. Additional logistical details will be provided in the siDMC and eDMC 
Charters.
Blinding to treatment assignment will be maintained at all investigational sites. The results of 
interim analyses will not be shared with the investigators prior to the completion of the study. 
Participant -level unblinding will be restricted to an internal (or external, as appropriate) 
unblinded cross -functional team performing the interim analyses and dose recommendation, 
who will have no other responsibili ties associated with the study.
There will be 4 interim analyses during the study as shown in Table 7 .
06FSHF
07X3DY
PRODUCT: MK-4482  86
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Table 7 Description of Interim Analyses
Interim Analysis TimingMK-4482 -002 Primary 
Data for AnalysisCommittee Action
IA1‚ÄìPart 1
Dose EvaluationTargeted to occur during Phase 2 after ~300 
participants complete EOT combined in 
MK-4482 -001aand MK -4482 -002. PK, available virologic, 
safety & efficacy data 
through EOTeDMC recommendation for discontinuation of the study 
or protocol modifications 
Sponsor siDMC review of interim safety data and review 
of preliminary virology data
Review by an unblinded team to inform dose selection 
models and analyses
IA2 ‚Äì Part 1b
Dose Selection Targeted to occur at the completion of Phase 2 
after ~300 participants complete Day 29 
(includes participants from IA1). PK, safety & efficacy 
data through Day 29 and 
available virologic dataeDMC recommendation for discontinuation of the study 
or protoco l modifications 
Sponsor siDMC approval of proposed MK -4482 dose for 
Part 2
IA3 ‚ÄìPart 2
Sample Size Re-
estimationTargeted to occur no earlier than at 30% of the 
full planned Part 2 enrollment and no later than 
IA4. Final timing to be based on enrollmen t 
timelines.  Primary efficacy endpoint 
at Day 29Sample size re- estimation to be assessed by eDMC 
based on review of conditional power for primary 
endpoint with potential to increase Part 2 sample size
IA4 ‚ÄìPart 2
Futility/Early 
EfficacyTargeted to occur during Phase 3 after ~ 775
participants complete Day 29 across the 
MK-4482 group and the placebo group (~50% 
of total enrollment).  Safety & efficacy data 
through Day 29Futility and early efficacy to be assessed by eDMC per 
eDMC Charter and guided by statistical criteria
eDMC=external Data Monitoring Committee; EOT=End of Treatment; IA=Interim Analysis; PK=pharmacokinetics; siDMC=standing inter nal Data 
Monitoring Commit tee. 
aMK-4482 -001 is a companion MK -4482 dose-ranging study in hospitalized adults with COVID -19
bIA2represents the analysis of the full Part 1 cohort of participants through Day 29.
06FSHF
07X3DY
PRODUCT: MK-4482  87
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Interim Analyses
IA1‚ÄìPart 1 : Dose Evaluation 
IA1 is targeted to occur during Phase 2 after data is available from ~300 participants 
completing EOT combined in MK -4482- 001 and MK -4482- 002. This IA will be used for 
eDMC interim data review ,Sponsor siDMC review of interim safety data and review of 
preliminary virology data, and for unblinded team review of data to inform dose selection 
models and analyses .
During this interim analysis, enrollment in each study will continue in the 4intervention 
groups in Phase 2 to the targeted enrollment of 300 partic ipants. 
IA2‚ÄìPart 1 : Dose Selection
This analysis is targeted to occur at the completion of Phase 2 after ~300 participants 
(~75 per group) have completed the Day 29 visit. This IA will be used to evaluate the 
dose/exposure -response to select the dose f or Phase 3.  
The relationship between dose and PK (plasma NHC and PBMC NHC -triphosphate), 
virologic endpoints (eg, rate of virologic RNA clearance, viral RNA mutation rate), safety, 
and key efficacy results will be evaluated. PK and virology data from other ongoing studies 
of MK -4482 including MK -4482- 001 will also be examined at the time of this IA to inform 
the Phase 3 dose selection.
Additional details regarding dose selection criteria will be described in the siDMC Charter. 
The dose selected for Phase 3 will be communicated directly to sites in accordance with local 
regulatory requirements .
Part2(Phase 3) enrollment will be initiated after all participants for Part 1 of this study have
completed the Day 29 visit, and after the completion of the IA2 analysis . 
IA3 ‚ÄìPart 2: Sample Size Re -estimation
IA3will include an unblinded sample size re -assessment targeted to occur no earlier than at 
30% of the full planned Part 2 enrollment and no later than IA4. Final timing should be as 
late as possible and prior to completion of enrollment based on enrollment timelines in order 
to obtain maximum study information for the sample size re -estimation . The conditional 
power approach will be employed in which the overall Part 2 sample size (see Section 9.9.1) 
can be adjusted upwards by 450 participants to a total of 2000 if the interim result is 
sufficiently promising (conditional power > 51% but < 80%, assuming continuing the interim 
analysis trend) without inflation of the type I error [Chen, Y. H. J., et al 2004] . The potential 
increase in total Part 2 sample size is to maintain adequate study power in th e event that the 
observed treatment effect at the interim analysis is smaller than the original assumption but 
still clinical meaningful (treatment difference ,MK-4482 minus placebo ,in the percentage of 
participants who are hospitalized and/or die through Day 29 is between -0.037and - 0.053
percentage points).
06FSHF
07X3DY
PRODUCT: MK-4482  88
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
While there is no intention to stop the study early attheunblinded sample size re -assessment
(for the situation when this occur sbefore IA 4) based on a positive efficacy outcome, it is
recognized that the eDMC might consider a recommendation to stop the study should
overwhelming efficacy in favor of MK -4482 be observed. To provide some guidance for the 
eDMC in this situation, a 1- sided p- value ‚â§ 0.0001 is proposed for the test of the prim ary 
endpoint .This conservative criterion for the superiority test will have no impact on the 
overall multiplicity strategy described in Section 9.8.
IA4 ‚ÄìPart 2 : Futility/Early Efficacy IA 
This study will include a futility/early efficacy interim analysis when ~5 0% of participants in 
the selected treatment group and the placebo group have completed the Day 29 visit (Phase 3 
Interim Analysis). The purpose of this interim analysis is to allow for early stopping in the 
case of futility and to allow for the initiation of marketing authorization applications in the 
case of a positive efficacy finding. Given the expected rapid enrollment, there are no plans in 
Part 2 of the study to discontinue enrollment prior to the planned final sample size in the case 
of a positive efficacy outcome.
The Gamma family spending function with Œ≥ = - 1 will be used to set both efficacy and 
futility boundaries for the primary endpoint as a guide for the eDMC in order to control 
overall type I error rate of 0.025, 1 -sided. Assuming the information fraction of 50%, the 
non-binding futility boundary expressed on the absolute difference scale is -0.011 . The 
boundary crossing probabilities for futility are 71% under H 0and 0.8% under H 1(absolute 
difference of - 0.06). The p-value boundary for efficacy is 0.009, corresponding to an absolute 
difference of - 0.048. The boundary crossing probabilities for efficacy are 0.9% under H 0and 
72% under H 1(absolute difference of -0.06).
9.8 Multiplicity 
The success of this study is based on a single primary endpoint ( a composite of 
hospitalization or death) and a single treatment comparison (selected dose of MK -4482 vs. 
placebo). There are no adjustments for multiplicity other than controlling type I error for 
interim analyses described in Section 9.7. The p -value boundary for efficacy at the final 
analysis is 0.019, corresponding to an absolute difference of -0.03.
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power Calculations for Efficacy Analyses (Part 2)
Theprimary analysis of the Phase 3 study endpoint will include ~1550 participants from 
Part2 of the study (~775 for the MK- 4482 800 mggroup and ~775 for the placebo group )
who meet the criteria for inclusion in the MITT population. The primary endpoint is a 
composite of hospitalization or death. The study has overall power of 97% to demonstrate the 
superiority of MK- 4482 800 mgover placebo at an over all one-sided, 2.5% alpha level, if the 
underlying treatment difference (MK -4482 minus placebo) in the percentage of participants 
who are hospitalized and/or die through Day 29 is -6 percentage points. 
06FSHF
07X3DY
PRODUCT: MK-4482  89
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
The power and sample size are based on the following assumptions: 1)an underlying 
percentage hospitalized/dying of 12% for placebo and 6% for MK-4482 (50% reduction in 
the relative risk) and 2) a futility/efficacy interim analysis at 50% information as outlined in 
Section 9.7. The calculation was computed using EAST. To meet the statistical criterion for 
success ( one-sided p ‚â§0.019at the final analysis), the observed treatment difference must be 
approximately - 3.0percentage points or lower, assuming a percentage of 12% for placebo.
The observed percentages from Part 1 of this study in the full MITT cohort were 5.4% in the 
placebo group and 4.1% in the 800 mg group, a difference of only 1.3 percentage points. 
However, higher percentages of placebo pa rticipants met this endpoint within various 
subgroups of the full study population: 21.4% in the subgroup of pa rticipants >60 years of 
age, 8.0% in the subgroup of pa rticipants with TSSO ‚â§5 days and 11.8% in the subgroup of 
participants with TSSO ‚â§5 days and who were at increased risk for severe illness . In these 
subgroups, the percentages of pa rticipants in the 800 mg group were 5.0% (difference of 16.4 
percentage points), 2.1% (difference of 5.9 percentage points) and 3.2% (difference of 8.6 
percentage points), respectively. In each of these subgroups, the observed reduction in the 
relative risk of hospitalization/death associated with 800 mg exceeded 70%. Given the 
modification to the study population for Part 2, the assumption of 12% for placebo and a 
50% reduction in the relative risk are reasonable.
Study power for different assumptions of the underlying percentage hospitalized/dying are 
presented in Table 8, all scenarios are based on a total sample size of 1550 participants and 
an overall one- sided, 2.5% alpha level [Stokes, E. K., et al 2020]. 
Table 8 Study Power by Percentage Hospitalized/ Dying
N=1550 participants ( 775for MK -4482 800 mg and 775for placebo ), alpha=0.025, 1- sided
Placebo Rate (%) MK-4482 Rate (%)Absolute Difference
(percentage points)Power
18% 12% 6 88%
16% 10% 6 92%
14% 8% 6 95%
12% 7% 5 89%
10% 5% 5 95%
8% 4% 4 89%
6% 2% 4 97%
9.9.2 Sample Size and Power Calculations for Virology Analyses (Part 1)
The sample size for Part 1 was not determined based on a specific hypothesis for a specific 
endpoint. The selection of the dose to advance to Part 2 will be based on analyses of the 
totality of data available acr oss the MK -4482 clinical program. Three hundred participants 
(75 per group) will be sufficient to provide reasonable precision to discriminate between 
treatment groups with regard to the virology endpoints. An important endpoint for assessing 
the dose -response relationship is viral RNA change from baseline in SARS -CoV -2 RNA 
06FSHF
07X3DY
PRODUCT: MK-4482  90
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
titer, calculated as log 10(post) minus log 10(baseline). Approximately 80% of this cohort 
(60/group) is expected to have a baseline VLof at least 106copies/mL. A 1 log -unit 
difference between treatment groups in the population mean is considered to be clinically 
relevant. Table 9provides power calculations for true log differences of 0.75 to 1.25 a nd for 
various assumptions about the true underlying standard deviation.
Table 9 Power by Detectable Difference and Standard Deviation Viral RNA change from 
baseline (log10 copies/mL) N=60/group, Œ±=0.025, 1 -sided
Between- Group Difference (log 10copies/mL)
Standard Deviation -0.75 -1.00 -1.25
1.25 90% 99% >99%
1.5 78% 95% >99%
1.75 64% 87% 97%
9.9.3 Sample Size and Power Calculations for Safety Analyses (Part 2)
Part 1 (Phase 2) and Part 2 (Phase 3) of the study will be combined for the final analysis of
safety endpoints. The planned sample size for safety analysis will be 850 for each of 
MK-4482 selected dose group and placebo group .The probability of observing at least 1 of a 
particular type of AE in this study depends on the number of participants treated and the 
underlying percentage of participants with an AE in the study population. If the underlying 
incidence of an AE is 1%, there is >99.9% chan ce of observ ing at least 1AE among 
850participants in the treatment group. If no AE of that type is observed among the 
850participants in any treatment group , this study will provide 97.5% confidence that the 
underlying percentage of participants with the AE is < 0.44 (1 of every 231participants). 
Table 10 summarizes the percentage point differences between the 2 treatment groups that 
could be detected with 9 0% probability for a variety of hypothetical underlying incidences of 
an AE. These calcu lations assume 850 participants in each group and are based on a 2 -sided 
5% alpha level. The calculations are based on Farrington and Manning [Farrington, C. P. and 
Manning, G. 1990] . No multiplicity adjustments were made.
06FSHF
07X3DY
PRODUCT: MK-4482  91
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Table 10 Differences in Incidence of AE Rates B etween the 2 Treatment Groups That Can 
be Detected With a ~9 0% Probability (Assuming 2- sided 5% Alpha L evel with
850Participants in Each Group)
Incidence of Adverse Event Risk Difference
Placebo (%) MK-4482 (%) Percentage Points
1.0 3.3 2.3
5.0 9.1 4.1
10.0 15.3 5.3
20.0 26.7 6.7
30.0 37.5 7.5
40.0 47.8 7.8
Incidences presented here are hypothetical and do not represent actual adverse experiences in either group. 
Calculations are based on Farrington and Manning [Farrington, C. P. and Manning, G. 1990]
9.10 Subgroup An alyses 
To determine whether the treatment effect is consistent across various subgroups, the 
estimate of the between- group treatment effect (with a nominal 95% CI) for the primary 
endpoint will be estimated and plotted within each category of each subgrou p. The following 
are examples of classification variables: 
‚Ä¢Age category ( ‚â§60 vs >60 years)
‚Ä¢Sex (female, male)
‚Ä¢Baseline (Day 1) disease severity ( mild, moderate) per Appendix 9
‚Ä¢Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White)
‚Ä¢Time from symptom onset prior to the day of randomization (‚â§5days, >5 days) [ Part 1 
only]
‚Ä¢Time from symptom onset prior to the day of randomization (‚â§3days, >3 days) [Part 2 
only]
‚Ä¢At increased risk for severe illness from COVID- 19 (yes, no) (Appendix 10) [Part 1 only]
‚Ä¢Geographic region (North America , Europe , Asia Pacific , Latin America)
‚Ä¢Baseline (Day 1) SARS -CoV -2 quantitative assay VLstatus ( undetectable
[<500 copies/mL], low VL [500 to ‚â§ 10^6 copies/mL] , high VL [>10^6 copies/mL] )
[Part 2 only]
06FSHF
07X3DY
PRODUCT: MK-4482  92
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
‚Ä¢Baseline (Day 1) SARS -CoV -2 qualitative assay VLstatus (undetectable, detectable)
[Part 2 only]
‚Ä¢Baseline (Day 1) SARS -CoV -2 antibody status (negative, positive) [Part 2 only]
Additional subgroups may be defined in the sSAP. Categories of the above subgroups with 
small sample sizes (<25 per treatment group) may be combined ‚Äìfurther detail will be 
provided in the sSAP.
9.11 Compliance (Medication Adherence) 
Compliance will be calculated based on capsule counts. For a participant who is followed for 
the entire study period, the ‚ÄúNumber of Capsules Should be Taken‚Äù is the total number of 
capsules should be taken from randomization to the last scheduled day for treatment 
administration for that participant. For a participant who discontinues from the study 
permanently, the ‚ÄúNumber of Capsules Should be Taken‚Äù is the total number of capsules
should be taken from randomization to the date of the last dose of study intervention. The 
‚ÄúNumber of Capsules Taken‚Äù will be based on data reported in the eCRF.
For each participant, percent compliance will then be calculated using the following formula:
Summary statistics will be provided on percent compliance by treatment group for the MITT 
population.
9.12 Extent of Exposure
The Extent of Exposure to study treatment will be evaluated by summary statistics (N, mean, 
median, standard deviation) for the ‚ÄúNumber of Capsules Taken ‚Äù by treatment group.
06FSHF
07X3DY
PRODUCT: MK-4482  93
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, E thical, and Study Oversight Considerations
10.1.1 Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and sc ientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted 
in compliance with local and/or national regulations (including all applicable data protection laws and
regulations), and International Council for Harmonisation Good Clinical Practice (ICH- GCP), and also in 
accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest eth ical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator- initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of th e trial and shall respect the data protection rights of all participants, trial site staff and, where 
applicable, third parties . Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by MSD personnel (or individuals acting on behalf of MSD) to assess the ability 
to successfully conduct the trial.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews cli nical data for accuracy, completeness, and consistency. Data are verified versus 
06FSHF
07X3DY
PRODUCT: MK-4482  94
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
source documentation according to standard operating procedures. Per MSD policies and procedures, if
potential fraud, scientific/research misconduct, privacy incidents/breache sorClinical Trial -related 
Significant Quality Issues are reported, such matters are investigated . When necessary, appropriate corrective 
and/or preventative actions are defined and regulatory authorities and /orethics review committees are 
notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis -generating rather 
than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as multiplicity.
MSD‚Äôs policy on authorship is consistent with the recommendations published by the In ternational Committee of 
Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by MSD for regulatory authority 
acceptance/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protoco l amendment(s), informed consent form, investigator‚Äôs brochure, and other relevant trial 
documents must be reviewed and approved by an IRB/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the proto col that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. 
MSD will inform regulatory authorities of such new measures to protect participant safety, in com pliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alt ernatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent p ossible , as well as all 
applicable data protection rights . Unless required by law, only the investigator, Sponsor (or individuals acting on 
behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records 
that might identify the participant by name.
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics committee.
06FSHF
07X3DY
PRODUCT: MK-4482  95
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time -and labor -intensive. It is MSD‚Äôs policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by MSD, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications result ing from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSD‚Äôs Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Finan cial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request fo r 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certificati on/Disclosure Form, commonly known as a financial disclosure form, provided by 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes. This may involve th e 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
The Sponsor will conduct this study in compliance with all applicable data protection 
regulations.
06FSHF
07X3DY
PRODUCT: MK-4482  96
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Participants will be assigned a unique identifier by the Sponsor. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be inf ormed that his/her personal study- related data will be used by the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may b e examined by Clinical 
Quality Assurance auditors or other authori zed personnel appointed by the S ponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.
10.1.3.1 Confidentiality of Data
By signing this protocol, the investigator affi rms to the Sponsor that information furnished to 
the investigator by the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an ap propriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by this study will be 
considered confidential by the investigator, except to the extent that it is included in a 
publication as pr ovided in the Publications section of this protocol.
10.1.3.2 Confidentiality of Participant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/ CRF data. By signing the consent form, the participant agrees to this 
process. If study documents will be photocopied during the process of verifying 
worksheet/ CRF information, the participant will be identified by unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable pr ivacy laws, rules 
and regulations.
10.1.3.3 Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory agency review upon request by those agencies .
06FSHF
07X3DY
PRODUCT: MK-4482  97
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.1.4 Committees Structure
10.1.4.1 Executive Oversight Committee
The EOC is comprise d of members of Sponsor Senior Management. The EOC will receive 
and decide on any recommendations made by the eDMC regarding the study.
10.1.4.2 Internal Data Monitoring Committee
A separate siDMC will review results of interim analysis(es) from Part 1 of this study. The 
siDMC is comprised of members of Sponsor Senior Management, none of whom are directly 
associated with the conduct of this study. The siDMC will review unblinded study data at t he 
determine dfrequency (Section 9.7 Interim Analyses) for dose selection as described in 
detailed monitoring guidelines. The siDMC will make recommendations for any actions ( eg,
approval of proposed dose) to the Sponsor Executive Oversight Committee.
Specific details regarding r esponsibilities of the siDMC will be described in a separate 
charter that is reviewed and approved by the siDMC.
10.1.4.3 External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the inter im data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they cannot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study.
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of the study. Also, the DMC will review interim 
study results, consider the over all risk and benefit to study participants (Section 9.7 [Interim 
Analysis] ) and recommend to the EOC whether the study should continue in accordance with 
the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC c harter that is 
reviewed and approved by all the DMC members.
10.1.5 Publication Policy
The results of this study may be published or presented at scientific meetings. The Sponsor 
will comply with the requirements for publication of study results. In accordance with 
standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator will be designated by mutual agreement.
06FSHF
07X3DY
PRODUCT: MK-4482  98
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
If publication activity is not directed by the Sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary inform ation and to provide comments.
Authorship will be determined by mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements .
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinic al trial Directive 2001/20/EC, the 
Sponsor of the study is solely responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local re gistries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by calling a central contact number for further 
information on appropriate study locations and study site contact information.
By signing this pro tocol, the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive ,or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about this study or i ts results to tho se 
registries.
10.1.7 Compliance with Law, Audit, and Debarmen t
By signing this protocol, the investigator agrees to conduct the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, Internationa l Council on Harmoni sation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally accepted 
standards of GCP ); and all applicable federal, state and local laws, rules and regulations 
relating to the conduct of the clinical study.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by MSD, is provided i n this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by the Sponsor.
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
06FSHF
07X3DY
PRODUCT: MK-4482  99
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on cli nical studies by any court or regulatory 
authority will not be allowed to conduct or work on this Sponsor‚Äôs studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or i f any proceeding for debarment is pending or, to the best 
of the investigator‚Äôs knowledge, threatened .
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or desi gnee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the CRF.
Detailed information regarding Data Management proced ures for this protocol will be 
provided separately.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the study site upon request for i nspection, 
copying, review, and audit at reasonable times by representatives of the Sponsor or any 
regulatory authorities. The investigator agrees to promptly take any reasonable steps that are 
requested by the Sponsor or any regulatory authorit ies as a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing sou rce data review and verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is bein g conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants‚Äô documented informed consent, pertaining to 
the conduct of thi s study must be retained by the investigator for 15 years after study 
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of t he 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor .
06FSHF
07X3DY
PRODUCT: MK-4482  100
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study records that include al lpertinent observations on each 
of the site‚Äôs participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator‚Äôs site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depend ing on the study. Also, current medical records must be available .
10.1.10 Study and Site Closure
The Sponsor or its designee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site‚Äôs IRB/IEC as specified by applicable regulatory 
requirement(s).
06FSHF
07X3DY
PRODUCT: MK-4482  101
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.2 Appendix 2: Clinical Laboratory Tests
‚Ä¢The tests detailed in Table 11will be performed by the central laboratory.
‚Ä¢Local laboratory test is required for initial COVID -19 SA RS-CoV -2 infection 
confirmation and determination of participant eligibility .
‚Ä¢All other l ocal laboratory results are only required in the event that the central 
laboratory results are not available in time for participant management, or for either 
study intervention administration and/or response evaluation. If a collection of a local 
sample is required, it is important that the sample for central analysis is obtained at 
the same time; however, if it is documented fora specific participant visit that centr al 
sample analysis will not be possible, then the parallel collection of the sample for 
central analysis is not required. Additionally, if the local laboratory results are used 
for participant management, or to make either a study intervention decision or 
response evaluation, the results must be entered into the CRF.
‚Ä¢Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section 5of the protocol.
‚Ä¢Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations.
‚Ä¢The i nvestigator (or medically qualified designee) must document their review of 
each laboratory safety report (eg, hematology, chemistry, pregnancy ).
‚Ä¢Laboratory/analyte results that could unblind the participant‚Äôs intervention group will 
not be reported to blinded site and Sponsor personnel. These laboratory results 
include but may not be limited to virology results with the exception of screening
resul ts and error reports .
06FSHF
07X3DY
PRODUCT: MK-4482  102
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Table 11 Protocol -require d Laboratory Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count RBC Indices:
MCV
MCH
RDWWBC count with Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
Calculation of: 
Neutrophil/lymphocyte ratio
Absolute Neutrophil CountRBC Count
Hemoglobin
Hematocrit
Chemistry BUN Chloride AST/SGOT
Albumin Calcium ALT/SGPT
Creatinine Phosphorous Alkaline phosphatase
Glucose 
(nonfasting )Amylase GGT
Potassium Lipase LDH
Bicarbonate Total Protein Total bilirubin (and direct bilirubin, if 
total bilirubin is elevated above the 
ULN )
Sodium Magnesium hs-CRP (inflammatory biomarker ) 
will be tested at all visits with 
chemistry collection as the test is 
performed on the same blood sample
CK
Pregnancy Testing ÔÇ∑Urine or Serum hCG pregnancy test (as needed for WOCBP)
Virology ÔÇ∑SARS- CoV- 2 RNA (real time PCR) OP (Part 1 only) and NP (Parts 1 and 2) swabs 
(quantitative and q ualitative)
ÔÇ∑SARS -CoV -2 Gene Sequenci ng 
Pharmacokinetics ÔÇ∑Plasma for NHC
ÔÇ∑PBMC for NHC -triphosphate
Exploratory 
Research SamplesSamples may be used for testing such as:
ÔÇ∑SARS- CoV- 2 Antibodies 
ÔÇ∑Infectious SARS -CoV- 2 presence/quantitation
ÔÇ∑Coinfection with other respiratory pathogens
ÔÇ∑Viral genotyping and treatment -emergent variant detection
ALT=alanine aminotransferase ;AST=aspartate aminotransferase ;BUN=blood urea nitrogen ;CK=creatine kinase; 
GGT=gamma -glutamyl transferase; hCG=human chorionic gonadotropin ;hs-CRP =High -sensitivity C- reactive protein ;
IL-6=Interleukin 6; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin ; MCV=mean corpuscular 
volume ;NHC=N- hydroxycytidine; NP=nasopharyngeal; OP=oropharyng eal; PBMC= peripheral blood mononuclear 
cells; PCR= polymerase chain reaction; RBC=red blood c ell;RDW=red cell distribution width; RNA=ribonucleic acid; 
SGOT=serum glutamic -oxaloacetic transaminase ; SGPT=serum glutamic -pyruvic transaminase ;ULN=upper limi t of 
normal ; WBC=white blood cell; WOCBP=women of childbearing potential .
06FSHF
07X3DY
PRODUCT: MK-4482  103
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Table 12 Approximate Whole Blood Volumes (mL)
Study Period:
Specimen or Matrix Type 
(Tube Type/Additive)Screening Intervention Follow -Up
Total 
Blood 
VolumesVisit Number/Title: 1 2 3 4 5 6 7 8 9
Scheduled Day (and 
Window):Screening Day 1 Day 2 Day 3 Day 4 EOTDay 10 
(¬±1 day)Day 15 
(+3 
days)Day 29 
(+3 
days)
Nasopharyngeal Swabflocked or polyester -
tipped swab (3 mL 
universal transport 
medium)X X X X X X
NAOropharyngeal Swabflocked or polyester -
tipped swab (3 mL 
universal transport 
medium)X X X X X X
Chemistry (Day 29 
includes serum 
pregnancy)Serum (no additive) 2.5 2.5 2.5 2.5 2.5 3.5
Hematology Whole Blood (EDTA) 2 2 2 2 2 2
Plasma/Serum Research 
SamplesWhole Blood (clot 
activator and EDTA) 
processed to both plasma 
and serum16 16 16 16
Serum for Antibody 
Exploratory ResearchSerum (no additive) 2.5 2.5 2.5 2.5
Sub Total for all 
Participants for 
Central Laboratory NA 0 23.5 0 4.5 0 23.5 23.5 4.5 24
Pharmacokinetics NA
Pharmacokinetic Plasma 
Sampling Part 1Plasma (EDTA) 6
Pharmacokinetic Plasma 
Sampling Part 2Plasma (EDTA) 6
06FSHF
07X3DY
PRODUCT: MK-4482  104
PROTOCOL/AMENDMENT NO.: 002-04 
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Study Period:
Specimen or Matrix Type 
(Tube Type/Additive)Screening Intervention Follow -Up
Total 
Blood 
VolumesVisit Number/Title: 1 2 3 4 5 6 7 8 9
Scheduled Day (and 
Window):Screening Day 1 Day 2 Day 3 Day 4 EOTDay 10 
(¬±1 day)Day 15 
(+3 
days)Day 29 
(+3 
days)
Pharmacokinetic PBMC 
Sampling Part 1Whole Blood (Sodium 
Heparin) processed to 
PBMCs32
Total For Participants 
in Part 1
NA0 23 0 4.5 0 29 23 4.5 24 108
Total For Participants 
in Part 20 23 0 4.5 0 29 23 4.5 24 108
Total For PBMC 
Cohort Participants in 
Part 10 23 0 4.5 0 61 23 4.5 24 140
EDTA: ethylenediaminetetraacetic acid; hCG: human chorionic gonadotropin; N/A: not applicable; PBMC: peripheral blood mononuclear cells; WOCBP: 
women of childbearing potential.
06FSHF
07X3DY
PRODUCT:   MK-4482  105
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
ÔÇ∑An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
ÔÇ∑NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
ÔÇ∑NOTE: For purposes of AE definition, study intervention (also referred to as Sponsor‚Äôs 
product) includes any pharmaceutical product, biological product, vaccine, diagnostic 
agent, medical device, combin ation product, or protocol specified procedure whether 
investigational or marketed (including placebo, active comparator product, or run -in 
intervention) , manufactured by, licensed by, provided by, or distributed by the Sponsor 
for human use in this study.
Events meeting the AE definition
ÔÇ∑Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, cons idered clinically significant in the medical 
and scientific judgment of the investigator.
ÔÇ∑Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.
ÔÇ∑New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
ÔÇ∑Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
ÔÇ∑Signs, symptoms, or the clinical se quelae of a suspected overdose of either study 
intervention or a concomitant medication.
ÔÇ∑For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. A n overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology ‚Äúaccidental or intentional overdose without adverse effect.‚Äù
ÔÇ∑Any new cancer or progression of existing cancer.
06FSHF
07X3DY
PRODUCT:   MK-4482  106
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Events NOT meeting the AE d efinition
ÔÇ∑Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
ÔÇ∑Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
ÔÇ∑Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
ÔÇ∑Surgery planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
ÔÇ∑Refe r to Section 8.4.6 for protocol -specific exceptions.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
‚Ä¢The term ‚Äú life-threatening ‚Äùin the definition of ‚Äúserious‚Äù refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of exis ting hospitalization
‚Ä¢Hospitalization is defined as an inpatient admission, regardless of length of stay, even 
if the hospitalization is a precautionary measure for continued observation. (Note: 
Hospitalization for an elective procedure to treat a pre -exist ing condition that has not 
worsened is not an SAE. )A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant‚Äôs 
medical history.
d.Results in persistent or significant disa bility/incapacity
‚Ä¢The term disability means a substantial disruption of a person‚Äôs ability to conduct 
normal life functions.
‚Ä¢This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nau sea, vomiting, diarrhea, influenza, 
06FSHF
07X3DY
PRODUCT:   MK-4482  107
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
‚Ä¢In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
‚Ä¢Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospitalization but may 
jeopardize the participant or may require medical or surgical intervention to prevent 1 
of the other outcomes listed in the above definition. These events should usually be 
conside red serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug depende ncy 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
‚Ä¢Is a cancer
‚Ä¢Is assoc iated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
ÔÇ∑When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to 
the event.
ÔÇ∑The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
ÔÇ∑It is not acceptable for the investigator to send photocopies of the participant‚Äôs medical 
records to the Sponsor in lieu of completion of the AE CRF page.
06FSHF
07X3DY
PRODUCT:   MK-4482  108
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
ÔÇ∑There may be instances when copies of medical records for certain cases are requested by 
the Sponsor. In this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the cop ies of the medical records before submission to the 
Sponsor.
ÔÇ∑The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/sympt oms) will be documented as the AE/SAE.
Assessment of i ntensity /toxicity
ÔÇ∑An event is defined as ‚Äúserious ‚Äùwhen it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
‚Ä¢The investigator w ill make an assessment of intensity for each AE and SAE (and other 
reportable safety event) by recording the grade according to the NIH DAIDS Table for 
Grading the Severity of Adult and Pediatric Adverse Events, version 2.1 . Any AE which 
changes DAIDS grad e over the course of a given episode will have each change of grade 
recorded on the AE CRFs/worksheets.
Grade 1 Mild event : Mild symptoms causing no or minimal interference with usual 
social and functional activities with intervention not indicated.
Grade 2 Moderate event : Moderate symptoms causing greater than minimal 
interference with usual social and functional activities with intervention indicated.
Grade 3 Severe event: Severe symptoms causing inability to perform usual social 
and func tional activities with intervention or hospitalization indicated.
Grade 4 Potentially life -threatening event: Potentially life -threatening symptoms 
causing inability to perform basic self -care fun ctions with intervention indicated to 
prevent permanent impa irment, persistent disability, or death.
Grade 5 Death: Deaths related to an AE.
Assessment of c ausality
‚Ä¢Did the Sponsor ‚Äôs product cause the AE?
‚Ä¢The determination of the likelihood that the Sponsor ‚Äôs product caused the AE will be 
provided by an investigato r who is a qualified physician. The investigator‚Äôs signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done . This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
06FSHF
07X3DY
PRODUCT:   MK-4482  109
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
‚Ä¢The following components are to be used to assess the relationship between the 
Sponsor ‚Äôs product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor ‚Äôs 
product c aused the AE:
Exposure: Is there evidence that the participant was actually exposed to the 
Sponsor ‚Äôs product such as: reliable history, acceptable compliance assessment (pill 
count, diary, etc), expected pharmacologic effect, or measurement of 
drug/metabol ite in bodily specimen?
Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ‚Äôs product? Is the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal 
product)?
Likely Cause: Is the AE not reasonably explained by another etiology such as 
underlying disease, other drug(s)/vaccine(s), or other host or environmental factors.
Dechallenge: Was the Sponsor ‚Äôs product discontinued or dose/exposure/frequency 
reduc ed?
‚ó¶If yes, did the AE resolve or improve?
‚ó¶If yes, this is a positive dechallenge.
‚ó¶If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability; (2) the AE resolved/improved despite continuation of the Sponsor ‚Äôs 
product; (3) the study is a single -dose drug study; or (4) Sponsor ‚Äôs product(s) is/are 
only used 1 time.)
Rechallenge: Was the participant re -exposed to the Sponsor ‚Äôs product in this 
study?
‚ó¶If yes, did the AE recur or worsen?
‚ó¶If yes, this is a positive rechallenge.
‚ó¶If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose drug study; or (3) Sponsor ‚Äôs 
product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR ‚ÄôS PRODUCT, OR IF RE -EXPOSURE 
TO THE SPONSOR ‚ÄôS PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
06FSHF
07X3DY
PRODUCT:   MK-4482  110
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY THE SPONSOR CLINICAL DIRECTOR, AND IF REQUIRED, THE 
IRB/IEC .
‚Ä¢Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor ‚Äôs product or drug class 
pharmacology or toxicology?
‚Ä¢The assessment of relationship will be reported on the case report forms/worksheets by 
an investigator who is a qualified physician according to his/her best clinical ju dgment, 
including consideration of the above elements.
‚Ä¢Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ‚Äôs product relationship).
Yes, there is a reasonable possibility of Sponso r‚Äôs product rela tionship:
‚ó¶There is evidence of exposure to the Sponsor ‚Äôs product. The temporal sequence 
of the AE onset relative to the administration of the Sponsor ‚Äôs product is 
reasonable. The AE is more likely explained by the Sponsor ‚Äôs product than by 
another cause.
No, there is not a re asonable possibility of Sponsor‚Äô s product relationship:
‚ó¶Participant did not receive the Sponsor ‚Äôs product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ‚Äôs product is not reasonable 
OR the AE is more likely explained by another cause than the Sponsor‚Äôs 
product. (Also entered for a participant with overdose without an associated 
AE.)
‚Ä¢For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an a ssessment of causality.
‚Ä¢There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
‚Ä¢The investigator may change his/her opinion of causality in light of follow -up 
information and send an SAE follow -up report with the updated causality assessment.
‚Ä¢The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
06FSHF
07X3DY
PRODUCT:   MK-4482  111
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Follow -up of AE and SAE
ÔÇ∑The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Sponsor to 
elucidate the nature and/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
ÔÇ∑New or updated information will be recorded in the CRF.
ÔÇ∑The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Ev ents to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
ÔÇ∑The primary mechanism for reporting to the Sponsor will be the EDC tool.
Electronic reporting procedures can be found in the EDC da ta entry guidelines (or 
equivalent).
If the electronic system is unavailable for more than 24 hours, then the site will 
use the paper AE Reporting form.
‚ó¶Reference Section 8.4.1 for reporting time requirements.
ÔÇ∑The site will enter the SAE data into the electronic system as soon as it becomes 
available.
ÔÇ∑After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
ÔÇ∑If a site receives a report of a new SAE from a st udy participant or receives updated data 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by telephone (see next section).
ÔÇ∑Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
06FSHF
07X3DY
PRODUCT:   MK-4482  112
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
SAE reporting to the Sponsor via paper CRF
ÔÇ∑If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
ÔÇ∑In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is a cceptable with a copy of the SAE data collection tool sent by overnight 
mail or courier service.
ÔÇ∑Initial notification via telephone does not replace the need for the investigator to complete 
and sign the SAE CRF pages within the designated reporting t ime frames.
ÔÇ∑Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent) .
06FSHF
07X3DY
PRODUCT:   MK-4482  113
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.4 Appendix 4: Medical Device and Drug- device Combination Products : Product 
Quality Complaints/Malfunction s: Definition s, Recording, and Follow -up
Not applicable.
06FSHF
07X3DY
PRODUCT:   MK-4482  114
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, addi tional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
‚Ä¢Premenarchal
‚Ä¢Premenopausal female with 1 of the following:
Documented hysterectomy
Documented bilateral salpingectomy
Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel‚Äôs review of the participant‚Äôs 
medical records, medical examination, or medical history interview.
‚Ä¢Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.
‚ó¶A high FSH level in the po stmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of 12 months of amenorrhea, confirmation with two 
FSH measurements in the postmenopausal range is required.
Females o n HRT and whose menopausal status is in doubt will be required to use 
one of the nonhormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.
06FSHF
07X3DY
PRODUCT:   MK-4482  115
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correct ly.
‚Ä¢Progestogen -only subdermal contraceptive implantb
‚Ä¢IUSc
‚Ä¢Non-hormonal IUD
‚Ä¢Bilateral tubal occlusion
‚Ä¢Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia for a male pa rticipant can come from the site personnel‚Äôs review of 
the participant‚Äôs medical records, medical examination, or medical history interview.
Sexual Abstinence
‚Ä¢Sexual abstinence is considered a highly effective method only if defined as refraining from het erosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant.
Highly Effective Contraceptive Methods That Are User Dependentd(must be used in combination with a 
barrier method)
ÔÇ∑Combined (estrogen -and progestogen -containing) hormonal contraceptionb
-Oral
-Intravaginal
-Transdermal
-Injectable
ÔÇ∑Progestogen -only hormonal contraceptionb
-Oral
-Injectable
Barrier methods to be used with user dependent hormonal contraceptives above (male condoms are preferred 
method)
ÔÇ∑Male or female condom with or without spermicide
ÔÇ∑Cervical cap, diaphragm, or spo nge with spermicide 
A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double barrier 
methods)
aContraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive 
methods for participants of clinical studies.
bIf locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are limited to those which 
inhibit ovulation.
cIUS is a progestin releasing IUD.
dFailure ra te of <1% per year when used consistently and correctly (and not in combination with barrier method). Typical 
use failure rates are higher than perfect -use failure rates (ie, when used consistently and correctly).
Note: The following are not acceptable met hods of contraception alone or in combination:
-Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and LAM.
-Male and female condom should not be used together (due to risk of failu re with friction). 
06FSHF
07X3DY
PRODUCT:   MK-4482  116
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that is 
a sign of a normal or abnormal process or of a condition or disease. A biomarker may 
be used to see how well the body responds to a treatment for a disease or condition.1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 8. 9will be 
used in various experiments to understand:
‚Ä¢The biology of how drugs/vaccines work
‚Ä¢Biomarkers responsible for how a drug/vaccine enters and is removed by the body
‚Ä¢Other pathways with which drugs/vaccines may interact
‚Ä¢The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specime ns offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with t he greatest need. All specimens will be used by the Sponsor or those working for or 
with the Sponsor.
3.Summary of Procedures for Future Biomedical Researc h
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in 
future biomedical research.
06FSHF
07X3DY
PRODUCT:   MK-4482  117
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study 
visit by the investigator or his or her d esignate. Informed consent for future 
biomedical research should be presented to the participants on the visit designated in 
the SoA. If delayed, prese nt consent at next possible Participant Visit. Consent forms 
signed by the participant will be kept at the clinical study site under secure storage for 
regulatory reasons.
A template of each study site‚Äôs approved informed consent will be stored in the 
Spon sor‚Äôs clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional blood specimens ar e being collected for future 
biomedical research , these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research
In order t o optimize the resea rch that can be conducted with fu ture biomedical research
specimens, it is critical to link participant s' clinical information with future test results. In 
fact,little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow spec ific analyses to be conducted. Knowing 
participant characteristics like sex, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical research
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifier s will 
appear on the specimen tube.
06FSHF
07X3DY
PRODUCT:   MK-4482  118
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices. Analyses using the future biomedical research s pecimens may be performed by 
the Sponsor, or an additional third party (eg, a university investigator) designated by the 
Sponsor. The investigator conducting the analysis will follow the Sponsor‚Äôs privacy and 
confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope of analysis outlined in future biomedical research protocol and consent. 
Future biomedical research specimens remaining with the third party after specific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Biomed ical Research
Participants may withdraw their consent for FBR and ask that thei r biospecimens not be 
used for FBR . Participants may withdraw consent at any time by contacting the study 
investigator. If medical records for the study are still available, the investigator will 
contact the Sponsor using the designated mailbox 
(clinical.specimen.management@merck.com). Subsequently, the participant's specimens 
will be flagged in the biorepository and restricted to study use only. If specimens were 
collected from study participants specifically for FBR , these specimens will be removed 
from the biorepository and destroyed. Documentation will be sent to the investigator 
confirming withdrawal and/or destruction, if applicable. It is the responsibility of the 
investigator to inform the participant of comple tion of the withdrawal and/or destruction, 
if applicable. Any analyses in progress at the time of request for withdrawal/destruction 
or already performed before the request being received by the Sponsor will continue to be 
used as part of the overall resea rch study data and results. No new analyses would be 
generated after the request is received.
If the medical records for the study are no longer available (eg, if the investigator is no 
longer required by regulatory authorities to retain the study records) or the specimens 
have been completely anonymized, there will no longer be a link between the 
participant‚Äôs personal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7.Rete ntion of Specimens
Future biomedical research specimens will be stored in the biorepository for potential 
analysis for up to 20 years from the end of the study. Specimens may be stored for longer 
if a regulatory or governmental authority has active questio ns that are being answered. In 
this special circumstance, specimens will be stored until these questions have been 
adequately addressed.
Specimens from the study site will be shipped to a central laboratory and then shipped to 
the Sponsor -designated biorepository. If a central laboratory is not u tilized in a particular 
study, the study site will ship directly to the Sponsor -designated biorepository. The 
specimens will be stored under strict supervision in a limited access facility which 
operates to assure t he integrity of the specimens. Specimens will be destroyed according 
06FSHF
07X3DY
PRODUCT:   MK-4482  119
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository database.
8.Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices base d on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: lack of relevance to participant health, limitations of pr edictive 
capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly report this information to doctors and participants. Participants will not be 
identified by name in any published reports about this study or in any other scientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for future biomedical research.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are
described in the future biomedical research informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible br each of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly to 
clinical.speci men.management@merck.com.
06FSHF
07X3DY
PRODUCT:   MK-4482  120
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=45618
2.International Council on Harmoni sation [Internet]: E15: Definitions for Genomic 
Biomar kers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding 
Categories. Available from http://www.ich.org/products/guidelines/efficacy/efficacy -
single/article/definitions -for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -
genomic -data-and-sample -cod.html 
3.Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope 
and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/ 
4.Indus try Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i-
pwg.org/
06FSHF
07X3DY
PRODUCT:   MK-4482  121
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.7 Appendix 7: Country -specific Requirements
10.7.1 Country -specific R equest for Germany
Legally Acceptable Representative
In order for a participant to be eligible to participate in Germany, he/she must be capable of 
signing the informed consent; therefore, all references to a participant‚Äôs ‚Äúlegally acceptable 
representative‚Äù in the protocol are not applicable for participants in Germany.
06FSHF
07X3DY
PRODUCT:   MK-4482  122
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.8 Appendix 8: Ordinal Outcome Scales
10.8.1 World Health Organization 11- Point Scale 
The WHO11-point ordinal scale for clinical progression is as follows, with 0 assigned to 
‚ÄúUninfected; no viral RNA detected‚Äù and 10 assigned to ‚ÄúDead‚Äù [Marshall, J. C., et al 2020] :
ÔÇ∑Patient State: ‚Äú Uninfected ‚Äù
oUninfected; no viral RNA detected
ÔÇ∑Patient State: ‚ÄúAmbulatory Mild Disease‚Äù
oAsymptomatic; viral RNA detected
oSymptomatic; independent
oSymptomatic; assistance needed
ÔÇ∑Patient State: ‚ÄúHospitalized; Moderate Disease‚Äù
oHospitalized; no oxygen therapy*
oHospitalized; oxygen by mask or nasal prongs
ÔÇ∑Patient State ‚Äú Hospitalized; Severe Disease‚Äù
oHospitalized; oxygen by non- invasive ventilation or high- flow
oIntubation and mechanical ventilation; pO 2/FiO 2‚â•150 or SpO 2/FiO 2‚â•200
oMechanical ventilation pO 2/FiO 2<150 (SpO 2/FiO 2<200) or vasopressors
oMechanical ventilati on pO 2/FiO 2<150 and vasopressors, dialysis, or 
extracorporeal membrane oxygenation
ÔÇ∑Patient State ‚ÄúDead‚Äù
oDead
Abbreviations: FiO 2=fraction of inspired oxygen; pO 2=partial pressure of oxygen; SpO 2=Oxygen saturation. 
* If hospitalized for isolation only, record status as for ambulatory patient.
06FSHF
07X3DY
PRODUCT:   MK-4482  123
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.9 Appendix 9: COVID -19 Severity Categorization
Adapted from ‚ÄúCOVID -19: Developing Drugs and Biological Products for Treatment or 
Prevention Guidance for Industry‚Äù US Food and Drug Industry (M AY2020), WHO 
COVID- 19 case definition, and COVID- 19 symptoms recognized by CDC [Food and Drug 
Administration 2020] [World Health Organization 2020] [Tenforde, M. W., et al 2020] .
For inclusion in th e study, the following are required of all participants:
ÔÇ∑A positive SARS -CoV- 2 test result (Inclusion Criterion #1)
ÔÇ∑Signs/symptoms attributable to COVID -19 present at randomization (Inclusion 
Criterion #2), including one or more of the following: fever >38.0¬∫C, chills, cough, 
sore throat, shortness of breath or difficulty breathing with exertion, fatigue, 
nasal congestion, runny nose, headache, muscle or body aches, nausea, vomiting, 
diarrhea, loss of taste, loss of smell
In addition to the above criteria, the participant must be categorized into one of the following 
COVID- 19 severity categories at the time of randomization: mild or moderate COVID- 19
(Inclusion Criterion #3). The COVID -19 severity category that is entered in IRT at 
randomization must be bas ed on assessments (vital signs, COVID -19 signs/symptoms, 
respiratory measures, oxygen therapy, ongoing medical history) completed and documented 
on Day 1 prior to calling IRT in order to randomize.
Vital sign measurements should be preceded by at least 5 m inutes of rest for the participant 
in a quiet setting without distractions .
Mild COVID -19: 
Must have ALL of the following:
ÔÇ∑Respiratory rate <20 breaths per minute 
ÔÇ∑Heart rate <90 beats per minute
ÔÇ∑SpO 2>93% on room air or on supplemental oxygen for a reason other than COVID -19 
which HAS NOT increased since onset of COVID -19 signs/symptoms
AND 
Must NOT have shortness of breath at rest or with exertion as assessed by the investigator , 
respiratory failure, shock, or multi -organ dysfunction/failure (see definitions in Critical COVID -19 
below)
06FSHF
07X3DY
PRODUCT:   MK-4482  124
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Moderate COVID -19: 
Must have ONE or MORE of the following:
ÔÇ∑Shortness of breath with exertion as assessed by the investigator
ÔÇ∑Respiratory rate ‚â•20 to <30 breaths per minute
ÔÇ∑Heart rate ‚â•90 to <125 beats per minute
AND
Must have SpO 2>93% on room air or on supplemental oxygen for a reason other than COVID -19 
which HAS NOT increased since onset of COVID -19 signs/symptoms [or only on ‚â§4liters/min 
supplemental oxygen for COVID -19 (but was not previously on supplemental oxygen), regardless 
of SpO 2]
AND
Must NOT have shortness of breath at rest as assessed by the investigator , respiratory failure, 
shock, or multi- organ dysfunction/failu re (see definitions in Critical COVID -19 below)
Severe COVID -19: 
Must have ONE or MORE of the following:
ÔÇ∑Shortness of breath at rest as assessed by the investigator
ÔÇ∑Respiratory rate ‚â•30 breaths per minute
ÔÇ∑Heart rate ‚â•125 beats per minute
ÔÇ∑SpO 2‚â§93% on room air or on supplemental oxygen for a reason other than COVID -19 
which HAS NOT increased since onset of COVID -19 signs/symptoms
ÔÇ∑On supplemental oxygen for a reason other than COVID -19 which HAS increased since 
onset of COVID -19 signs/symptoms, regardless of SpO 2
ÔÇ∑On >4 liters/min supplemental oxygen for COVID -19 (but was not previously on 
supplemental oxygen) , regardless of SpO 2
ÔÇ∑PaO 2/FiO 2<300
AND
Must NOT have respiratory failure, shock, or multi -organ dysfunction/failure (see definitions in 
Critical COVID -19 below)
06FSHF
07X3DY
PRODUCT:   MK-4482  125
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Critical COVID -19: 
Must have ONE or MORE of the following:
ÔÇ∑Respiratory failure defined based on resource utilization requiring at least 1 of the
following:
oEndotracheal intubation and mechanical ventilation
oOxygen delivered by high- flow nasal cannula (heated, humidified, oxygen delivered 
via reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen 
‚â•0.5)
oNoninvasive positive pressure ventilation
oECMO
oClinical diagnosis of respiratory failure (ie, clinical need for 1 of the preceding 
therapies, but preceding therapies not able to be administered in setting of resource 
limitation)
ÔÇ∑Shock defined as requiring vasopressors
ÔÇ∑Multi -organ dysfunction/failure defined as participants that are acutely ill with evidence 
of either dysfunction or failure, at the discretion of the investigator, of more than 1 of the 
following organ systems: respiratory, cardiovascular, ren al, hematologic, hepatic, and/or 
central nervous systems
06FSHF
07X3DY
PRODUCT:   MK-4482  126
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.10 Appendix 10:Individuals at Increased Risk for Severe Illness from COVID -19
Individuals with at least 1 of the following characteristics or underlying medical conditions 
areat increased riskfor severe illness from COVID-19,as adapted from the US CDC
[Centers for Disease Control and Prevention 2020] [Centers for Disease Control and 
Prevention 2021] [Centers for Disease Control and Prevention 2020] and the WHO [World 
Health Organization 2020] . Immunocompromised state from solid organ transplant and 
sickle cel l disease were considered high risk conditions in Part 1; however , these conditions 
were removed for Part 2 to align with updated CDC guidance supported by meta -
analysis/systematic review rather than mostly observational studies .
ÔÇ∑Age >60years
ÔÇ∑Active c ancer (excluding minor cancers not associated with immuno suppression or 
significant morbidity/mortality [eg, basal cell carcinomas ])
ÔÇ∑Chronic kidney disease (excluding participants on dialysis or has reduced eGFR 
<30mL/min/1.73 m2; See Section 5.2)
ÔÇ∑Chronic obstructive pulmonary disease
ÔÇ∑Obesity ( body mass index* of 30 or higher)
ÔÇ∑Serious heart conditions (heart failure, coronary artery disease, or cardiomyopathies )
ÔÇ∑Diabetes mellitus
* Body mass index = weight (kg)/[height (m)]2
06FSHF
07X3DY
PRODUCT:   MK-4482  127
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.11 Appendix 11: Calculation of eGFR
Modification of Diet in Renal Disease Study (MDRD) equation
eGFR (mL/min/1.73 m2) = 175 x (SCr)-1.154x (age)-0.203 x 0.742 [if female] x 1.212 
[ifAfrican American]
Notes:
ÔÇ∑eGFR = estimated glomerular filtration rate
ÔÇ∑SCr = standardized serum creatinine
ÔÇ∑age = years
06FSHF
07X3DY
PRODUCT:   MK-4482  128
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
10.12 Appendix 12: Abbreviations
Abbreviation Expanded Term
ACTT 1 Adaptive COVID -19 Treatment Trial
AE adverse event 
ALT alanine aminotransferase
ANOVA analysis of variance
APaT all-participants -as-treated
AST aspartate aminotransferase
AUC area under the curve
BID twice daily
BUN blood urea nitrogen
C2hr plasma concentration value collected at 2 hours
C12hr plasma concentration value collected at 12 hours
CBC complete blood count
CDC Centers for Disease Control and Prevention
CD4 cluster of differentiation 4
CI confidence interval
Cmax maximum plasma concentration
CMH Cochran ‚ÄìMantel ‚ÄìHaenszel
CONSORT Consolidated Standards of Reporting Trials
COVID -19 coronavirus infectious disease 2019
CRF case report form 
CRP C-reactive protein
CSR clinical study report
CTFG clinical trial facilitation group
Ctrough lowest plasma concentration
CYP cytochrome P450
DAIDS Division of Acquired Immunodeficiency Syndrome
DAO data as observed
DDI drug-drug interaction
DILI drug-induced liver injury
DMC data monitoring committee
EAST software platform for the statistical design, simulation and monitoring of clinical trials
ECG electrocardiogram 
ECI event of clinical interest
ECMO extracorporeal membrane oxygenation
eCRF electronic Case Report Form
EDC electronic data collection 
eDMC external data monitoring committee
EEA European Economic Area
EFD embryo -fetal development
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
EOC Executive Oversight Committee
EOT end of treatment
ePROs electronic patient -reported outcomes
ESD early stage development
ESR erythrocyte sedimentation rate
EUA emergency use authorization
FBR future biomedical research
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act
06FSHF
07X3DY
PRODUCT:   MK-4482  129
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Abbreviation Expanded Term
FiO 2 fraction of inspired oxygen
FSH follicle -stimulating hormone
GCP good clinical practice 
H1 hypothesis 1
H1N1 Hemagglutinin Type 1 and Neuraminidase Type 1 (influenza strain)
H2 hypothesis 2
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
hCG human chorionic gonadotropin
HCV hepatitis C virus
HIV human immunodeficiency virus
HRT hormone replacement therapy
IA interim analysis
IB investigator‚Äôs brochure 
ICF informed consent form
ICH International Council forHarmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
ICU intensive care unit
IEC Independent Ethics Committee
Ig immunoglobulin
IgA immunoglobulin A
IgG immunoglobulin G
IgM immunoglobulin M
IL-6 interleukin 6
IMP investigational medicinal product
IRB Institutional Review Board
IRT intervention randomization system
IUD intrauterine device
IUS intrauterine hormone -releasing system
IV intravenous
LAM lactational amenorrhoea method
LAR legally acceptable representative 
LFT liver function test
LFU late follow -up
LOCF last observation carries forward
LSD late stage development
MAD multiple ascending dose
MAP modeling analysis plan
MCH mean corpuscular hemoglobin
MCV mean corpuscular volume
MDRD modification of diet in renal disease
MERS Middle East respiratory syndrome
MHP medical history pre -specified 
MITT modified intent -to-treat
MOV molnupiravir
MOVe -OUT non-hospitalized outpatient study
MSD Merck Sharp & Dohme
N/A not applicable
NCT National Clinical Trial
NEJM New England Journal of Medicine
NHC N-hydroxycytidine
NHC -TP N-hydroxycytidine pharmacologically -active triphosphate
06FSHF
07X3DY
PRODUCT:   MK-4482  130
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
Abbreviation Expanded Term
NIMP non-investigational medicinal product
NP nasopharyngeal
NSAE nonserious adverse event
OP oropharyngeal
PaO 2 partial pressure of oxygen
PBMC peripheral blood mononuclear cells
PCR polymerase chain reaction
PCT procalcitonin
PDLC pre-defined limit of change
pINN proposed International Nonproprietary Name
PK pharmacokinetic
PPE personal protective equipment
PQC product quality complaint
PRO patient -reported outcome
PT preferred term 
Q12H administered once every 12 hours
QP2 department of quantitative pharmacology and pharmacometrics
RBC red blood cell
RdRp RNA -dependent RNA polymerase
RDW red cell distribution width 
RNA ribonucleic acid
RSV respiratory syncytial virus
RT-PCR real time polymerase chain reaction
SAD single ascending dose
SAE serious adverse event 
SAP statistical analysis plan
SARS severe acute respiratory syndrome
SARS -CoV -2 severe acute respiratory syndrome coronavirus 2
SCr standardized serum creatinine
SGOT serum glutamic -oxaloacetic transaminase
SGPT serum glutamic -pyruvic transaminase
siDMC standing internal data monitoring committee
SLAB supplem ental laboratory test(s)
SoA schedule of activities
SOC system organ class
SOP standard operating procedure
SpO 2 oxygen saturation
sSAP supplemental statistical analysis plan
SUSAR suspected unexpected serious adverse reaction
TBD to be determined
Tmax time to maximum plasma concentration
TSSO time since symptom onset
t1/2 half-life
ULN upper limit of normal
US United States
VL viral load
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potential 
06FSHF
07X3DY
PRODUCT:   MK-4482  131
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
11 REFERENCES
[Beigel, J. H., et al 
2020]Beigel JH, Tomashek KM, Dodd LE, Mehta AK, 
Zingman BS, Kalil AC, et al. Remdesivir for the 
treatment of Covid- 19 -preliminary report. N Engl 
J Med. In press 2020.[05JL53]
[Bhimraj, A., et al 
2020]Bhimraj A, Morgan RL, Shumaker AH, Lavergne 
V, Baden L, Cheng VCC, et al. Infectious 
Diseases Society of America guidelines on the 
treatment and management of patients with 
COVID- 19. Arlington (VA): Infectious Diseases 
Society of Am erica (IDSA); 2020. 82 p.[05JSVV]
[Centers for Disease 
Control and 
Prevention 2020]Centers for Disease Control and Prevention 
[Internet]. Washington (DC): Department of 
Health and Human Services (HHS). Coronavirus 
disease 2019 (COVID- 19): people with certain 
medical conditions; [updated 2020 Jun 30; cited 
2020 Jul 31]; [about 30 screens]. Available from: 
https://www.cdc.gov/coronavirus/2019- ncov/need -
extra -precautions/people -with-medical -
conditions.html.[05K6RY]
[Centers for Disease 
Control and 
Prevention 2020]Centers for Disease Control and Prevention 
[Internet]. Washington (DC): Department of 
Health and Human Services (HHS). Coronavirus 
disease 2019 (COVID- 19): older adults; [updated 
2020 Jul 30; cited 2020 Jul 31]; [about 17 
screens]. Availab le from: 
https://www.cdc.gov/coronavirus/2019- ncov/need -
extra -precautions/older -adults.html.[05K6T3]
[Centers for Disease 
Control and 
Prevention 2021]Centers for Disease Control and Prevention 
[Internet]. Washington (DC): Department of 
Health and Human Services (HHS). Underlying 
medical conditions associated with high risk for 
severe COVID- 19: information for healthcare 
providers; [updated 2021 Mar 29; cited 2021 Apr 
2]; [about 19 screens]. Available from: 
https://www.cdc.gov/coronavirus/2019-
ncov/hcp/cl inical- care/underlyingconditions.html.[05RJ2F]
[Cevik, M., et al 2020] Cevik M, Bamford CGG, Ho A. COVID- 19 
pandemic - a focused review for clinicians. Clin 
Microbiol Infect. 2020;26:842 -7.[05JLPP]
06FSHF
07X3DY
PRODUCT:   MK-4482  132
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
[Chen, Y. H. J., et al 
2004]Chen YHJ, DeMets DL, Lan KKG. Increasing the 
sample size when the unblinded interim result is 
promising. Statist Med 2004;23:1023- 38.[03QBFQ]
[Clark, A., et al 2020] Clark A, Jit M, Warren -Gash C, Guthrie B, Wang 
HHX, Mercer SW, et al. Global, regional, and 
national estimates of the population at increased 
risk of severe COVID -19 due to underlying health 
conditions in 2020: a modelling study. Lancet 
Glob Health. In press 2020.[05JF2D]
[COVID- 19 Treatment 
Guidelines Panel 
2020]COVID- 19 Treatment Guidelines Panel. 
Coronavirus disease 2019 (COVID -19) treatment 
guidelines. Bethesda (MD): National Institutes of 
Health (NIH); 2020. 146 p.[05JQGC]
[D'Abramo, A., et al 
2020]D'Abramo A, Lepore L, Palazzolo C, Barreca F, 
Liuzzi G, Lalle E, et al. Acute respiratory distress
syndrome due to SARS -CoV -2 and influenza A 
co-infection in an Italian patient: mini- review of 
the literature. Int J Infect Dis. 2020;97:236- 9.[05K876]
[European 
Commission 2020]European Commission. Guidance on the 
management of clinical trials during the COVID-
19 (coronavirus) pandemic: version 3. Brussels 
(Belgium): European Commission; 2020 Apr 28. 
21 p.[05J46H]
[Farrington, C. P. and 
Manning, G. 1990]Farrington CP, Manning G. Test statistics and 
sample size formulae for comparative binomial 
trials with null hypothesis of non- zero risk 
difference or non- unity relative risk. Stat Med 
1990;9:1447- 54.[03QK0P]
[Food and Drug 
Administration 2020]Food and Drug Administration. COVID- 19: 
developing drugs and biological products for 
treatment or preventio n: guidance for industry. 
Silver Spring, MD. May 2020.[05JNM2]
[Gordon, C. J., et al 
2020]Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, 
Feng JY, Porter DP, et al. Remdesivir is a direct -
acting antiviral that inhibits RNA -dependent RNA 
polymerase from severe acute respiratory 
syndrome coronavirus 2 with high potency. J Biol 
Chem. 2020;295(20):6785- 97.[05JT9R]
06FSHF
07X3DY
PRODUCT:   MK-4482  133
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
[Kim, D., et al 2020] Kim D, Quinn J, Pinsky B, Shah NH, Brown I. 
Rates of co- infection between SARS -CoV -2 and 
other respiratory pathogens [letter]. JAMA. 2020 
May 26;323(20):2085 -6.[05K879]
[Klok, F. A., et al 
2020]Klok FA, Kruip MJHA, van der Meer NJM, 
Arbous MS, Gommers DAMPJ, Kant KM, et al. 
Incidence of thrombotic complications in critically 
ill ICU patients with COVID- 19. Thromb Res. 
2020;191:145- 7.[05JLPX]
[Lai, C. C., et al 2020] Lai CC, Wang CY, Hsueh PR. Co -infections 
among patients with COVID -19: the need for 
combination therapy with non- anti-SARS -CoV -2 
agents? J Microbiol Immunol Infect. In press 
2020.[05K8X5]
[Marshall, J. C., et al 
2020]Marshall JC, Murthy S, Diaz J, Cheng A, 
Denholm J, Hodgson C, et al. A minimal common 
outcome measure set for COVID -19 clinical 
research. Lancet Infect Dis. In press 2020.[05JNMB]
[McCullagh, P. 1980] McCullagh P. Regression models for ordinal data. 
J Royal Stat Soc B 1980;42(2):109 -42.[03NZCC]
[Mendoza, E. J., et al 
2020]Mendoza EJ, Manguiat K, Wood H, Drebot M. 
Two detailed plaque assay protocols for the 
quantification of infectious SARS -CoV -2. Curr 
Protoc Micr obiol. 2020;57:e105.[05K87C]
[Miettinen, O. 1985] Miettinen O, Nurminen M. Comparative analysis 
of two rates. Stat Med 1985;4:213- 26.[00VMQY]
[Ovsyannikova, I. G., 
et al 2020]Ovsyannikova IG, Haralambieva IH, Crooke SN, 
Poland GA, Kennedy RB. The role of host 
genetics in the immune response to SARS -CoV -2 
and COVID- 19 susceptibility and severity. 
Immunol Rev. 2020;296:205 -19.[05K875]
[Painter, W. P., et al 
2021]Painter WP, Holman W, Bush JA, Almazedi F, 
Malik H, Eraut NCJE, et al. Human safety, 
tolerability, and pharmacokinetics of molnupiravir, 
a novel broad -spectrum oral antiviral agent with 
activity against SARS -CoV -2 [manuscript]. 
Antimicrob Agents Chemother. 2021. 35 p.[05QSYX]
06FSHF
07X3DY
PRODUCT:   MK-4482  134
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
[Stokes, E. K., et al 
2020]Stokes EK, Zambrano LD, Anderson KN, Ma rder 
EP, Raz KM, El Burai Felix S, et al. Coronavirus 
disease 2019 case surveillance - United States, 
January 22 -May 30, 2020. MMWR Morb Mortal 
Wkly Rep. 2020 Jun 19;69(24):759 -65.[05JG6C]
[Tenforde, M. W., et 
al 2020]Tenforde MW, Billig Rose E, Lindsell CJ, Shapiro 
NI, Files DC, Gibbs KW, et al. Characteristics of 
adult outpatients and inpatients with COVID -19 -
11 academic medical centers, United States, 
March -May 2020. MMWR Morb Mortal Wkly 
Rep. 2020 Jul 3;69(26):841 -6.[05L39W]
[U.S. Prescrib ing 
Information 2021]U.S. Prescribing Information: VEKLURY 
(remdesivir) for injection, for intravenous use; 
VEKLURY (remdesivir) injection, for intravenous 
use: Feb 2021.[05QSYW]
[Wadman, M., et al 
2020]Wadman M, Couzin -Frankel J, Kaiser J, Matacic 
C. A rampage through the body. Science. 2020 
Apr 24;368(6489):356 -60.[05JM53]
[Wang, T., et al 2020] Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. 
Comorbidities and multi -organ injuries in the 
treatment of COVID -19 [correspondence]. Lancet. 
2020 Mar 21;395:e52.[05JM59]
[World health 
Organization 2020]World health Organization. Coronavirus disease 
(COVID- 19): situation report -171. Geneva 
(Switzerland): World Health Organization 
(WHO); 2020. 18 p.[05JSVX]
[World health 
Organization 2020]World health Organization. Clinical management 
of COVID- 19: interim guidance. Geneva 
(Switzerland): World Health Organization 
(WHO); 2020 May 27. 62 p.[05JSVW]
[World Health 
Organization 2020]World Health Organization. WHO COVID- 19 
case definition. Geneva (Sw itzerland): World 
Health Organization (WHO); 2020 Aug 7.[05L0V2]
06FSHF
07X3DY
PRODUCT:   MK-4482  135
PROTOCOL/AMENDMENT NO.:   002 -04  
MK-4482 -002-04 FINAL PROTOCOL 15-AUG -2021
[World Health 
Organization 2020]World Health Organization [Internet]. Geneva 
(Switzerland): World Health Organization 
(WHO); c2020. COVID -19: vulnerable and high 
risk groups; [cited 2020 J ul 29]; [about 6 screens]. 
Available from: 
https://www.who.int/westernpacific/emergencies/c
ovid-19/information/high -risk-groups.[05K6T7]
[Wu, X., et al 2020] Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et 
al. Co- infection with SARS -CoV -2 and influenza a 
virus in patient with pneumonia, China [letter]. 
Emerg Infect Dis. 2020 Jun;26(6):1324 -6.[05K87F]
[Wu, Z. 2020] Wu Z, McGoogan JM. Characteristics of and 
important lessons from the coronavirus disease 
2019 (COVID- 19) outbreak in China: summary of 
a repor t of 72 314 cases from the Chinese Center 
for Disease Control and Prevention. JAMA. 2020 
Apr 7;323(13):1239 -42.[05J92M]
06FSHF
07X3DY